


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2022**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

Department of Health and Human Services

Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**Cumulative Supplement 8
August 2022**

CONTENTS

	<i>PAGE</i>
Contents	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT	vi
1.3 APPLICANT NAME CHANGES	vii
1.4 LEVOTHYROXINE SODIUM	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Products Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

42nd EDITION

**CUMULATIVE SUPPLEMENT 8
AUGUST 2022**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE PHARMS)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)
LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)

LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
MERCK AND CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK AND CO INC (MERCK AND CO INC)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK RESEARCH LABORATORIES DIV MERCK CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP (MERCK SHARP DOHME)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC (MSD MERCK CO)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter,

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at

<http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2021</u>	<u>MAR 2022</u>	<u>JUN 2022</u>	<u>SEP 2022</u>	<u>DEC 2022</u>
DRUG PRODUCTS	21133	21339	21640		
LISTED SINGLE SOURCE	2701 (12.8%)	2716 (12.7%)	2748 (12.7%)		
MULTISOURCE	18432 (87.2%)	18623 (87.3%)	18892 (87.3%)		
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)	18762 (86.7%)		
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)	130 (.6%)		
EXCEPTIONS ⁴	54 (0.3%)	53 (0.2%)	53 (.2%)		
NEW MOLECULAR ENTITIES APPROVED	13	11	23		
NUMBER OF APPLICANTS	1190	1204	1219		

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD

+! VIIV HLTHCARE EQ 60MG BASE;EQ 5MG BASE;30MG N215413 001 Mar 30, 2022 Mar NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL
ABACAVIR SULFATE AND LAMIVUDINE

AB	@ AUROBINDO PHARMA LTD LAURUS	EQ 600MG BASE;300MG EQ 600MG BASE;300MG	A206151 001 Mar 28, 2017 Jun DISC A216332 001 Jul 25, 2022 Jul NEWA
----	-------------------------------	--	--

ABAMETAPIR

LOTION;TOPICAL
XEGLYZE
+ @ HATCHTECH 0.74%

N206966 001 Jul 24, 2020 Jul CAHN

ABIRATERONE ACETATE

TABLET;ORAL
ABIRATERONE ACETATE

AB	GLENMARK PHARMS NOVUGEN	500MG 250MG	A209227 002 May 19, 2022 May NEWA A215947 001 Jan 05, 2022 Aug CAHN
>A> AB		500MG	A215947 002 Jan 05, 2022 Aug CAHN
>D> AB	ONCOGEN PHARMA	250MG	A215947 001 Jan 05, 2022 Aug CAHN
>D> AB		500MG	A215947 002 Jan 05, 2022 Aug CAHN
AB	TEVA PHARMS USA YONSA	125MG	A212206 001 Jun 24, 2022 Jun NFTG
AB	+! SUN PHARM +!	125MG 125MG	N210308 001 May 22, 2018 Jun CFTG N210308 001 May 22, 2018 Feb CAHN

ABROCITINIB

TABLET;ORAL
CIBINQO
+ PFIZER 50MG
+ 100MG
+! 200MG

N213871 001 Jan 14, 2022 Jan NEWA
N213871 002 Jan 14, 2022 Jan NEWA
N213871 003 Jan 14, 2022 Jan NEWA

ACALABRUTINIB MALEATE

>A>	TABLET;ORAL		
>A>	CALQUENCE		
>A>	+! ASTRAZENECA	EQ 100MG BASE	N216387 001 Aug 03, 2022 Aug NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL
ACEBUTOLOL HYDROCHLORIDE

AB	! AMNEAL PHARM !	EQ 200MG BASE EQ 200MG BASE	A075047 001 Dec 30, 1999 Jul CTEC A075047 001 Dec 30, 1999 Apr CTEC
AB	!	EQ 400MG BASE	A075047 002 Dec 30, 1999 Jul CTEC
AB	!	EQ 400MG BASE	A075047 002 Dec 30, 1999 Apr CTEC
AB	ANI PHARMS	EQ 200MG BASE	A074007 001 Oct 18, 1995 Jul CMFD
AB		EQ 400MG BASE	A074007 002 Oct 18, 1995 Jul CMFD
AB	@ MYLAN	EQ 200MG BASE	A074288 001 Apr 24, 1995 Apr DISC
AB	@	EQ 200MG BASE	A074288 001 Apr 24, 1995 Apr CAHN
AB		EQ 400MG BASE	A074288 002 Apr 24, 1995 Apr DISC
AB		EQ 400MG BASE	A074288 002 Apr 24, 1995 Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS
ACETAMINOPHEN

AP	ASPIRO	1GM/100ML (10MG/ML)	A216617 001 Jul 27, 2022 Jul NEWA
>D> AP	CUSTOPHARM INC	1GM/100ML (10MG/ML)	A202605 001 Jun 13, 2016 Aug CAHN
>A> AP	HIKMA	1GM/100ML (10MG/ML)	A202605 001 Jun 13, 2016 Aug CAHN
	+!	1GM/100ML (10MG/ML)	N206968 001 Jun 03, 2022 Jun CAHN
	+! INNOPHARMA	1GM/100ML (10MG/ML)	N206968 001 Jun 03, 2022 Jun NEWA
AP	! SANDOZ INC OFIRMEV	1GM/100ML (10MG/ML)	A204052 001 Mar 22, 2016 Feb CHRS
	+ @ MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450 001 Nov 02, 2010 Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

AA	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015	Apr CTEC
		BUTALBITAL AND ACETAMINOPHEN					
>A>	AA	AACE PHARMS	50MG;300MG	A214955	001	Aug 16, 2022	Aug NEWA
AA		HAVIX	300MG;50MG	A214088	001	Apr 07, 2022	Apr NEWA
AA			325MG;25MG	A214088	002	Apr 07, 2022	Apr NEWA
AA			325MG;50MG	A214088	003	Apr 07, 2022	Apr NEWA
AA		SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Jun CAHN
AA			325MG;25MG	A214088	002	Apr 07, 2022	Jun CAHN
AA			325MG;50MG	A214088	003	Apr 07, 2022	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022	Mar NEWA
AA			325MG;50MG;40MG	A215135	002	Mar 25, 2022	Mar NEWA
>A>	AA	NOVAST LABS	300MG;50MG;40MG	A215047	001	Nov 17, 2021	Aug CAHN
>D>	AA	RICONPHARMA LLC	300MG;50MG;40MG	A215047	001	Nov 17, 2021	Aug CAHN
		TABLET;ORAL					
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
AA		GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jul CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA	300MG;50MG;40MG;30MG	A215138	002	Jan 26, 2022	Jan NEWA
AB			325MG;50MG;40MG;30MG	A215138	001	Jan 26, 2022	Jan NEWA
AB		LGM PHARMA	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Apr CAHN
AA		MIKART	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Mar CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	CHARTWELL	300MG;15MG	A089997	001	Dec 28, 1994	Feb CAHN
@		300MG;30MG	A089998	001	Dec 28, 1994	Feb CAHN
@		300MG;60MG	A089999	001	Dec 28, 1994	Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Apr CAHN
AA	!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010	Apr CTEC
AA	!		325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Mar CAHN
	@	TRIS PHARMA INC	300MG/15ML;10MG/15ML	A201295	002	Dec 30, 2021	Apr DISC
	@		325MG/15ML;7.5MG/15ML	A201295	001	Dec 30, 2021	Apr DISC

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018	May CHRS	
		325MG;2.5MG	A211487	001	Nov 07, 2018	May CTEC	
AA	!	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Apr CAHN
AA	!		300MG;7.5MG	A040658	002	Mar 24, 2006	Apr CAHN
AA	!		300MG;10MG	A040658	003	Jun 23, 2004	Apr CAHN
	@		325MG;7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
AA			325MG;7.5MG	A040432	001	Jan 22, 2003	Apr CAHN
	@		325MG;10MG	A040248	002	Apr 28, 2000	Feb CAHN
AA	MIKART	325MG;7.5MG	A040432	001	Jan 22, 2003	Mar CAHN	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

MIKART		300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	Mar CAHN
TABLET;ORAL						
OXYCODONE 5/APAP 500						
@ BRISTOL MYERS SQUIBB		500MG;5MG	A085911	001		Jun CRLD

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
ACETAZOLAMIDE

AB	! CADILA	500MG	A205301	001	Jan 16, 2019	May CHRS
	@ INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011	May DISC

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC
ACETIC ACID
@ WOCKHARDT BIO AG VOSOL

AT	! AKORN	2%	A040166	001	Jul 26, 1996	Jun DISC
			N012179	001		Jun CHRS

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

AP	ASPEN	6GM/30ML (200MG/ML)	A213693	001	Feb 03, 2022	Jan NEWA
	@ EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb DISC
AP	INDOCO	6GM/30ML (200MG/ML)	A215620	001	Feb 23, 2022	Feb NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION
TUDORZA PRESSAIR

+!	COVIS	0.4MG/INH	N202450	001	Jul 23, 2012	Apr CAHN
----	-------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION
DUAKLIR PRESSAIR

+!	COVIS	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Apr CAHN
----	-------	-----------------------	---------	-----	--------------	----------

ACYCLOVIR

OINTMENT;TOPICAL
ACYCLOVIR

@ PRINSTON INC	5%	A212202	001	Nov 15, 2021	Mar DISC
----------------	----	---------	-----	--------------	----------

SUSPENSION;ORAL
ACYCLOVIR

AB	AUROBINDO PHARMA LTD	200MG/5ML	A216331	001	Mar 31, 2022	Mar NEWA
AB	HETERO LABS LTD III	200MG/5ML	A215669	001	Jul 01, 2022	Jun NEWA
>AB	RUBICON	200MG/5ML	A215724	001	Aug 18, 2022	Aug NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

AP	AM INJECTABLES	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Apr CAHN
	@ CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997	Mar CAHN
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Mar CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	0.3%;2.5%	A209641	001	Jun 22, 2022	Jun NEWA
AB	ALEOR DERMACEUTICALS	0.3%;2.5%	A214185	001	Aug 04, 2022	Jul NEWA
AB	PADAGIS ISRAEL	0.3%;2.5%	A212464	001	May 31, 2022	May NEWA
AB	ZYDUS PHARMS	0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA
AT		0.3%;2.5%	A214553	001	Jun 03, 2022	May NEWA

ALBENDAZOLE

TABLET;ORAL
ALBENDAZOLE

AB	! DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jun CHRS
	ALBENZA					
	+ @ IMPAX LABS INC	200MG	N020666	001	Jun 11, 1996	Jun DISC

ALBUTEROL SULFATE

SOLUTION;INHALATION
ALBUTEROL SULFATE

@ BAUSCH	EQ 0.083% BASE	A075358	001	Mar 29, 2000	Jun CAHN
@	EQ 0.5% BASE	A075050	001	Jun 18, 1998	Jun CAHN

SYRUP;ORAL

ALBUTEROL SULFATE

AA	CHARTWELL RX	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007	May CMFD
	TABLET;ORAL					

ALBUTEROL SULFATE

@ CHARTWELL RX

EQ 4MG BASE

A072151 002 Dec 05, 1989 Feb CMS1

ALCOHOLSOLUTION;INTRA-ARTERIAL

ABLYSINOL

+ BPI LABS

99% (1ML)

N207987 001 Jun 21, 2018 Jul CAHN

+!

99% (5ML)

N207987 002 Jun 21, 2018 Jul CAHN

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

@ ATLANTIDE

10MG

A090221 001 Aug 10, 2012 Apr CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLORTIAZIDETABLET;ORAL

TEKURNA HCT

+ @ NODEN PHARMA

EQ 300MG BASE;12.5MG

N022107 003 Jan 18, 2008 May DISC

+ @

EQ 300MG BASE;25MG

N022107 004 Jan 18, 2008 May DISC

ALLOPURINOLINJECTABLE;INJECTION

ALLOPURINOL

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan NEWA
	TABLET;ORAL					
	ALLOPURINOL					
AB	! ACCORD HLTHCARE	300MG	A203154	002	May 06, 2013	Apr CHRS
AB	HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb NEWA
AB		300MG	A214443	002	Mar 07, 2022	Feb NEWA
	ZYLOPRIM					
>A>	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Aug NEWA
AB	+	300MG	N016084	002		Apr CHRS

ALLOPURINOL SODIUMINJECTABLE;INJECTION

ALOPRIM

AP	+! MYLAN	EQ 500MG BASE/VIAL	N020298	001	May 17, 1996	Apr CAHN
----	----------	--------------------	---------	-----	--------------	----------

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDETABLET;ORAL

OSENI

+ @ TAKEDA PHARMS USA

EQ 12.5MG BASE;EQ 15MG BASE

N022426 004 Jan 25, 2013 Mar DISC

+ @

EQ 12.5MG BASE;EQ 45MG BASE

N022426 006 Jan 25, 2013 Mar DISC

ALOSETRON HYDROCHLORIDETABLET;ORAL

ALOSETRON HYDROCHLORIDE

@ PAR PHARM INC

EQ 0.5MG BASE

A206113 001 Feb 23, 2018 Apr DISC

@

EQ 1MG BASE

A206113 002 Feb 23, 2018 Apr DISC

ALPELISIBTABLET;ORAL

VIJOICE

+ NOVARTIS

50MG

N215039 001 Apr 05, 2022 Apr NEWA

+

125MG

N215039 002 Apr 05, 2022 Apr NEWA

+!

200MG

N215039 003 Apr 05, 2022 Apr NEWA

ALPROSTADILSUPPOSITORY;URETHRAL

MUSE

+ @ MYLAN SPECIALITY LP

0.125MG

N020700 001 Nov 19, 1996 Jul DISC

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	STRIDES PHARMA	100MG	A211354	001	Feb 18, 2022	Aug DISC
>A>		@	100MG	A211354	001	Feb 18, 2022	Aug DISC
	AB		100MG	A211354	001	Feb 18, 2022	Feb NEWA
		CAPSULE, EXTENDED RELEASE;ORAL					
		GOCOVRI					
>A>		+ ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
>A>		+!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN
>D>		+ ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
>D>		+!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN
		SYRUP;ORAL					
		AMANTADINE HYDROCHLORIDE					
AA		! CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar CAHN
		TABLET;ORAL					
		AMANTADINE HYDROCHLORIDE					
AB		EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	May NEWA
		@ JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May DISC
		TABLET, EXTENDED RELEASE;ORAL					
		OSMOLEX ER					
>A>		+ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
>A>		+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
>A>		+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
>A>		+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN
>D>		+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
>D>		+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
>D>		+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
>D>		+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB		APOTEX	5MG	A210701	001	May 19, 2022	May NEWA
AB			10MG	A210701	002	May 19, 2022	May NEWA
AB		AUROBINDO PHARMA LTD	5MG	A216531	001	Jul 21, 2022	Jul NEWA
AB			10MG	A216531	002	Jul 21, 2022	Jul NEWA

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

>D>	AB	! FOUGERA PHARMS	0.1%	A076065	001	May 15, 2003	Aug CAHN
>A>	AB	! GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003	Aug CAHN
		LOTION;TOPICAL					
		AMCINONIDE					
>D>		! FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002	Aug CAHN
>A>		! GENUS LIFESCIENCES	0.1%	A076329	001	Nov 06, 2002	Aug CAHN
		OINTMENT;TOPICAL					
		AMCINONIDE					
>D>	AB	! FOUGERA PHARMS	0.1%	A076096	001	Nov 19, 2002	Aug CAHN
>A>	AB	! GENUS LIFESCIENCES	0.1%	A076096	001	Nov 19, 2002	Aug CAHN

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

@ EUGIA PHARMA SPEC LTS 500MG/VIAL

A204363 001 Jul 17, 2017 Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

>A>		@ CHARTWELL RX	5MG	A204180	001	Aug 07, 2015	Aug CAHN
>D>		@ USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	Aug CAHN
		@	5MG	A204180	001	Aug 07, 2015	May DISC

AMINO ACIDS

INJECTABLE;INJECTION

NEPHRAMINE 5.4%

@ B BRAUN 5.4% (5.4GM/100ML)

N017766 001 Mar DISC

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA	AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar NEWA
AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Jun CAHN
	TABLET;ORAL					
	AMINOCAPROIC ACID					
AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Jun CAHN
AB		1GM	A213928	002	Feb 12, 2021	Jun CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

@ EUGIA PHARMA 50MG/ML

A204550 001 Oct 25, 2017 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	May NEWA
AB		25MG	A216243	002	Jun 06, 2022	May NEWA
AB		50MG	A216243	003	Jun 06, 2022	May NEWA
AB		75MG	A216243	004	Jun 06, 2022	May NEWA
AB		100MG	A216243	005	Jun 06, 2022	May NEWA
AB		150MG	A216243	006	Jun 06, 2022	May NEWA
	@ UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	May DISC
	@	25MG	A212654	001	Apr 07, 2020	May DISC
	@	50MG	A212654	003	Sep 29, 2021	May DISC
	@	75MG	A212654	004	Sep 29, 2021	May DISC
	@	100MG	A212654	005	Sep 29, 2021	May DISC
	@	150MG	A212654	006	Sep 29, 2021	May DISC
	@ VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997	Jun DISC
	@	25MG	A040218	002	Sep 11, 1997	Jun DISC
	@	50MG	A040218	003	Sep 11, 1997	Jun DISC
	@	75MG	A040218	004	Sep 11, 1997	Jun DISC
	@	100MG	A040218	005	Sep 11, 1997	Jun DISC
	@	150MG	A040218	006	Sep 11, 1997	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan NEWA
AB		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan CTEC
AB	!	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan CTEC
	@ UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr CAHN
	@	EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

+! CMP DEV LLC EQ 1MG BASE/ML

N214439 001 Feb 24, 2022 Feb NEWA

TABLET;ORAL

AMLODIPINE BESYLATE

@	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN
AB	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar CMFD
AB		EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar CMFD
AB		EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar CMFD
	NORVASC					
AB	+ VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan CAHN
AB	+	EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan CAHN
AB	+!	EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan CAHN

AMLODIPINE BESYLATE; HYDROCHLORTIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLORTIAZIDE

AB	STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun CMFD
AB		EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun CMFD
AB		EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun CMFD

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLORTIAZIDE

AB EQ 10MG BASE;25MG;320MG A201087 005 Jun 01, 2015 Jun CMFD

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMILTABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

>D> AB	TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Aug DISC
>A>	@	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Aug DISC
>D> AB		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Aug DISC
>A>	@	EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Aug DISC
>D> AB		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Aug DISC
>A>	@	EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Aug DISC
>D> AB		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Aug DISC
>A>	@	EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Aug DISC

AMLODIPINE BESYLATE; TELMISARTANTABLET;ORAL

TELMISARTAN AND AMLODIPINE

@ TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Mar DISC
@	EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Mar DISC
@	EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Mar DISC
@	EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Mar DISC

AMLODIPINE BESYLATE; VALSARTANTABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

>A> AB	HETERO LABS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Aug CAHN
>A> AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Aug CAHN
>A> AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Aug CAHN
>A> AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Aug CAHN
>D> AB	INVAGEN PHARMS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Aug CAHN
>D> AB		EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Aug CAHN
>D> AB		EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Aug CAHN
>D> AB		EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Aug CAHN
AB	STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun CMFD
AB		EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun CMFD
AB		EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun CMFD
AB		EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun CMFD

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

>D>	@ SUN PHARM INDs INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Aug CRLD
>A>	+ @	EQ 12% BASE	N020508	001	Aug 29, 1996	Aug CRLD

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	MICRO LABS	250MG	A207471	001	Jun 24, 2022	Jun NEWA
AB		500MG	A207471	002	Jun 24, 2022	Jun NEWA

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PACK

+! PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May NEWA
VOQUEZNA TRIPLE PAK		N215152	001	May 03, 2022	May CMS1
+! PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PACK

+! PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May NEWA
VOQUEZNA DUAL PAK		N215153	001	May 03, 2022	May CMS1
+! PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@ LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	May DISC
@	2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	May DISC
@	3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	May DISC

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@	5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	May DISC
@	6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	May DISC
@	7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	May DISC

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@ ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jul DISC
--------------	-------------------------	---------	-----	--------------	----------

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

@ ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021	Jul DISC
@	1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021	Jul DISC
@	2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021	Jul DISC
@	3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021	Jul DISC
@	3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021	Jul DISC
@	5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021	Jul DISC
@	7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021	Jul DISC
AB CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jun NEWA
AB	2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jun NEWA
AB	3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jun NEWA
AB	5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jun NEWA
AB	7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jun NEWA
AB LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Jul NEWA
AB	1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Jul NEWA
AB	2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Jul NEWA
AB	3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Jul NEWA
AB	3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Jul NEWA
AB	5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Jul NEWA
AB	7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Jul NEWA
AB ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Mar CAHN
AB	1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Mar CAHN
AB	2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Mar CAHN
AB	3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Mar CAHN
AB	3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar CAHN
AB	5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar CAHN
AB	7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar CAHN

AMPHETAMINE SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+ @ AZURITY	2.5MG	N209905	005	Apr 16, 2021	Apr CAHN
+	5MG	N209905	001	Jan 30, 2019	Apr CAHN
+	10MG	N209905	002	Jan 30, 2019	Apr CAHN
+	15MG	N209905	003	Jan 30, 2019	Apr CAHN
+	20MG	N209905	004	Jan 30, 2019	Apr CAHN

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>D> AP MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug DISC
>A>	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug DISC
>D> AP	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug DISC
>A>	EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug DISC
	EQ WYTELLS PHARMA	A065499	001	Aug 17, 2010	Jul CAHN
AP	EQ 125MG BASE/VIAL	A065499	002	Aug 17, 2010	Jul CAHN
AP	EQ 250MG BASE/VIAL	A065499	003	Aug 17, 2010	Jul CAHN
AP	EQ 500MG BASE/VIAL	A065499	004	Aug 17, 2010	Jul CAHN
AP	EQ 1GM BASE/VIAL	A065499	005	Aug 17, 2010	Jul CAHN
AP	EQ 2GM BASE/VIAL	A065499	006	Aug 17, 2010	Jul CAHN
AP	EQ 10GM BASE/VIAL	A065493	001	Aug 17, 2010	Jul CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@ AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	May DISC
@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	May DISC
@ WYTELLS PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Jul CAHN
AP	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Jul CAHN
@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Jul CAHN
AP	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Jul CAHN
AP	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Jul CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS
APOKYN

AP	+! MDD US	30MG/3ML (10MG/ML)	N 021264	002	Apr 20, 2004	Feb CFTG
AP	SAGE CHEMS	30MG/3ML (10MG/ML)	A 212025	001	Feb 23, 2022	Feb NFTG

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
IOPIDINE

AT	+! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N 020258	001	Jul 30, 1993	Jun CAHN
	+!	EQ 1% BASE	N 019779	001	Dec 31, 1987	Jun CAHN

APREMILAST

TABLET; ORAL
APREMILAST

@ AMNEAL	10MG	A 211782	001	Jun 30, 2021	Jan DISC
@	20MG	A 211782	002	Jun 30, 2021	Jan DISC
@	30MG	A 211782	003	Jun 30, 2021	Jan DISC
>A> AB TEVA PHARMS USA INC	10MG	A 211897	001	Aug 18, 2022	Aug NEWA
>A> AB	20MG	A 211897	002	Aug 18, 2022	Aug NEWA
>A> AB	30MG	A 211897	003	Aug 18, 2022	Aug NEWA

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION
ARFORMOTEROL TARTRATE

AN ALEMBIC PHARMS LTD	EQ 0.015MG BASE/2ML	A 214779	001	May 10, 2022	Apr NEWA
AN LUPIN	EQ 0.015MG BASE/2ML	A 213068	001	Feb 07, 2022	Jan NEWA
AN SUN PHARM	EQ 0.015MG BASE/2ML	A 215385	001	May 26, 2022	May NEWA
AN TAP	EQ 0.015MG BASE/2ML	A 213762	001	Jun 22, 2021	Apr CAHN
>D> AN VISTAPHARM	EQ 0.015MG BASE/2ML	A 214736	001	Mar 02, 2022	Aug DISC
>A> @	EQ 0.015MG BASE/2ML	A 214736	001	Mar 02, 2022	Aug DISC
AN	EQ 0.015MG BASE/2ML	A 214736	001	Mar 02, 2022	Feb NEWA

ARGATROBAN

INJECTABLE; INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE

+ @ CIPLA	50MG/50ML (1MG/ML)	N 022434	001	Jun 29, 2011	Apr CAHN
-----------	--------------------	----------	-----	--------------	----------

ARSENIC TRIOXIDE

INJECTABLE; INJECTION
ARSENIC TRIOXIDE

AP ! FRESENIUS KABI USA	1MG/ML	A 208231	001	Aug 31, 2018	Apr CHRS
AP GLAND PHARMA LTD	1MG/ML	A 215059	002	Apr 22, 2022	Apr NEWA

ARTESUNATE

POWDER; INTRAVENOUS
ARTESUNATE

+! AMIVAS	110MG/VIAL	N 213036	001	May 26, 2020	Feb CAHN
-----------	------------	----------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

FOR SOLUTION; INTRAVENOUS

M.V.I. PEDIATRIC

+ @ HOSPIRA	80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG/G/VIAL; 0.7MG/VIAL; 7MG/VIAL	N 018920	001	Sep 21, 2000	Jan DISC
-------------	--	----------	-----	--------------	----------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

+ @ HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL	N 021625	001	Jan 30, 2004	Jan DISC
-------------	---	----------	-----	--------------	----------

INJECTABLE; INTRAVENOUS

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ @ HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 1 5MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG /5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG /5ML; 10MG/5ML; 0.15MG/5ML	N 021643	001	Feb 18, 2004	Jan DISC
-------------	--	----------	-----	--------------	----------

ASENAPINESYSTEM; TRANSDERMAL
SECUDO

+! HISAMITSU	3.8MG/24HR	N 212268	001	Oct 11, 2019	Mar CHRS
+	7.6MG/24HR	N 212268	003	Oct 11, 2019	Mar CHRS

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA @ LGM PHARMA	500MG; 50MG; 40MG	A 205230	001	Oct 18, 2021	Apr DISC
AA NOSTRUM LABS INC	325MG; 50MG; 40MG	A 078149	001	Jun 13, 2007	Apr CMFD
AA FIORINAL					
AA + @ ALLERGAN	325MG; 50MG; 40MG	N 017534	005	Apr 16, 1986	Jun DISC
AA + LANORINAL	325MG; 50MG; 40MG	N 017534	005	Apr 16, 1986	Apr CHRS
AA ! LANNETT	325MG; 50MG; 40MG	A 086996	002	Oct 11, 1985	Apr CHRS
AA TABLET; ORAL					
AA BUTALBITAL, ASPIRIN AND CAFFEINE					
AA + @ HIKMA INTL PHARMS	325MG; 50MG; 40MG	A 086162	002	Feb 16, 1984	Mar CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB @ MAYNE PHARMA INC	325MG; 50MG; 40MG; 30MG	A 203335	001	Oct 30, 2015	Jan DISC
AB ! STEVENS J	325MG; 50MG; 40MG; 30MG	A 074951	001	Aug 31, 1998	May CHRS
AB FIORINAL W/CODEINE					
AB + @ ALLERGAN	325MG; 50MG; 40MG; 30MG	N 019429	003	Oct 26, 1990	May DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENGESIC

GALT PHARMS 385MG; 30MG; 25MG

A 075141 001 May 29, 1998 Mar CMFD

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ INGENUS PHARMS NJ 325MG; 200MG; 16MG

A 040860 001 Jan 07, 2010 Jul DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

! LGM PHARMA 500MG; 5MG

A 205479 001 May 28, 2021 Jul CMFD

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB HETERO LABS LTD III	EQ 150MG BASE	A 212278	001	Feb 02, 2022	Jan NEWA
AB	EQ 200MG BASE	A 212278	002	Feb 02, 2022	Jan NEWA
AB	EQ 300MG BASE	A 212278	003	Feb 02, 2022	Jan NEWA
REYATAZ					
+ @ BRISTOL MYERS SQUIBB	EQ 150MG BASE	N 021567	002	Jun 20, 2003	Apr DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

>D@ DR REDDYS	EQ 10MG BASE	A 214659	001	Jul 14, 2021	Aug CMFD
>A@ AB	EQ 10MG BASE	A 214659	001	Jul 14, 2021	Aug CMFD
>D@	EQ 20MG BASE	A 214659	002	Jul 14, 2021	Aug CMFD
>A@ AB	EQ 20MG BASE	A 214659	002	Jul 14, 2021	Aug CMFD
>D@	EQ 40MG BASE	A 214659	003	Jul 14, 2021	Aug CMFD
>A@ AB	EQ 40MG BASE	A 214659	003	Jul 14, 2021	Aug CMFD
>D@	EQ 80MG BASE	A 214659	004	Jul 14, 2021	Aug CMFD
>A@ AB	EQ 80MG BASE	A 214659	004	Jul 14, 2021	Aug CMFD

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROOPEN

+!	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May CAHN
+!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May CAHN
+!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May CAHN
+!		EQ 2MG SULFATE/0.7ML	N017106	001		May CAHN

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	+!	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	May CFTG
AP	+!		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	May CFTG
AP		AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	May NFTG
AP			1MG/ML (1MG/ML)	A216120	002	May 26, 2022	May NFTG
AP		AMNEAL	0.5MG/5ML (0.1MG/ML)	A215342	001	Jan 26, 2022	Jan NEWA
AP	+!	HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jan CMFD

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AT		AMNEAL	1%	A214752	001	Jul 14, 2022	Jul NEWA
	+!	BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022	Jul CAHN
	+!	PARAGON BIOTECK	1%	N213581	001	Mar 15, 2022	Jul NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		CHARTWELL RX	0.025MG;2.5MG	A207128	001	Oct 21, 2020	Jun CAHN
	@	MAYNE PHARMA INC	0.025MG;2.5MG	A210789	001	Jun 03, 2020	Jan DISC

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+!	MMT	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006	Jan CAHN
----	-----	-----------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Jan NEWA
----	--	--------	------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

>D> AT		AKORN	0.05%	A203660	001	Nov 08, 2016	Aug DISC
>A>	@		0.05%	A203660	001	Nov 08, 2016	Aug DISC
		SPRAY, METERED; NASAL					
		AZELASTINE HYDROCHLORIDE					
	@	APOTEX INC	0.2055MG/SPRAY	A201846	001	Aug 31, 2012	May DISC
	@	AUROBINDO PHARMA LTD	0.2055MG/SPRAY	A212775	001	Nov 12, 2020	May DISC
	@	HIKMA	0.2055MG/SPRAY	A207243	001	Sep 22, 2017	May DISC

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

AZILSARTAN MEDOXOMIL

>D> AB		LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Aug DISC
>A>	@		EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Aug DISC
	AB		EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Jul NFTG
>D> AB			EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Aug DISC
>A>	@		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Aug DISC
	AB		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Jul NFTG
		EDARBI					
>D> AB	+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Aug CTEC
>A>	+		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Aug CTEC
	AB	+	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jul CFTG
		+	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Mar CAHN
>D> AB	+	!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Aug CTEC
>A>	+	!	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Aug CTEC
	AB	+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jul CFTG
		+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL EDARBYCLOR					
+ AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N 202331	001	Dec 20, 2011	Mar CAHN
+!	EQ 40MG MEDOXOMIL;25MG	N 202331	002	Dec 20, 2011	Mar CAHN

AZITHROMYCIN

SOLUTION/DROPS;OPHTHALMIC AZASITE					
+! THEA PHARMA	1%	N 050810	001	Apr 27, 2007	Apr CAHN

TABLET;ORAL AZITHROMYCIN					
AB ACI	EQ 250MG BASE	A 215772	001	Jul 15, 2022	Jul NEWA
AB	EQ 500MG BASE	A 215773	001	Jul 12, 2022	Jul NEWA
AB ATLANTIDE	EQ 250MG BASE	A 065404	001	Feb 11, 2008	Apr CAHN
AB	EQ 500MG BASE	A 065405	001	Feb 11, 2008	Apr CAHN
AB	EQ 600MG BASE	A 065302	003	Feb 11, 2008	Apr CAHN
AB YUNG SHIN PHARM	EQ 250MG BASE	A 211317	001	Jul 26, 2022	Jul NEWA

BACLOFEN

GRANULES;ORAL LYVISPAH					
+ AMNEAL	5MG/PACKET	N 215422	001	Nov 22, 2021	Feb CAHN
+	10MG/PACKET	N 215422	002	Nov 22, 2021	Feb CAHN
+!	20MG/PACKET	N 215422	003	Nov 22, 2021	Feb CAHN

INJECTABLE;INTRATHECAL BACLOFEN					
AP AMNEAL	0.05MG/ML	A 091193	001	May 03, 2016	Jun CAHN
AP	0.5MG/ML	A 091193	002	May 03, 2016	Jun CAHN
AP	2MG/ML	A 091193	003	May 03, 2016	Jun CAHN

LIORESAL					
AP +! AMNEAL	0.05MG/ML	N 020075	003	Nov 07, 1996	Feb CAHN
AP +!	0.5MG/ML	N 020075	001	Jun 17, 1992	Feb CAHN
AP +!	2MG/ML	N 020075	002	Jun 17, 1992	Feb CAHN

SUSPENSION;ORAL FLEQSUVY					
+! AZURITY	25MG/5ML	N 215602	001	Feb 04, 2022	Feb NEWA
TABLET;ORAL BACLOFEN					
AB MANKIND PHARMA	5MG	A 215885	001	Jan 25, 2022	Jan NEWA
AB	10MG	A 215885	002	Jan 25, 2022	Jan NEWA
AB	20MG	A 215885	003	Jan 25, 2022	Jan NEWA

BARICITINIB

TABLET;ORAL OLUMIANT					
+ ELI LILLY AND CO	4MG	N 207924	003	May 10, 2022	May NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL LOTENSIN					
+ @ VALIDUS PHARMS	5MG	N 019851	001	Jun 25, 1991	Jun DISC

BENZONATATE

CAPSULE;ORAL BENZONATATE					
AA ACELLA	100MG	A 091310	001	Jan 16, 2015	Jan CAHN
AA	200MG	A 091310	002	Jan 16, 2015	Jan CAHN
AA ! THEPHARMANETWORK LLC	100MG	A 040627	002	Mar 30, 2007	Jan CMS1
AA !	150MG	A 040627	003	Sep 24, 2014	Jan CMS1
AA !	200MG	A 040627	002	Jul 25, 2007	Mar CMS1

BENZOYL PEROXIDE

CREAM;TOPICAL EPSOLAY					
+! GALDERMA LABS LP	5%	N 214510	001	Apr 22, 2022	Jun CAHN
+! SOL GEL TECHNOLOGIES	5%	N 214510	001	Apr 22, 2022	Apr NEWA

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE
@ ENCUBE 5%;3%

A065112 001 Mar 29, 2004 Jul CAHN

BENZOYL PEROXIDE; TRETINOINCREAM;TOPICAL
TWYNEO+! GALDERMA LABS LP 3%;0.1%
+ @ 3%;0.1%
+ @ SOL-GEL TECHNOLOGIES 3%;0.1%N214902 001 Jul 26, 2021 Mar CMFD
N214902 001 Jul 26, 2021 Feb CAHN
N214902 001 Jul 26, 2021 Jan DISCBENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	CHARTWELL	25MG	A090473 001 Sep 15, 2010 Apr CAHN
		50MG	A090473 002 Sep 15, 2010 Apr CAHN
AA	MIKART	25MG	A090473 001 Sep 15, 2010 Mar CAHN
		50MG	A090473 002 Sep 15, 2010 Mar CAHN

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

AP	! HIKMA FARMACEUTICA	1MG/ML	A090287 001 Aug 31, 2009 Mar CHRS
	COGENTIN		
+ @ AKORN		1MG/ML	N012015 001 Mar DISC

BETAINEFOR SOLUTION;ORAL
BETAINE

AB	LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508 001 Jan 28, 2022 Jan NEWA
----	--------------------	--------------	-----------------------------------

BETAMETHASONE DIPROPIONATELOTION, AUGMENTED;TOPICAL
BETAMETHASONE DIPROPIONATE

>A> AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389 001 Feb 13, 2018 Aug CAHN
>D> AB	TELIGENT	EQ 0.05% BASE	A206389 001 Feb 13, 2018 Aug CAHN

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	PADAGIS ISRAEL	EQ 0.05% BASE	A215847 001 Apr 12, 2022 Apr NEWA
AB	TASMAN PHARMA	EQ 0.05% BASE	A215186 001 Feb 18, 2022 Feb NEWA

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

>A> AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118 001 Nov 09, 2017 Aug CAHN
>D> AB	TELIGENT	EQ 0.05% BASE	A206118 001 Nov 09, 2017 Aug CAHN

BETAMETHASONE VALERATEAEROSOL, FOAM;TOPICAL
BETAMETHASONE VALERATE

>A>	@ NOVAST LABS	0.12%	A207144 001 May 24, 2017 Aug CAHN
>D>	@ RICONPHARMA LLC	0.12%	A207144 001 May 24, 2017 Aug CAHN

BEXAROTENEGEL;TOPICAL
BEXAROTENE

AB	AMNEAL	1%	A215398 001 Apr 27, 2022 Apr NFTG
	TARGRETIN		
AB	+! BAUSCH	1%	N021056 001 Jun 28, 2000 Apr CFTG

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

AB	CADILA	5MG	A215680 001 Jul 25, 2022 Jul NEWA
AB		10MG	A215680 002 Jul 25, 2022 Jul NEWA
AB	UNITED RES LABS	5MG	A075474 001 Oct 25, 2002 Apr CAHN
AB		10MG	A075474 002 Oct 25, 2002 Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	GLENMARK PHARMS LTD	2.5MG; 6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB		5MG; 6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB		10MG; 6.25MG	A215995	003	Jan 26, 2022	Jan NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

AP	MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN
----	----------	------------	---------	-----	--------------	----------

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Jul NEWA
AP	APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
AP	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
AP	DR REDDYS	3.5MG/VIAL	A202963	001	Jul 26, 2022	Jul NEWA
AP	EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG
AP	FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr NFTG
AP	HOSPIRA	3.5MG/VIAL	A208460	001	Jul 26, 2022	Jul NEWA
AP	JIANGSU HANSOH PHARM	3.5MG/VIAL	A215011	001	Jul 26, 2022	Jul NEWA
AP	KINDOS	3.5MG/VIAL	A212958	001	Jul 26, 2022	Jul NEWA
AP	MSN	3.5MG/VIAL	A209622	001	Jul 26, 2022	Jul NEWA
AP	PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr NFTG
AP	QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr NFTG
AP	SANDOZ INC	3.5MG/VIAL	A203654	001	Jul 26, 2022	Jul NEWA
AP	TEVA PHARMS USA	3.5MG/VIAL	A205857	001	May 02, 2022	Apr NFTG
AP	ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr NFTG
	VELCADE					
AP	+! TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	Apr CFTG
	POWDER; INTRAVENOUS, SUBCUTANEOUS					
	BORTEZOMIB					
+!	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022	May NEWA
+!		2.5MG/VIAL	N209191	002	May 02, 2022	May NEWA
	SOLUTION; INTRAVENOUS					
	BORTEZOMIB					
+!	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Jul NEWA
+!		3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Jul NEWA
+!	MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331	001	Jul 27, 2022	Jul NEWA
+!		3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022	Jul NEWA

BOSENTAN

TABLET; ORAL

BOSENTAN

@	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
@		125MG	A210342	002	Jan 03, 2020	Mar CAHN

BREXPIPRAZOLE

TABLET; ORAL

BREXPIPRAZOLE

>A>	TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Aug NFTG
>A> AB		0.5MG	A213692	002	Aug 11, 2022	Aug NFTG
>A> AB		1MG	A213692	003	Aug 11, 2022	Aug NFTG
>A> AB		2MG	A213692	004	Aug 11, 2022	Aug NFTG
>A> AB		3MG	A213692	005	Aug 11, 2022	Aug NFTG
>A> AB		4MG	A213692	006	Aug 11, 2022	Aug NFTG

REXULTI

>D>	+	OTSKUA	0.25MG	N205422	001	Jul 10, 2015	Aug CFTG
>A> AB	+		0.25MG	N205422	001	Jul 10, 2015	Aug CFTG
>D>	+		0.5MG	N205422	002	Jul 10, 2015	Aug CFTG
>A> AB	+		0.5MG	N205422	002	Jul 10, 2015	Aug CFTG
>D>	+		1MG	N205422	003	Jul 10, 2015	Aug CFTG
>A> AB	+		1MG	N205422	003	Jul 10, 2015	Aug CFTG
>D>	+		2MG	N205422	004	Jul 10, 2015	Aug CFTG
>A> AB	+		2MG	N205422	004	Jul 10, 2015	Aug CFTG
>D>	+		3MG	N205422	005	Jul 10, 2015	Aug CFTG
>A> AB	+		3MG	N205422	005	Jul 10, 2015	Aug CFTG
>D>	+		4MG	N205422	006	Jul 10, 2015	Aug CFTG
>A> AB	+		4MG	N205422	006	Jul 10, 2015	Aug CFTG

BRIMONIDINE TARTRATE

GEL;TOPICAL

	BRIMONIDINE TARTRATE						
@	PADAGIS ISRAEL	EQ 0.33% BASE		A209158	001	Sep 23, 2021	Apr DISC
MIRVASO							
+!	GALDERMA LABS LP	EQ 0.33% BASE		N204708	001	Aug 23, 2013	Apr CTEC
SOLUTION/DROPS;OPHTHALMIC							
BRIMONIDINE TARTRATE							
AT	APOTEX	0.15%		A078479	001	Jan 31, 2022	Jan NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

	BRIMONIDINE TARTRATE AND TIMOLOL MALEATE						
AB	APOTEX INC	0.2%;EQ 0.5% BASE		A091442	001	Apr 20, 2022	Apr NEWA
AB	SANDOZ INC	0.2%;EQ 0.5% BASE		A091087	001	Apr 04, 2022	Mar NFTG
COMBIGAN							
+!	ALLERGAN	0.2%;EQ 0.5% BASE		N021398	001	Oct 30, 2007	Mar CFTG

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

	BRINZOLAMIDE						
AB	BAUSCH AND LOMB	1%		A204884	001	Aug 18, 2021	Mar CAHN

BRIVARACETAM

TABLET;ORAL

>D>	BRIVARACETAM						
>D> AB	SUNSHINE	10MG		A214748	001	Jun 09, 2022	Aug DISC
>A>	@	10MG		A214748	001	Jun 09, 2022	Aug DISC
AB		10MG		A214748	001	Jun 09, 2022	Jun NFTG
>D> AB		25MG		A214748	002	Jun 09, 2022	Aug DISC
>A>	@	25MG		A214748	002	Jun 09, 2022	Aug DISC
AB		25MG		A214748	002	Jun 09, 2022	Jun NFTG
>D> AB		50MG		A214748	003	Jun 09, 2022	Aug DISC
>A>	@	50MG		A214748	003	Jun 09, 2022	Aug DISC
AB		50MG		A214748	003	Jun 09, 2022	Jun NFTG
>D> AB		75MG		A214748	004	Jun 09, 2022	Aug DISC
>A>	@	75MG		A214748	004	Jun 09, 2022	Aug DISC
AB		75MG		A214748	004	Jun 09, 2022	Jun NFTG
>D> AB		100MG		A214748	005	Jun 09, 2022	Aug DISC
>A>	@	100MG		A214748	005	Jun 09, 2022	Aug DISC
AB		100MG		A214748	005	Jun 09, 2022	Jun NFTG
	BRIVIACT						
>D> AB	+ UCB INC	10MG		N205836	001	May 12, 2016	Aug CTEC
>A>	+	10MG		N205836	001	May 12, 2016	Aug CTEC
AB	+	10MG		N205836	001	May 12, 2016	Jun CFTG
>D> AB	+	25MG		N205836	002	May 12, 2016	Aug CTEC
>A>	+	25MG		N205836	002	May 12, 2016	Aug CTEC
AB	+	25MG		N205836	002	May 12, 2016	Jun CFTG
>D> AB	+	50MG		N205836	003	May 12, 2016	Aug CTEC
>A>	+	50MG		N205836	003	May 12, 2016	Aug CTEC
AB	+	50MG		N205836	003	May 12, 2016	Jun CFTG
>D> AB	+	75MG		N205836	004	May 12, 2016	Aug CTEC
>A>	+	75MG		N205836	004	May 12, 2016	Aug CTEC
AB	+	75MG		N205836	004	May 12, 2016	Jun CFTG
>D> AB	+!	100MG		N205836	005	May 12, 2016	Aug CTEC
>A>	+!	100MG		N205836	005	May 12, 2016	Aug CTEC
AB	+!	100MG		N205836	005	May 12, 2016	Jun CFTG

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

	BROMFENAC SODIUM						
@	CHARTWELL RX	EQ 0.09% ACID		A201941	001	Feb 10, 2015	Apr CAHN
AT2	EUGIA PHARMA	EQ 0.09% ACID		A204813	001	Mar 18, 2022	Mar NEWA
@	VISTAPHARM	EQ 0.09% ACID		A201941	001	Feb 10, 2015	Feb CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML		A202955	001	Nov 05, 2020	Jun DISC
-----------------	---------------------------	--	---------	-----	--------------	----------

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

@ NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
@ SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Jul DISC
ORTIKOS					
+ SUN PHARM INDNS INC	6MG	N211929	001	Jun 13, 2019	Jul CDFR
+!	9MG	N211929	002	Jun 13, 2019	Jul CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BREYNA

AB	MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Jul CTNA
AB		0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
AB		0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Jul CTNA
AB		0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG
	SYMBICORT					
AB	+! ASTRazeneca	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
AB	+!	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
AP	GLAND PHARMA LTD	0.25MG/ML	A216434	001	May 26, 2022	May NEWA
AP	MSN	0.25MG/ML	A215364	001	Aug 04, 2022	Jul NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

+! DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CMFD
+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

@ CIVICA	0.5%	A211096	001	Feb 19, 2019	Apr CAHN
@ NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
@ STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
@	0.5%	A091503	002	Oct 18, 2011	Feb CAHN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE		A091487	002	Oct 18, 2011	Feb CAHN
@ STERISCIENCE	0.25%	A091487	001	Oct 18, 2011	Feb CAHN
@	0.5%	A091487	003	Oct 18, 2011	Feb CAHN
@	0.75%				

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

ZYNRELEF KIT

+ @ HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML	N211988	001	May 12, 2021	Apr DISC
+ @	300MG/10.5ML (29.25MG/ML);9MG/10.5ML	N211988	003	May 12, 2021	Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB	ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	May CAHN
AB		10MCG/HR	A207490	002	May 17, 2022	May CAHN
AB		15MCG/HR	A207490	003	May 17, 2022	May CAHN
AB		20MCG/HR	A207490	004	May 17, 2022	May CAHN
AB	ALVOGEN PINE BROOK	5MCG/HR	A207490	001	May 17, 2022	May NEWA
AB		10MCG/HR	A207490	002	May 17, 2022	May NEWA
AB		15MCG/HR	A207490	003	May 17, 2022	May NEWA
AB		20MCG/HR	A207490	004	May 17, 2022	May NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

+ BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
+	EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
+	EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
+	EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC

FILM;BUCCAL
BELBUCA

+	EQ 0.6MG BASE	N 207932	005	Oct 23, 2015	Jan CTEC
+	EQ 0.75MG BASE	N 207932	006	Oct 23, 2015	Jan CTEC
+!	EQ 0.9MG BASE	N 207932	007	Oct 23, 2015	Jan CTEC
BUPRENORPHINE HYDROCHLORIDE					
@ ALVOGEN	EQ 0.075MG BASE	A 211594	001	Aug 03, 2021	Jan DISC
@	EQ 0.15MG BASE	A 211594	002	Aug 03, 2021	Jan DISC
@	EQ 0.3MG BASE	A 211594	003	Aug 03, 2021	Jan DISC
@	EQ 0.45MG BASE	A 211594	004	Aug 03, 2021	Jan DISC
@	EQ 0.6MG BASE	A 211594	005	Aug 03, 2021	Jan DISC
@	EQ 0.75MG BASE	A 211594	006	Aug 03, 2021	Jan DISC
@	EQ 0.9MG BASE	A 211594	007	Aug 03, 2021	Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AVEVA	EQ 8MG BASE;EQ 2MG BASE	A 212756	001	Jun 02, 2022	May NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A 212756	002	Jun 02, 2022	May NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	@ GRANULES	150MG	A 215568	001	Feb 02, 2022	Jul DISC
	@	300MG	A 215568	001	Feb 02, 2022	Jan NEWA
AB3		300MG	A 215568	002	Feb 02, 2022	Jul DISC
AB3	WOCKHARDT LTD	300MG	A 215568	002	Feb 02, 2022	Jan NEWA

A 202189 002 Jan 28, 2022 Feb NEWA

>A> BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

>A> TABLET, EXTENDED RELEASE;ORAL

>A> AUVELITY

>A> +! AXSOME 105MG;45MG N 215430 001 Aug 18, 2022 Aug NEWA

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	! ACCORD HLTHCARE	15MG	A 202557	004	Dec 30, 2014	Feb CHRS
	@ MYLAN	7.5MG	A 075467	002	Mar 28, 2001	Feb DISC
AB	TEVA	15MG	A 075022	003	Feb 28, 2002	Feb CHRS

BUSULFAN

TABLET;ORAL

MYLERAN

+! WOODWARD SPECL 2MG N 009386 001 Apr CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

AP	+ @ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N 207949	001	Dec 29, 2021	Jul DISC
	@ BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A 207619	001	Jun 23, 2022	Jul DISC
		60MG/1.5ML (40MG/ML)	A 207619	001	Jun 23, 2022	Jun NFTG
JEVTONA KIT						
AP	+! SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N 201023	001	Jun 17, 2010	Jul CTEC
AP	+!	60MG/1.5ML (40MG/ML)	N 201023	001	Jun 17, 2010	Jun CFTG

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB	STRIDES PHARMA	0.5MG	A 076310	001	Dec 29, 2005	Mar CMFD
----	----------------	-------	----------	-----	--------------	----------

CAFFEINE CITRATE

SOLUTION;ORAL

CAFACIT

AA	+ @ HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N 020793	002	Apr 12, 2000	Jan DISC
AA	CAFFEINE CITRATE					

AA	! EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 077304	001	Sep 21, 2006	Jan CHRS
----	----------------	------------------------------------	----------	-----	--------------	----------

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

+! COSETTE

100MG;2MG

A086557 001 Oct 04, 1983 Jul CRLD

CALCITONIN SALMON

SPRAY, METERED;NASAL

CALCITONIN-SALMON

! APOTEX INC

200 IU/SPRAY

A076396 001 Nov 17, 2008 Jul CTEC

@ PAR PHARM

200 IU/SPRAY

A076979 001 Jun 08, 2009 Jul DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

AP FRESENIUS KABI USA 20MG/100ML;5GM/100ML;30MG/100ML;60 0MG/100ML;310MG/100ML A210332 001 Mar 28, 2022 Mar NEWA
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 @ FRESENIUS KABI USA 20MG/100ML;5GM/100ML;179MG/100ML;6 00MG/100ML;310MG/100ML A211428 001 Nov 09, 2021 Apr DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

>D> AT AKORN 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG /ML;6.4MG/ML;1.7MG/ML A075503 001 Sep 27, 2006 Aug DISC
 >A> @ 0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG /ML;6.4MG/ML;1.7MG/ML A075503 001 Sep 27, 2006 Aug DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

>D> AT FRESENIUS KABI USA 17.6MG/100ML;325.3MG/100ML;119.3MG /100ML;643MG/100ML A214623 001 Feb 18, 2022 Aug DISC
 >A> @ 17.6MG/100ML;325.3MG/100ML;119.3MG /100ML;643MG/100ML A214623 001 Feb 18, 2022 Aug DISC
 AT 17.6MG/100ML;325.3MG/100ML;119.3MG /100ML;643MG/100ML A214623 001 Feb 18, 2022 Feb NEWA

CAPTOPRIL

TABLET;ORAL

Captopril

AB ATLANTIDE 12.5MG A074532 001 Mar 28, 1997 Mar CAHN
 AB 25MG A074532 002 Mar 28, 1997 Mar CAHN
 AB 50MG A074532 003 Mar 28, 1997 Mar CAHN
 AB 100MG A074532 004 Mar 28, 1997 Mar CAHN

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

>A> AB UNICHEM 200MG A213284 001 Aug 22, 2022 Aug NEWA
 @ VGYAAN 200MG A214328 001 Aug 16, 2021 Feb DISC

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

>D> AB ! TARO PHARM INDS 100MG A075687 001 Oct 24, 2000 Aug CHRS
 >A> AB 100MG A075687 001 Oct 24, 2000 Aug CHRS

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

>A> AB UMEDICA LABS PVT LTD 100MG A216594 001 Aug 18, 2022 Aug NEWA
 >A> AB 200MG A216594 002 Aug 18, 2022 Aug NEWA
 >A> AB 400MG A216594 003 Aug 18, 2022 Aug NEWA
 AB ZHEJIANG JIUZHOU 100MG A215591 001 Mar 31, 2022 Mar NEWA
 AB 200MG A215591 002 Mar 31, 2022 Mar NEWA
 AB 400MG A215591 003 Mar 31, 2022 Mar NEWA

CARBIDOPA

TABLET;ORAL

CARBIDOPA

@ ANI PHARMS

25MG

A203261 001 Mar 10, 2014 Jun DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	RISING	12.5MG;200MG;50MG	A213212	001	Jan 25, 2022	Jan NEWA
AB		18.75MG;200MG;75MG	A213212	002	Jan 25, 2022	Jan NEWA
AB		25MG;200MG;100MG	A213212	003	Jan 25, 2022	Jan NEWA
AB		31.25MG;200MG;125MG	A213212	004	Jan 25, 2022	Jan NEWA
AB		37.5MG;200MG;150MG	A213212	005	Jan 25, 2022	Jan NEWA
AB		50MG;200MG;200MG	A213212	006	Jan 25, 2022	Jan NEWA
	STALEVO 125					
AB	+ ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Jan CTEC
	STALEVO 200					
AB	+! ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Jan CTEC
	STALEVO 50					
AB	+! ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Jan CTEC
	STALEVO 75					
AB	+ ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Jan CTEC

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP	TEYRO LABS	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Apr CAHN
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Apr CAHN
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Apr CAHN
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Apr CAHN

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

AP	AMNEAL	EQ 0.25MG BASE/ML	A215337	001	Jan 27, 2022	Jan NEWA
AP	LONG GROVE PHARMS	EQ 0.25MG BASE/ML	A214499	001	Aug 09, 2022	Jul NEWA

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARGLUMIC ACID

AB	NAVINTA LLC	200MG	A213395	001	Jun 22, 2022	Jun NEWA
----	-------------	-------	---------	-----	--------------	----------

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	WANBANG BIOPHARMS	350MG	A081025	001	Apr 13, 1989	Jun CAHN
----	-------------------	-------	---------	-----	--------------	----------

CARMUSTINEIMPLANT; INTRACRANIAL
GLIADEL

+! AZURITY 7.7MG

N020637 001 Sep 23, 1996 Jun CAHN

INJECTABLE; INJECTION
CARMUSTINE

AP	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Jun NEWA
	POWDER; INTRAVENOUS					
	CARMUSTINE					
+!	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May NEWA
+!		300MG/VIAL	N215000	002	May 16, 2022	May NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET;ORAL

CEFADROXIL

AB	! TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987	Mar CTEC
----	---------------	-------------	---------	-----	--------------	----------

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM
QILIU

EQ 2GM BASE/VIAL A203661 002 Mar 11, 2022 Mar NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jan CMFD
AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jan CMFD

CEFIXIME

CAPSULE;ORAL						
CEFIXIME						
>D>	! ALKEM LABS LTD	400MG	A210574	001	Oct 09, 2018	Aug CTEC
>A> AB		400MG	A210574	001	Oct 09, 2018	Aug CTEC
	SUPRAX					
>D>	+ @ LUPIN LTD	400MG	N203195	001	Jun 01, 2012	Aug CMFD
>A> AB	+!	400MG	N203195	001	Jun 01, 2012	Aug CMFD

CEFOTETAN DISODIUM

INJECTABLE;INJECTION						
CEFOTAN IN PLASTIC CONTAINER						
@ PAI HOLDINGS PHARM	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN	
@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN	
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER					
+ @ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jul DISC	
+ @	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jul DISC	

CEFPODOXIME PROXETIL

TABLET;ORAL						
CEFPODOXIME PROXETIL						
AB ALKEM LABS LTD	EQ 100MG BASE	A210568	001	May 18, 2022	May NEWA	
AB	EQ 200MG BASE	A210568	002	May 18, 2022	May NEWA	

CEFPROZIL

FOR SUSPENSION;ORAL						
CEFPROZIL						
@ CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005	Mar CAHN	
@	250MG/5ML	A065236	002	Dec 08, 2005	Mar CAHN	

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS						
CEFTAROLINE FOSAMIL						
@ APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC	
@	600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC	
TEFLARO						
+! ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC	
+!	600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC	

CEFTAZIDIME

INJECTABLE;INJECTION						
CEFTAZIDIME IN DEXTROSE CONTAINER						
+ @ B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jul DISC	
+ @	EQ 2GM BASE	N050823	002	Jun 13, 2011	Jul DISC	

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION						
CEFTRIAXONE						
AP ATLANTIDE	EQ 1GM BASE/VIAL	A065180	001	May 12, 2006	Apr CAHN	
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS						
CEFTRIAXONE						
AP ATLANTIDE	EQ 250MG BASE/VIAL	A065391	001	Apr 12, 2007	Apr CAHN	
AP	EQ 500MG BASE/VIAL	A065391	002	Apr 12, 2007	Apr CAHN	
AP	EQ 2GM BASE/VIAL	A065391	003	Apr 12, 2007	Apr CAHN	

CEFUROXIME AXETIL

TABLET;ORAL						
CEFUROXIME AXETIL						
AB ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN	
AB	EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN	
AB	EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN	

CEFUROXIME SODIUM

INJECTABLE;INJECTION						
ZINACEF						
AP +! PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN	
AP +!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN	
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS						
ZINACEF						
AB +! PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN	

CELECOXIB

CAPSULE;ORAL					
CELECOXIB					
@ UNICHEM	50MG		A213301	001	Jan 12, 2021
@	100MG		A213301	002	Jan 12, 2021
@	200MG		A213301	003	Jan 12, 2021
@	400MG		A213301	004	Jan 12, 2021

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL					
CETIRIZINE HYDROCHLORIDE					
@ ATLANTIDE	5MG/5ML		A078757	001	Aug 28, 2009
AA BAJAJ	5MG/5ML		A090191	001	Nov 12, 2009
@ TORRENT	5MG/5ML		A078870	001	Apr 27, 2009
AA	5MG/5ML		A078870	001	Apr 27, 2009

>D> CETRORELIIX

>D>	INJECTABLE; INJECTION				
>D>	CETROTIDE				
>D>	+! EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000
>D>	@	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000

CETRORELIIX ACETATE

POWDER;SUBCUTANEOUS					
>A> CETRORELIIX ACETATE					
>A> AP AKORN	EQ 0.25MG BASE/VIAL		A215737	001	Aug 12, 2022
>A> CETROTIDE					
>A> AP +! EMD SERONO INC	EQ 0.25MG BASE/VIAL		N021197	001	Aug 11, 2000
>A> + @	EQ 3MG BASE/VIAL		N021197	002	Aug 11, 2000

CHLORAMBUCIL

TABLET;ORAL					
LEUKERAN					
+! WOODWARD SPECL	2MG		N010669	002	

Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL					
CHLORDIAZEPOXIDE HYDROCHLORIDE					
>D> AB BARR	25MG		A084769	001	Aug CHRS
>A> AB !	25MG		A084769	001	Aug CHRS
AB CHARTWELL RX	5MG		A084678	001	Jul CMFD
AB	10MG		A084041	001	Jul CMFD
AB	25MG		A084679	002	Jul CMFD
LIBRIUM					
>D> AB +! BAUSCH	25MG		A085475	001	Aug CHRS
>A> AB +	25MG		A085475	001	Aug CHRS
AB +!	25MG		A085475	001	Jul CAHN
AB + VALEANT PHARM INTL	5MG		A085461	001	Jan CRLD
AB +	10MG		A085472	001	Jan CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL					
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE					
AB CHARTWELL RX	5MG;2.5MG		A213530	001	Oct 20, 2020
AB COREPHARMA	5MG;2.5MG		A215453	001	Jul 29, 2022
AB MICRO LABS	5MG;2.5MG		A215835	001	Jul 19, 2022
@ TEVA PHARMS USA	5MG;2.5MG		A211476	001	Nov 02, 2021

Jun CAHN
Jul NEWA
Jul NEWA
Jun DISCCHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL					
CHLORHEXIDINE GLUCONATE					
@ AKORN	0.12%		A074356	001	May 07, 1996
PERIOGARD					
@ COLGATE PALMOLIVE CO	0.12%		A073695	001	Jan 14, 1994
TABLET;DENTAL					
>D> PERIOCHIP					
>D> +! DEXCEL PHARMA	2.5MG		N020774	001	May 15, 1998
>A> + @	2.5MG		N020774	001	May 15, 1998

Jul DISC
Aug DISC
Aug DISC

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

+! TRIS PHARMA INC EQ 2.8MG BASE/5ML;EQ 14.7MG
BASE/5ML N207768 001 Apr 30, 2015 Jun CAHN

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL
TUSSICAPS

@ ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A 077273	002	Sep 24, 2007	Feb DISC
@	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A 077273	001	Sep 24, 2007	Feb DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ APPCO	10MG	A 213590	001	Aug 31, 2020	Mar CAHN
@	25MG	A 213590	002	Aug 31, 2020	Mar CAHN
@	50MG	A 213590	003	Aug 31, 2020	Mar CAHN
@	100MG	A 213590	004	Aug 31, 2020	Mar CAHN
@	200MG	A 213590	005	Aug 31, 2020	Mar CAHN
AB MSN	25MG	A 214827	001	Jan 27, 2022	Jan NEWA
AB	50MG	A 214827	002	Jan 27, 2022	Jan NEWA
AB	100MG	A 214827	003	Jan 27, 2022	Jan NEWA
AB	200MG	A 214827	004	Jan 27, 2022	Jan NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

>A> AB ALEMBIC PHARMS LTD	25MG	A 216262	001	Aug 26, 2022	Aug NEWA
>A> AB	50MG	A 216262	002	Aug 26, 2022	Aug NEWA
AB CHARTWELL RX	25MG	A 211063	001	Feb 26, 2019	Jan CAHN
AB	50MG	A 211063	002	Feb 26, 2019	Jan CAHN
AB INVENTIA	25MG	A 211320	001	Feb 09, 2022	Jan NEWA
AB	50MG	A 211320	002	Feb 09, 2022	Jan NEWA
AB MANKIND PHARMA	25MG	A 215587	001	Aug 04, 2022	Jul NEWA
AB	50MG	A 215587	002	Aug 04, 2022	Jul NEWA
@ SUNNY	25MG	A 209068	001	Jan 25, 2022	May DISC
AB	25MG	A 209068	001	Jan 25, 2022	Jan NEWA
@	50MG	A 209068	002	Jan 25, 2022	May DISC
AB	50MG	A 209068	002	Jan 25, 2022	Jan NEWA
AB TAGI	25MG	A 212878	001	Feb 24, 2022	Feb NEWA
AB	50MG	A 212875	001	Feb 24, 2022	Feb NEWA
>D> BX UMEDICA LABS PVT LTD	25MG	A 207222	001	May 24, 2018	Aug CTEC
>A> AB	25MG	A 207222	001	May 24, 2018	Aug CTEC
>D> BX	50MG	A 207222	002	May 24, 2018	Aug CTEC
>A> AB	50MG	A 207222	002	May 24, 2018	Aug CTEC

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AB RISING	375MG	A 213126	001	Apr 05, 2022	Mar NEWA
AB	500MG	A 213126	002	Apr 05, 2022	Mar NEWA
AB	750MG	A 213126	003	Apr 05, 2022	Mar NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB @ UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A 214877	001	Jan 21, 2022	Mar DISC
AB	EQ 4GM RESIN/PACKET	A 214877	001	Jan 21, 2022	Jan NEWA
@	EQ 4GM RESIN/SCOOPFUL	A 214877	002	Jan 21, 2022	Mar DISC
AB	EQ 4GM RESIN/SCOOPFUL	A 214877	002	Jan 21, 2022	Jan NEWA

CICLOPIROX

GEL;TOPICAL

CICLOPIROX

>D> AB +! ALVOGEN	0.77%	N 020519	001	Jul 21, 1997	Aug DISC
>A> + @	0.77%	N 020519	001	Jul 21, 1997	Aug DISC
>D> AB GLENMARK GENERICS	0.77%	A 091595	001	Feb 29, 2012	Aug CHRS
>A> AB !	0.77%	A 091595	001	Feb 29, 2012	Aug CHRS

SHAMPOO;TOPICAL
CICLOPIROX

AT	PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Mar CAHN
	SOLUTION;TOPICAL					
	CICLOPIROX					
AT	CHARTWELL RX	8%	A078046	001	Sep 18, 2007	Mar CAHN

CIMETIDINE

TABLET;ORAL						
CIMETIDINE						
@ CHARTWELL RX	200MG	A074100	001	Jan 31, 1995	Jan CAHN	
@	300MG	A074100	002	Jan 31, 1995	Jan CAHN	
@	400MG	A074100	003	Jan 31, 1995	Jan CAHN	
@	800MG	A074100	004	Jan 31, 1995	Jan CAHN	

CINACALCET HYDROCHLORIDE

TABLET;ORAL						
CINACALCET HYDROCHLORIDE						
@ AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb DISC	
@	60MG	A204364	002	Dec 02, 2021	Feb DISC	
@	90MG	A204364	003	Dec 02, 2021	Feb DISC	

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL						
CIPROFLOXACIN HYDROCHLORIDE						
@ AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN	
@	EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN	
@	EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN	

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC						
CIPROFLOXACIN AND DEXAMETHASONE						
>A> AB	SUN PHARM	0.3%;0.1%	A210470	001	Aug 30, 2022	Aug NEWA

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION						
CISATRACURIUM BESYLATE						
AP	HIKMA	EQ 10MG BASE/ML	A203078	001	Jun 28, 2022	Jun NEWA
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	001	May 24, 2022	May NEWA
AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	May NEWA
AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Mar NEWA
AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Mar NEWA
AP	SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL						
CITALOPRAM HYDROBROMIDE						
+! ALMATICHA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Jan NEWA	

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL						
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID						
! HETERO LABS LTD V	12GM/PACKET;3.5GM/PACKET;10MG/PACK	A212789	001	Jul 18, 2022	Jul NFTG	
	ET					

CLARITHROMYCIN

TABLET;ORAL						
CLARITHROMYCIN						
AB	ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan NEWA
AB		500MG	A210459	002	Jan 31, 2022	Jan NEWA

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL						
CLINDAMYCIN PHOSPHATE						
AB2	AMNEAL	EQ 1% BASE	A214668	001	Aug 05, 2022	Jul NEWA
	LOTION;TOPICAL					
	CLINDAMYCIN PHOSPHATE					
AB	ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan NEWA
	SOLUTION;TOPICAL					
	CLINDAMYCIN PHOSPHATE					
AT	PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
AB2	SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb NFTG
	VELTIN					
AB2	+! ALMIRALL ZIANA	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CFTG
AB1	+! BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb CTEC

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

>A> AB	ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Aug NEWA
AB	AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar NEWA
	TABLET;ORAL					
	CLOBAZAM					
AB	MSN	10MG	A213404	001	May 11, 2021	Feb CMFD
AB		20MG	A213404	002	May 11, 2021	Feb CMFD

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A215838	001	Apr 21, 2022	Apr NEWA
	CREAM;TOPICAL					
	CLOBETASOL PROPIONATE					
>A>	@ GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Aug CAHN
>D>	@ PAI HOLDINGS PHARM	0.05%	A211207	001	Mar 26, 2021	Aug CAHN
	GEL;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Mar CAHN
	LOTION;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Mar CAHN
	OINTMENT;TOPICAL					
	CLOBETASOL PROPIONATE					
AB	PAI HOLDINGS PHARM	0.05%	A208589	001	Jan 23, 2019	Mar CAHN
	SOLUTION;TOPICAL					
	CLOBETASOL PROPIONATE					
>D> AT	@ ENCUBE	0.05%	A076977	001	Aug 05, 2005	Jul CAHN
	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Aug DISC
>A>	@	0.05%	A213139	001	Feb 08, 2021	Aug DISC
AT	SOLARIS PHARMA CORP	0.05%	A211240	001	Feb 17, 2022	Feb NEWA
	@ TOLMAR	0.05%	A076977	001	Aug 05, 2005	Feb DISC
	@ WOCKHARDT BIO AG	0.05%	A075205	001	Nov 13, 1998	Jun DISC

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

!	COSETTE	50MG	A075528	001	Aug 30, 1999	Jun CAHN
---	---------	------	---------	-----	--------------	----------

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Feb CMFD
@	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Jan CAHN
@	EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Jan CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988	May CMFD
AB		0.2MG	A070886	001	Aug 31, 1988	May CMFD
AB		0.3MG	A070886	003	Aug 31, 1988	May CMFD
>D>	@ CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Aug CMFD
>A> AB		0.1MG	A071785	002	Apr 05, 1988	Aug CMFD
>D>	@	0.2MG	A071785	003	Apr 05, 1988	Aug CMFD
>A> AB		0.2MG	A071785	003	Apr 05, 1988	Aug CMFD
>D>	@	0.3MG	A071785	001	Apr 05, 1988	Aug CMFD
>A> AB		0.3MG	A071785	001	Apr 05, 1988	Aug CMFD

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	URL LABS	0.1MG	A070923	003	Sep 04, 1987	Apr CAHN
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CAHN
AB		0.3MG	A070923	001	Sep 04, 1987	Apr CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	CLONIDINE HYDROCHLORIDE					
	@ MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Feb DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	DR REDDYS	EQ 75MG BASE	A076273	001	Jan 14, 2008	Apr CAHN
----	-----------	--------------	---------	-----	--------------	----------

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

TRANXENE

>A>	+ @ KEY THERAP	3.75MG	N017105	001	Aug CAHN
>A>	+ @	7.5MG	N017105	002	Aug CAHN
>A>	+ @	15MG	N017105	003	Aug CAHN
>D>	+ @ RECORDATI RARE	3.75MG	N017105	001	Aug CAHN
>D>	+ @	7.5MG	N017105	002	Aug CAHN
>D>	+ @	15MG	N017105	003	Aug CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	COREPHARMA	3.75MG	A215566	001	Jun 14, 2022	Jun NEWA
AB		7.5MG	A215566	002	Jun 14, 2022	Jun NEWA
AB		15MG	A215566	003	Jun 14, 2022	Jun NEWA
AB	NOVITIUM PHARMA	3.75MG	A213730	001	Jun 16, 2022	Jun NEWA
AB		7.5MG	A213730	002	Jun 16, 2022	Jun NEWA

TRANXENE

>A>	+ @ KEY THERAP	3.75MG	N017105	006	Aug CAHN	
>A> AB	+ @	7.5MG	N017105	007	Aug CAHN	
>A>	+ @	15MG	N017105	008	Aug CAHN	
>D>	+ @ RECORDATI RARE	3.75MG	N017105	006	Aug CAHN	
>D> AB	+ @	7.5MG	N017105	007	Aug CAHN	
>D>	+ @	15MG	N017105	008	Aug CAHN	
	TRANXENE SD					
>A>	+ @ KEY THERAP	11.25MG	N017105	005	Aug CAHN	
>A>	+ @	22.5MG	N017105	004	Aug CAHN	
>D>	+ @ RECORDATI RARE	11.25MG	N017105	005	Aug CAHN	
>D>	+ @	22.5MG	N017105	004	Aug CAHN	

COLCHICINE

SOLUTION;ORAL

GLOPERBA

+! SCILEX PHARMS

0.6MG/5ML

N210942 001 Jan 30, 2019 Jun CAHN

TABLET;ORAL

COLCHICINE

@ PAR PHARM INC

0.6MG

A203976 001 Aug 12, 2021 Feb DISC

AB	STRIDES PHARMA	0.6MG	A209173	001	Mar 10, 2022	Mar NEWA
----	----------------	-------	---------	-----	--------------	----------

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ LUPIN LTD

625MG

A201354 001 Dec 17, 2020 May DISC

AB	SPH	625MG	A213456	001	Jan 21, 2022	Jan NEWA
----	-----	-------	---------	-----	--------------	----------

COlestipol Hydrochloride

TABLET;ORAL

COlestid

AB	+ PFIZER	1GM	N020222	001	Jul 19, 1994	Apr CHRS
	COlestipol HYDROCHLORIDE					
AB	! IMPAX LABS	1GM	A077510	001	Oct 24, 2006	Apr CHRS
AB	ZYDUS PHARMS	1GM	A215223	001	Mar 10, 2022	Feb NEWA

CROMOLYN SODIUM

SOLUTION; INHALATION					
CROMOLYN SODIUM					
@ BAUSCH	10MG/ML	A075585	001	Dec 21, 2000	Jun CAHN
AN FERRA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar CMFD
AN MICRO LABS	10MG/ML	A213658	001	Apr 29, 2022	Apr NEWA

CUPRIC SULFATE

INJECTABLE; INJECTION					
CUPRIC SULFATE					
+ @ ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987	Apr DISC

CYANOCOBALAMIN

INJECTABLE; INJECTION					
CYANOCOBALAMIN					
AP WELDING	1MG/ML	A215417	001	Apr 15, 2022	Apr NEWA
AP ZYDUS PHARMS	1MG/ML	A214655	001	Apr 15, 2022	Apr NEWA
AP DODEX					
AP ACCORD HLTHCARE	1MG/ML	A083022	001		May CTEC
	1MG/ML	A083022	001		Apr CMFD

CYCLOPHOSPHAMIDE

CAPSULE; ORAL					
CYCLOPHOSPHAMIDE					
@ ANI PHARMS	25MG	A207014	001	Mar 19, 2018	May DISC
@	50MG	A207014	002	Mar 19, 2018	Apr DISC

CYCLOSPORINE

CAPSULE; ORAL					
CYCLOSPORINE					
AB1 STRIDES PHARMA	25MG	A216046	001	Aug 02, 2022	Jul NEWA
AB1	50MG	A216046	002	Aug 02, 2022	Jul NEWA
AB1	100MG	A216046	003	Aug 02, 2022	Jul NEWA
EMULSION; OPHTHALMIC					
CYCLOSPORINE					
AB MYLAN RESTASIS	0.05%	A205894	001	Feb 02, 2022	Jan NFTG
AB +! ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan CFTG
SOLUTION; ORAL					
CYCLOSPORINE					
@ MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL					
CYPROHEPTADINE HYDROCHLORIDE					
AA CHARTWELL MOLECULAR	2MG/5ML	A203191	001	Jul 13, 2017	Jun CAHN
@ TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021	Apr DISC

CYSTEAMINE BITARTRATE

GRANULE, DELAYED RELEASE; ORAL					
PROCYSB					
+ HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May CAHN
+!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS					
CYSTEINE HYDROCHLORIDE					
AP DR REDDYS LABS SA	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun CAHN
AP ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr NFTG
AP ELCYS					
AP +! EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr CFTG

CYTARABINE

INJECTABLE; INJECTION					
CYTARABINE					
AP HONG KONG	20MG/ML	A208485	001	Feb 28, 2022	Feb NEWA
@ MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020	Jun CAHN

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

>D>	AB	ALKEM LABS LTD	EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug CMFD
>A>	AB		EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug CMFD

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

DALFAMPRIDINE

@ HIKMA 10MG

A206646 001 Oct 24, 2018 May DISC

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

+ PFIZER 10,000IU/4ML (2,500IU/ML)

N020287 012 Mar 15, 2022 Mar NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION

DANTROLENE SODIUM

@ EUGIA PHARMA SPECLETS 20MG/VIAL

A205239 001 Feb 18, 2016 Mar CAHN

DAPAGLIFLOZIN

TABLET;ORAL

DAPAGLIFLOZIN

AB	@ ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Jul DISC
	@	5MG	A211582	001	Feb 22, 2022	Feb NFTG
AB		10MG	A211582	002	Feb 22, 2022	Jul DISC
		10MG	A211582	002	Feb 22, 2022	Feb NFTG
	FARXIGA					
AB	+ ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Jul CTEC
AB	+	5MG	N202293	001	Jan 08, 2014	Feb CFTG
	+!	10MG	N202293	002	Jan 08, 2014	Jul CTEC
AB	+!	10MG	N202293	002	Jan 08, 2014	Feb CFTG

DAPSONE

GEL;TOPICAL

DAPSONE

AB	MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan NEWA
AB	SEEGPHARM SA	5%	A210178	001	Mar 31, 2022	Mar NEWA
AB	TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb NEWA
	TABLET;ORAL					
	DAPSONE					
AB	@ VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Jan DISC
	@	100MG	A204074	002	May 10, 2016	Jan DISC

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

>A>	AP	HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Aug NEWA
		DAPZURA RT					
		+! BAXTER HLTHCARE CORP	500MG/VIAL	N213645	001	Jan 25, 2022	Jan NEWA

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL

QUVIVIQ

+ IDORSIA

+!

EQ 25MG BASE

EQ 50MG BASE

N214985 001 Apr 07, 2022

Apr NEWA

N214985 002 Apr 07, 2022

Apr NEWA

DASATINIB

TABLET;ORAL

DASATINIB

@ APOTEX

@

80MG

140MG

A203180 001 Nov 23, 2021

May DISC

A203180 002 Nov 23, 2021

May DISC

SPRYCEL

+ BRISTOL MYERS SQUIBB

+ 80MG

140MG

N021986 005 Oct 28, 2010

May CTEC

N021986 006 Oct 28, 2010

May CTEC

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

>D>	AP	INGENUS PHARMS LLC	50MG/VIAL	A210984	001	Sep 16, 2019	Aug CAHN
	AP	JIANGSU HANSOH PHARM	50MG/VIAL	A213472	001	Apr 15, 2022	Apr NEWA
>A>	AP	NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Aug CAHN

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

@	AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar DISC
@		180MG	A214194	001	Feb 09, 2021	Jul DISC
@		360MG	A214194	002	Feb 09, 2021	Jul DISC
AB	CIPLA	90MG	A215026	001	Feb 23, 2022	Feb NEWA
AB		180MG	A215026	002	Feb 23, 2022	Feb NEWA
AB		360MG	A215026	003	Feb 23, 2022	Feb NEWA
AB	MSN	90MG	A214650	003	Apr 20, 2022	Apr NEWA
>D>	@ TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Aug CMFD
>A>	AB	90MG	A214180	001	Nov 19, 2021	Aug CMFD
	@	90MG	A214180	001	Nov 19, 2021	Jun DISC
>D>	@	180MG	A214180	002	Nov 19, 2021	Aug CMFD
>A>	AB	180MG	A214180	002	Nov 19, 2021	Aug CMFD
	@	180MG	A214180	002	Nov 19, 2021	Jun DISC
>D>	@	360MG	A214180	003	Nov 19, 2021	Aug CMFD
>A>	AB	360MG	A214180	003	Nov 19, 2021	Aug CMFD
	@	360MG	A214180	003	Nov 19, 2021	Jun DISC

TABLET; ORAL

DEFERASIROX

@	AMNEAL	180MG	A210727	003	Jun 15, 2020	Apr DISC
---	--------	-------	---------	-----	--------------	----------

DEFERIPRONE

TABLET; ORAL

DEFERIPRONE

AB	HIKMA	1GM	A213239	002	Feb 08, 2022	Jan NFTG
AB	+ CHIESI	1GM	N021825	002	Jul 25, 2019	Jan CFTG

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

>A>	AP	DR REDDYS	0.004MG/ML	A215961	001	Aug 19, 2022	Aug NEWA
		SPRAY, METERED; NASAL					
		DESMOPRESSIN ACETATE					

AB	! BAUSCH	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Jun CAHN
----	----------	--------------	---------	-----	--------------	----------

DESOGESTREL; ETHINYLEDRASTROL

TABLET; ORAL-28

DESOGESTREL AND ETHINYLEDRASTROL

@	MAYNE PHARMA	0.15MG, N/A; 0.02MG, 0.01MG	A076916	001	Dec 29, 2008	Jan DISC
@		0.1MG, 0.125MG, 0.15MG; 0.025MG, 0.025MG	A077182	001	Jan 24, 2006	Jan DISC

MG, 0.025MG

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar CAHN
----	--------------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+	@ SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CAHN
+	@	EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022	Apr NEWA
----	-----------	--------------	---------	-----	--------------	----------

DEXAMETHASONE

SOLUTION;ORAL

DEXAMETHASONE

+! HIKMA 0.5MG/5ML

A088248 001 Sep 01, 1983 Mar CRLD

TABLET;ORAL

DEXAMETHASONE

BP	+	HIKMA	0.5MG	A084611 001 Jan CRLD
AB		NOVITIUM PHARMA	1.5MG	A215604 001 Aug 08, 2022 Jul NEWA
AB			4MG	A215604 002 Aug 08, 2022 Jul NEWA
AB			6MG	A215604 003 Aug 08, 2022 Jul NEWA
AB		PRASCO	4MG	A080399 002 Apr 20, 2022 Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP +! FRESENIUS KABI USA EQ 4MG PHOSPHATE/ML

A084916 001 Feb CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT +! IMPRIMIS PHARMS USA 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N050023 002 Jun CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB PADAGIS US 0.1%;0.3%

A212715 001 Feb 11, 2022 Feb NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA +! PAI HOLDINGS PHARM 2MG/5ML

A088251 001 Mar 23, 1984 Apr CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB + TAKEDA PHARMS USA 30MG

N022287 001 Jan 30, 2009 Jun CFTG

AB PAR PHARM INC 30MG

A202294 002 Jun 16, 2022 Jun NFTG

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

+! BIOXCEL EQ 0.12MG BASE

N215390 001 Apr 05, 2022 Apr NEWA

+! EQ 0.18MG BASE

N215390 002 Apr 05, 2022 Apr NEWA

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP MEITHEAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)

A204843 001 Jan 18, 2019 Apr CAHN

@ PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)

A214794 001 Sep 03, 2021 Feb DISC

DEXTROAMPHETAMINE

SYSTEM;TRANSDERMAL

XELSTRYM

+ NOVEN PHARMS INC 4.5MG/9HR

N215401 001 Mar 22, 2022 Mar NEWA

+ 9MG/9HR

N215401 002 Mar 22, 2022 Mar NEWA

+ 13.5MG/9HR

N215401 003 Mar 22, 2022 Mar NEWA

+! 18MG/9HR

N215401 004 Mar 22, 2022 Mar NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

@ MAYNE PHARMA 5MG

A076137 001 Jan 18, 2002 Feb DISC

@ 10MG

A076137 002 Jan 18, 2002 Feb DISC

@ 15MG

A076137 003 Jan 18, 2002 Feb DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

ARBOR PHARMS LLC 2.5MG

A090533 001 Oct 25, 2011 Jan CTEC

7.5MG

A090533 003 Oct 25, 2011 Jan CTEC

15MG

A090533 005 Oct 25, 2011 Jan CTEC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

>A> AA	TRIS PHARMA INC	20MG 30MG	A090533 006 Oct 25, 2011	Jan CTEC
>A> AA		5MG	A090533 007 Oct 25, 2011	Jan CTEC
		10MG	A206095 001 Aug 18, 2022	Aug NEWA
	@ WINDER LABS LLC	2.5MG	A206095 002 Aug 18, 2022	Aug NEWA
	@	5MG	A212160 001 Jun 07, 2021	Jan DISC
	@	7.5MG	A212160 002 Jun 07, 2021	Jan DISC
	@	10MG	A212160 003 Jun 07, 2021	Jan DISC
	@	15MG	A212160 004 Jun 07, 2021	Jan DISC
	@	20MG	A212160 005 Jun 07, 2021	Jan DISC
	@	30MG	A212160 006 Jun 07, 2021	Jan DISC
			A212160 007 Jun 07, 2021	Jan DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

AA	GUARDIAN DRUG	66%;10%	A214201 001 Jun 27, 2022	Jun NEWA
----	---------------	---------	--------------------------	----------

DIAZEPAM

CONCENTRATE;ORAL

DIAZEPAM

>D>	@ CHARTWELL MOLECULAR	5MG/ML	A204433 001 Apr 14, 2014	Aug CMFD
>A> AA		5MG/ML	A204433 001 Apr 14, 2014	Aug CMFD
	@	5MG/ML	A204433 001 Apr 14, 2014	Jun CAHN
	DIAZEPAM INTENSOL			
>D>	! HIKMA	5MG/ML	A071415 001 Apr 03, 1987	Aug CTEC
>A> AA	!	5MG/ML	A071415 001 Apr 03, 1987	Aug CTEC
	GEL;RECTAL			
	DIASTAT			
	+! BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648 001 Jul 29, 1997	May CHRS
	DIASTAT ACUDIAL			
	+! BAUSCH	10MG/2ML (5MG/ML)	N020648 007 Sep 15, 2005	May CHRS
	SOLUTION;ORAL			
	DIAZEPAM			
AA	CHARTWELL MOLECULAR	5MG/5ML	A206477 001 Jun 24, 2016	Jun CAHN
	TABLET;ORAL			
	VALIUM			
AB	+ WAYLIS THERAP	2MG	N013263 002	Mar CAHN
AB	+	5MG	N013263 004	Mar CAHN
AB	+!	10MG	N013263 006	Mar CAHN

DICLOFENAC

CAPSULE;ORAL

ZORVOLEX

+ @ ZYLA

35MG

N204592 002 Oct 18, 2013 Jul DISC

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB	STRIDES PHARMA	25MG	A210078 001 Dec 03, 2019	Apr CMFD
	FOR SOLUTION;ORAL			
	DICLOFENAC POTASSIUM			
AB	ALKEM LABS LTD	50MG	A216635 001 Jul 20, 2022	Jul NEWA
AB	ANNORA PHARMA	50MG	A215375 001 Mar 04, 2022	Feb NEWA
	TABLET;ORAL			
	DICLOFENAC POTASSIUM			
>A> AB	NOVAST LABS	50MG	A215585 001 Oct 08, 2021	Aug CAHN
>D> AB	RICONPHARMA LLC	50MG	A215585 001 Oct 08, 2021	Aug CAHN
AB	UMEDICA LABS PVT LTD	50MG	A215750 001 May 11, 2022	Apr NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB	ALEOR DERMACEUTICALS	3%	A212351 001 Jul 27, 2022	Jul NEWA
	CIPLA	1%	A209903 001 Aug 03, 2018	Mar CTEC
	SOLUTION;TOPICAL			
	DICLOFENAC SODIUM			
>A> AB	AMNEAL	2%	A208198 001 Aug 18, 2022	Aug NEWA
AB	APOTEX	2%	A207714 001 May 06, 2022	Apr NFTG

SOLUTION;TOPICAL
PENNSAID

AB	+! HORIZON	2%	N 204623	001	Jan 16, 2014	Apr CFTG
	SOLUTION/DROPS;OPHTHALMIC DICLOFENAC SODIUM					
>D> AT	AKORN	0.1%	A 077845	001	Apr 17, 2008	Aug DISC
>A>	@	0.1%	A 077845	001	Apr 17, 2008	Aug DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE
@ GENE YORK PHARMS 10MG/ML

A 212058 001 Apr 26, 2019 Feb DISC

DIGOXIN

ELIXIR;ORAL
DIGOXIN

AA	AMICI	0.05MG/ML	A 215209	001	Mar 11, 2022	Mar NEWA
	TABLET;ORAL DIGOXIN					
AB	AUROBINDO PHARMA LTD	0.0625MG	A 214982	001	Feb 08, 2022	Jan NFTG
AB		0.125MG	A 214982	002	Feb 08, 2022	Jan NEWA
AB		0.25MG	A 214982	003	Feb 08, 2022	Jan NEWA
>A> AB	NOVITIUM PHARMA	0.0625MG	A 215307	003	Aug 25, 2022	Aug NEWA
	LANOXIN					
AB	+ CONCORDIA	0.0625MG	N 020405	001	Sep 30, 1997	Jan CFTG

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
D.H.E. 45
+ @ BAUSCH 1MG/ML
DIHYDROERGOTAMINE MESYLATE
AP ! HIKMA PHARMS 1MG/ML
SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE
@ AMNEAL 0.5MG/SPRAY
>D> AB CUSTOPHARM INC 0.5MG/SPRAY
>A> AB HIKMA 0.5MG/SPRAY
TRUDHESA
+! IMPEL PHARMS 0.725MG/SPRAY

N 005929	001		Jul DISC
A 206621	001	Sep 15, 2017	Jul CHRS
A 214105	001	Jan 04, 2022	Jul DISC
A 211393	001	Feb 28, 2020	Aug CAHN
A 211393	001	Feb 28, 2020	Aug CAHN
N 213436	001	Sep 02, 2021	May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	AMTA	120MG	A 216304	001	Aug 08, 2022	Jul NEWA
AB2		180MG	A 216304	002	Aug 08, 2022	Jul NEWA
AB2		240MG	A 216304	003	Aug 08, 2022	Jul NEWA
AB1	MAYNE PHARMA INTL	60MG	A 215775	001	May 05, 2022	Apr NEWA
AB1		90MG	A 215775	002	May 05, 2022	Apr NEWA
AB1		120MG	A 215775	003	May 05, 2022	Apr NEWA
	SOLUTION;INTRAVENOUS					
	DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%					
+ @ EXELA PHARMA		125MG/125ML (1MG/ML)	N 215252	001	Oct 28, 2021	Feb DISC
+ @		250MG/250ML (1MG/ML)	N 215252	002	Oct 28, 2021	Feb DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

@ PHARMATHEN	120MG	A 210436	001	Mar 26, 2021	Apr DISC
@	240MG	A 210436	002	Mar 26, 2021	Apr DISC
@ SAWAI USA	120MG	A 210285	001	Dec 21, 2021	Jun DISC
@	240MG	A 210285	002	Dec 21, 2021	Jun DISC
@ SOLA PHARMS	120MG	A 210436	001	Mar 26, 2021	Jul CAHN
@	240MG	A 210436	002	Mar 26, 2021	Jul CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE
AP ! CHARTWELL INJECTABLE 5MG/ML
@ EUGIA PHARMA SPECLTS 5MG/ML

A 074939	001	Apr 13, 1998	Mar CAHN
A 075769	001	Nov 27, 2002	Mar CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL						
DISOPYRAMIDE PHOSPHATE						
AB MAYNE PHARMA	EQ 100MG BASE		A070173	001	May 31, 1985	Feb CMFD
	EQ 150MG BASE		A070173	002	May 31, 1985	Feb CMFD

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL						
DIVALPROEX SODIUM						
>D> @ MYLAN	EQ 125MG VALPROIC ACID		A090407	001	Mar 28, 2011	Aug CAHN
>A> @ RISING	EQ 125MG VALPROIC ACID		A090407	001	Mar 28, 2011	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL						
DIVALPROEX SODIUM						
AB UNICHEM	EQ 250MG VALPROIC ACID		A214643	001	Feb 25, 2022	Feb NEWA
AB	EQ 500MG VALPROIC ACID		A214643	002	Feb 25, 2022	Feb NEWA

DOCETAXEL

INJECTABLE; INJECTION						
DOCETAXEL						
AP MEITHEAL	20MG/2ML (10MG/ML)		A209634	001	Aug 24, 2018	Apr CAHN
AP	80MG/8ML (10MG/ML)		A209634	002	Aug 24, 2018	Apr CAHN
AP	160MG/16ML (10MG/ML)		A209634	003	Aug 24, 2018	Apr CAHN

DOFETILIDE

CAPSULE;ORAL						
DOFETILIDE						
AB TEVA PHARMS USA	0.125MG		A210018	001	Apr 15, 2022	Apr NEWA
AB	0.25MG		A210018	002	Apr 15, 2022	Apr NEWA
AB	0.5MG		A210018	003	Apr 15, 2022	Apr NEWA
TABLET;ORAL						
DOFETILIDE						
>A> AB NUVO PHARM	0.125MG		A215323	001	Apr 14, 2022	Aug CAHN
>A> AB	0.25MG		A215323	002	Apr 14, 2022	Aug CAHN
>A> AB	0.5MG		A215323	003	Apr 14, 2022	Aug CAHN
>D> AB VGYAAN	0.125MG		A215323	001	Apr 14, 2022	Aug CAHN
AB	0.125MG		A215323	001	Apr 14, 2022	Apr NEWA
>D> AB	0.25MG		A215323	002	Apr 14, 2022	Aug CAHN
AB	0.25MG		A215323	002	Apr 14, 2022	Apr NEWA
>D> AB	0.5MG		A215323	003	Apr 14, 2022	Aug CAHN
AB	0.5MG		A215323	003	Apr 14, 2022	Apr NEWA

DONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL						
ADLARITY						
+ CORIUM	5MG/DAY		N212304	001	Mar 11, 2022	Mar NEWA
+!	10MG/DAY		N212304	002	Mar 11, 2022	Mar NEWA
TABLET;ORAL						
DONEPEZIL HYDROCHLORIDE						
AB CHARTWELL RX	5MG		A090425	001	May 31, 2011	Mar CAHN
AB	10MG		A090425	002	May 31, 2011	Mar CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC						
DORZOLAMIDE HYDROCHLORIDE						
AT GLAND PHARMA LTD	EQ 2% BASE		A215660	001	Jan 27, 2022	Jan NEWA
AT ! MICRO LABS	EQ 2% BASE		A204778	001	Nov 08, 2019	May CHRS
TRUSOPT						
+ @ MERCK	EQ 2% BASE		N020408	001	Dec 09, 1994	May DISC
+ @ MSD SUB MERCK	EQ 2% BASE		N020408	001	Dec 09, 1994	Jun CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC						
COSOPT						
AT +! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE		N020869	001	Apr 07, 1998	Apr CAHN
COSOPT PF						
AT +! THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE		N202667	001	Feb 01, 2012	Apr CAHN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
AT MICRO LABS	EQ 2% BASE;EQ 0.5% BASE		A215936	001	Jan 25, 2022	Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

AP CHARTWELL INJECTABLE 20MG/ML A076266 001 Jan 10, 2003 Mar CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB +!	VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan CAHN
AB +		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan CAHN
AB +		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan CAHN
AB +		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan CAHN
DOXAZOSIN MESYLATE						
@ CHARTWELL RX		EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN
AB METHOD		EQ 1MG BASE	A212727	001	Mar 15, 2022	Mar NEWA
AB		EQ 2MG BASE	A212727	002	Mar 15, 2022	Mar NEWA
AB		EQ 4MG BASE	A212727	003	Mar 15, 2022	Mar NEWA
AB		EQ 8MG BASE	A212727	004	Mar 15, 2022	Mar NEWA
TABLET, EXTENDED RELEASE; ORAL						
CARDURA XL						
+ VIATRIS		EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan CAHN
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

AB EDENBRIDGE PHARMS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Apr NEWA	
AB EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb NEWA	
AB	EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb NEWA	
AB JUBILANT CADISTA	EQ 10MG BASE	A215483	001	Mar 14, 2022	Mar NEWA	
AB	EQ 25MG BASE	A215483	002	Mar 14, 2022	Mar NEWA	
AB	EQ 50MG BASE	A215483	003	Mar 14, 2022	Mar NEWA	
AB	EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar NEWA	
AB	EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar NEWA	
AB MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA	
AB	EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA	
AB	EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA	
AB	EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA	
AB	EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA	
AB MSN	EQ 10MG BASE	A215113	001	Jun 24, 2022	Jun NEWA	
AB	EQ 25MG BASE	A215113	002	Jun 24, 2022	Jun NEWA	
AB	EQ 50MG BASE	A215113	003	Jun 24, 2022	Jun NEWA	
AB	EQ 75MG BASE	A215113	004	Jun 24, 2022	Jun NEWA	
AB	EQ 100MG BASE	A215113	005	Jun 24, 2022	Jun NEWA	
AB ! PAR PHARM	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr CTEC	
TABLET; ORAL						
DOXEPIH HYDROCHLORIDE						
AB STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun CMFD	
@	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN	
AB	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD	
@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN	

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

>D> AP AKORN	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Aug DISC
>A> @	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Aug DISC
>D> AP	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Aug DISC
>A> @	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Aug DISC
AP EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP	4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

>D>	@ IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
>A>	@ MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	Aug CAHN
>A>	@ STRIDES PHARMA	EQ 150MG BASE	A202778	001	Jun 08, 2012	Aug CAHN

CAPSULE;ORAL
MONODOX

AB	+ CHARTWELL RX	EQ 150MG BASE	N 050641	004	Feb 17, 2022	Feb NEWA
	TABLET;ORAL DOXYCYCLINE					
AB	STRIDES PHARMA	EQ 50MG BASE	A 065070	001	Dec 15, 2000	Jul CMFD
AB		EQ 75MG BASE	A 065070	003	Dec 30, 2002	Jul CMFD
AB		EQ 100MG BASE	A 065070	002	Dec 15, 2000	Jul CMFD
AB		EQ 150MG BASE	A 065070	004	Jul 14, 2005	Jul CMFD

DOXYCYCLINE HYCLATE

CAPSULE;ORAL
DOXYCYCLINE HYCLATE

AB	CADILA	EQ 50MG BASE	A 207774	001	May 31, 2018	May CAHN
AB		EQ 100MG BASE	A 207774	002	May 31, 2018	May CAHN
	TABLET;ORAL DOXYCYCLINE HYCLATE					
AB	! CHARTWELL MOLECULAR	EQ 20MG BASE	A 065277	001	Nov 10, 2005	Jun CAHN
	@ EMCURE PHARMS LTD	EQ 100MG BASE	A 209969	001	Nov 09, 2018	Jan DISC
>D> AB	PRAZGEN	EQ 100MG BASE	A 212487	001	Mar 30, 2022	Aug DISC
>A>	@	EQ 100MG BASE	A 212487	001	Mar 30, 2022	Aug DISC
AB		EQ 100MG BASE	A 212487	001	Mar 30, 2022	Mar NEWA

DROSPIRENONE

TABLET, CHEWABLE;ORAL
DROSPIRENONE

+! EXELTIS USA INC 3.5MG

N 216285 001 Jun 29, 2022 Jun NEWA

DROXIDOPA

CAPSULE;ORAL
DROXIDOPA

AB	CELLTRION	100MG	A 214217	001	May 05, 2022	Apr NEWA
AB		200MG	A 214217	002	May 05, 2022	Apr NEWA
AB		300MG	A 214217	003	May 05, 2022	Apr NEWA
	@ SLATE	100MG	A 215265	001	Nov 01, 2021	May DISC
	@	200MG	A 215265	002	Nov 01, 2021	May DISC
	@	300MG	A 215265	003	Nov 01, 2021	May DISC
>D> AB	TASMAN PHARMA	100MG	A 213661	001	Feb 18, 2021	Aug CAHN
>D> AB		200MG	A 213661	002	Feb 18, 2021	Aug CAHN
>D> AB		300MG	A 213661	003	Feb 18, 2021	Aug CAHN
>A> AB	UPSHER SMITH LABS	100MG	A 213661	001	Feb 18, 2021	Aug CAHN
>A> AB		200MG	A 213661	002	Feb 18, 2021	Aug CAHN
>A> AB		300MG	A 213661	003	Feb 18, 2021	Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE

+ SUN PHARM EQ 20MG BASE
+ EQ 30MG BASE
+ EQ 40MG BASE
+! EQ 60MG BASE

N 212516 001 Jul 19, 2019 Feb CAHN
N 212516 002 Jul 19, 2019 Feb CAHN
N 212516 003 Jul 19, 2019 Feb CAHN
N 212516 004 Jul 19, 2019 Feb CAHN

DUVELISIE

CAPSULE;ORAL
COPIKTRA

+ SECURA 15MG
+ @ 15MG
+ 25MG
+ @ 25MG

N 211155 001 Sep 24, 2018 May CMFD
N 211155 001 Sep 24, 2018 Apr DISC
N 211155 002 Sep 24, 2018 May CMFD
N 211155 002 Sep 24, 2018 Apr DISC

ECONAZOLE NITRATE

CREAM;TOPICAL

>D>	SPECTAZOLE					
>D> AB	+ ALVOGEN	1%	N 018751	001	Dec 23, 1982	Aug DISC
>A>	+ @	1%	N 018751	001	Dec 23, 1982	Aug DISC

EDARAVONE

SUSPENSION;ORAL

RADICAVA ORS

+! MITSUBISHI TANABE 105MG/5ML

N 215446 001 May 12, 2022 May NEWA

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ
@ AUROBINDO PHARMA LTD 600MG A205322 001 Aug 30, 2018 Apr DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE
AB HETERO LABS LTD V 600MG;200MG;300MG A203053 001 Jan 24, 2022 Jan NEWA

EFINACONAZOLE

SOLUTION;TOPICAL
EFINACONAZOLE
>D> AB ACRUX DDS 10% A211969 001 Jun 21, 2021 Aug CAHN
@ LUPIN LTD 10% A212169 001 Mar 02, 2022 May DISC
AB 10% A212169 001 Mar 02, 2022 Feb NEWA
>A> AB NIVAGEN PHARMS INC 10% A211969 001 Jun 21, 2021 Aug CAHN
AB ZYDUS 10% A212178 001 Jul 15, 2022 Jul NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL
VANIQA
+ @ SKINMEDICA 13.9% N021145 001 Jul 27, 2000 Feb DISC

ELBASVIR; GRAZOPREVIR

TABLET;ORAL
ZEPATIER
+! MSD SUB MERCK 50MG;100MG N208261 001 Jan 28, 2016 Jun CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL
ELETRIPTAN HYDROBROMIDE
AB BEXIMCO PHARMS USA EQ 20MG BASE A215467 001 Jul 13, 2022 Jul NEWA
AB EQ 40MG BASE A215467 002 Jul 13, 2022 Jul NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL
ELIGLUSTAT TARTRATE
AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Feb CAHN
>A> AB DR REDDYS EQ 84MG BASE A212449 001 Aug 17, 2022 Aug NEWA
@ TEVA PHARMS USA INC EQ 84MG BASE A212474 001 Dec 27, 2021 Jun DISC

EMPAGLIFLOZIN

TABLET;ORAL
EMPAGLIFLOZIN
AB ZYDUS PHARMS 10MG A212138 001 Aug 03, 2022 Jul NFTG
AB 25MG A212138 002 Aug 03, 2022 Jul NFTG
JARDIANCE
AB + BOEHRINGER INGELHEIM 10MG N204629 001 Aug 01, 2014 Jul CFTG
AB +! 25MG N204629 002 Aug 01, 2014 Jul CFTG

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
AB ZYDUS PHARMS 5MG;500MG A212198 001 Jul 07, 2022 Jul NFTG
AB 5MG;1GM A212198 002 Jul 07, 2022 Jul NFTG
AB 12.5MG;500MG A212198 003 Jul 07, 2022 Jul NFTG
AB 12.5MG;1GM A212198 004 Jul 07, 2022 Jul NFTG
SYNJARDY
AB + BOEHRINGER INGELHEIM 5MG;500MG N206111 001 Aug 26, 2015 Jul CFTG
AB + 5MG;1GM N206111 002 Aug 26, 2015 Jul CFTG
AB + 12.5MG;500MG N206111 003 Aug 26, 2015 Jul CFTG
AB +! 12.5MG;1GM N206111 004 Aug 26, 2015 Jul CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
DESCOVY
+ GILEAD SCIENCES INC 120MG;EQ 15MG BASE N208215 002 Jan 07, 2022 Jan NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB	ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar NEWA
AB	AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Jun NEWA
AB	ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb NEWA
	TABLET;ORAL					
	ENALAPRIL MALEATE					
@	AIIPPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001	Jun CAHN
@		5MG	A075178	001	Mar 23, 2001	Jun CAHN
@		10MG	A075178	003	Mar 23, 2001	Jun CAHN
@		20MG	A075178	004	Mar 23, 2001	Jun CAHN
AB	PRINSTON INC	2.5MG	A213273	001	Jul 07, 2022	Jul NEWA
AB		5MG	A213273	002	Jul 07, 2022	Jul NEWA
AB		10MG	A213273	003	Jul 07, 2022	Jul NEWA
AB		20MG	A213273	004	Jul 07, 2022	Jul NEWA

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jan CHRS
AP	CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
AP	! HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan CHRS
AP	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan CHRS

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB	NANJING KING-FRIEND	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Jun NEWA
----	---------------------	----------------------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

@	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Apr DISC
@		1MG	A205824	002	Aug 25, 2017	Apr DISC
@	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	May DISC
@		1MG	A208195	002	Nov 10, 2021	May DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB	@ ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	Feb DISC
	APOTEX	40MG	A209645	001	Apr 22, 2022	Apr NEWA
	XTANDI					
AB	+! ASTELLAS	40MG	N203415	001	Aug 31, 2012	Apr CTEC
	+!	40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

+!	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun CAHN
+ @		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun CAHN
+ @		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun CAHN

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

AP	AGGREGA	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Apr NEWA
+!	ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	May NEWA
+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CMFD
AP	GLAND PHARMA LTD	50MG/ML (50MG/ML)	A216146	001	Feb 25, 2022	Feb NEWA
AP	MANKIND PHARMA	50MG/ML (50MG/ML)	A216129	001	Apr 14, 2022	Apr NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ELESTAT

>D>	+! ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Aug DISC
>A>	+ @	0.05%	N021565	001	Oct 16, 2003	Aug DISC
	EPINASTINE HYDROCHLORIDE					
>D> AT	AKORN	0.05%	A204055	001	May 05, 2017	Aug DISC
>A>	@	0.05%	A204055	001	May 05, 2017	Aug DISC

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>D> AT	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Aug CHRS
>A> AT	!	0.05%	A090951	001	Oct 31, 2011	Aug CHRS

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Mar NEWA
------------	--------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
EPINEPHRINE

>A>	+! INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022	Aug NEWA
-----	------------------------	---------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014	Mar CDFR
------------	-----------------	---------	-----	--------------	----------

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIGNOSPAN FORTE

+! DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD
------------	----------------------	---------	-----	--------------	----------

LIGNOSPAN STANDARD

+! DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan CRLD
------------	----------------------	---------	-----	--------------	----------

EPLERENONE

TABLET;ORAL
EPLERENONE

AB	KARTHA	25MG	A214663	001	Mar 23, 2022	Mar NEWA
AB		50MG	A214663	002	Mar 23, 2022	Mar NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

>D> AP	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Aug DISC
>A>	@	2MG/ML	A204589	001	Apr 18, 2017	Aug DISC
>D> AP		75MG/100ML	A204589	002	Apr 18, 2017	Aug DISC
>A>	@	75MG/100ML	A204589	002	Apr 18, 2017	Aug DISC
AP	SHUANGCHENG	75MG/100ML	A213081	002	Apr 20, 2022	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

AB	EUGIA PHARMA	EQ 25MG BASE	A216342	001	Jun 22, 2022	Jun NEWA
AB		EQ 100MG BASE	A216342	002	Jun 22, 2022	Jun NEWA
AB		EQ 150MG BASE	A216342	003	Jun 22, 2022	Jun NEWA

ERTUGLIFLOZIN

TABLET;ORAL STEGLATRO						
+! MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jun CAHN	
+!	15MG	N209803	002	Dec 19, 2017	Jun CAHN	

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL SEGLUROMET						
+! MSD SUB MERCK	2.5MG;500MG	N209806	001	Dec 19, 2017	Jun CAHN	
+!	2.5MG;1GM	N209806	002	Dec 19, 2017	Jun CAHN	
+!	7.5MG;500MG	N209806	003	Dec 19, 2017	Jun CAHN	
+!	7.5MG;1GM	N209806	004	Dec 19, 2017	Jun CAHN	

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL STEGLUJAN						
+! MSD SUB MERCK	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN	
+!	15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN	

ERYTHROMYCIN

SOLUTION;TOPICAL
ERYTHRA-DERM

>A> AT	MICRO LABS	2%	A062687	001	Feb 05, 1988	Aug CAHN
>D> AT	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Aug CAHN

SOLUTION;TOPICAL

ERYTHROMYCIN

@ BAUSCH

2%

A064039 001 Jan 27, 1994 Jul CAHN

TABLET;ORAL

ERYTHROMYCIN

AB ALKEM LABS LTD

250MG

A216066 001 Jul 13, 2022 Jul NEWA

AB

500MG

A216066 002 Jul 13, 2022 Jul NEWA

TABLET, COATED PARTICLES;ORAL

PCE

+ @ AZURITY

333MG

N050611 001 Sep 09, 1986 May CAHN

+ @

500MG

N050611 002 Aug 22, 1990 May CAHN

ERYTHROMYCIN ETHYLSUCCINATEGRANULE;ORAL

E.E.S.

AB

+ AZURITY

EQ 200MG BASE/5ML

N050207 001

May CAHN

ERYPED

AB

+ AZURITY

EQ 200MG BASE/5ML

N050207 003 Mar 30, 1987 May CAHN

+!

EQ 400MG BASE/5ML

N050207 002

May CAHN

TABLET, CHEWABLE;ORAL

E.E.S.

@ AZURITY

EQ 200MG BASE

N050297 002

May CAHN

ERYPED

@ AZURITY

EQ 200MG BASE

N050297 003 Jul 05, 1988 May CAHN

ERYTHROMYCIN LACTOBIONATEINJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

AP

NEXUS PHARMS

EQ 500MG BASE/VIAL

A215290 001 Feb 14, 2022 Feb NEWA

ESMOLOL HYDROCHLORIDEINJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

AP

EUGIA PHARMA

10MG/ML

A216244 001 Mar 21, 2022 Mar NEWA

AP

20MG/ML

A216244 002 Mar 21, 2022 Mar NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXENTABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

>A> AB

ACTAVIS LABS FL INC

EQ 20MG BASE;375MG

A204470 001 Aug 24, 2022 Aug NEWA

>A> AB

EQ 20MG BASE;500MG

A204470 002 Aug 24, 2022 Aug NEWA

ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP

HAINAN POLY

EQ 40MG BASE/VIAL

A215732 001 Feb 10, 2022 Feb NEWA

@ MYLAN

EQ 20MG BASE/VIAL

A202686 001 May 17, 2017 Apr CAHN

@

EQ 40MG BASE/VIAL

A202686 002 May 17, 2017 Apr CAHN

@ MYLAN LABS LTD

EQ 40MG BASE/VIAL

A202686 002 May 17, 2017 Apr DISC

@ SUN PHARM

EQ 20MG BASE/VIAL

A200882 001 Mar 18, 2013 Feb CAHN

AP

EQ 40MG BASE/VIAL

A200882 002 Mar 18, 2013 Feb CAHN

ESTRADIOLGEL; TRANSDERMAL

DIVIGEL

AB

+! VERTICAL PHARMS LLC

0.1%

N022038 001 Jun 04, 2007 Jul CFTG

ESTRADIOL

AB

CHEMO RESEARCH SL

0.1%

A211783 001 Aug 10, 2022 Jul NFTG

SYSTEM; TRANSDERMAL

ESTRADIOL

>D> BX

AMNEAL

0.025MG/24HR

A211293 001 Feb 04, 2019 Aug CTEC

>A> AB

0.025MG/24HR

A211293 001 Feb 04, 2019 Aug CTEC

>D> BX

0.0375MG/24HR

A211293 002 Feb 04, 2019 Aug CTEC

>A> AB

0.0375MG/24HR

A211293 002 Feb 04, 2019 Aug CTEC

>D> BX

0.05MG/24HR

A211293 003 Feb 04, 2019 Aug CTEC

>A> AB

0.05MG/24HR

A211293 003 Feb 04, 2019 Aug CTEC

>D> BX

0.075MG/24HR

A211293 004 Feb 04, 2019 Aug CTEC

>A> AB

0.075MG/24HR

A211293 004 Feb 04, 2019 Aug CTEC

>D> BX

0.1MG/24HR

A211293 005 Feb 04, 2019 Aug CTEC

>A> AB

0.1MG/24HR

A211293 005 Feb 04, 2019 Aug CTEC

TABLET;ORAL

ESTRADIOL

@ LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998	May CAHN
@	1MG	A040138	002	Jan 30, 1998	May CAHN
@	2MG	A040138	003	Jan 30, 1998	May CAHN
@ MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
@	1MG	A040114	001	Mar 14, 1996	Feb DISC
@	2MG	A040114	002	Mar 14, 1996	Feb DISC

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

+ @ THERAPEUTICSMD INC	0.5MG;100MG	N210132	002	Dec 28, 2021	Apr DISC
+!	1MG;100MG	N210132	001	Oct 28, 2018	May CTEC
AB +!	1MG;100MG	N210132	001	Oct 28, 2018	May CFTG
ESTRADIOL AND PROGESTERONE					
@ AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022	May DISC
	1MG;100MG	A214293	001	May 16, 2022	May NFTG

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan CAHN
@	2MG	A091165	002	Jul 14, 2011	Jan CAHN
@	3MG	A091165	003	Jul 14, 2011	Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

>D> AB ALVOGEN	25MG	A205709	001	Jul 24, 2018	Aug DISC
>A> @	25MG	A205709	001	Jul 24, 2018	Aug DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ZOVIA 1/35E-28

@ MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan DISC
----------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

HALOETTE

AB MAYNE PHARMA	0.015MG/24HR;0.12MG/24HR	A211328	001	Aug 05, 2022	Jul NEWA
AB +! ORGANON USA ORGANON	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Jul CAHN
VERARING @ DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>D> AB MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Aug DISC
>A> @	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Aug DISC

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 NAARI PTE LTD	0.02MG;0.1MG	A207065	001	Aug 17, 2020	Apr CTEC
-------------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Jul CTEC
-----------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

FEMCON FE

+ @ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	May CDFR
NEXESTA FE					

AB AUROBINDO PHARMA LTD	0.035MG;0.4MG	A207535	001	Feb 02, 2017	May CDFR
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					

AB AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	May CDFR
BARR	0.035MG;0.4MG	A078965	001	Aug 05, 2010	May CDFR

AB LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	May CDFR
AB ! MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	May CDFR

AB NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	May CDFR
------------------	---------------	---------	-----	--------------	----------

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL
© MAYNE PHARMA 0.035MG;0.5MG

A070686 001 Jan 29, 1987 Jan DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A213418	001	Jul 27, 2022	Jul NEWA
AB	MAYNE PHARMA	0.02MG;1MG	A213901	001	Apr 28, 2022	Apr NEWA

TABLET;ORAL

FINZALA

AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May CDFR
	MIBELAS 24 FE					

AB	LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May CDFR
	MINASTRIN 24 FE					

AB	+! APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CDFR
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					

© AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun DISC
©	0.02MG;1MG	A207514	001	Sep 11, 2017	May CDFR

AB	! GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Jun CHRS
AB		0.02MG;1MG	A210369	001	Dec 26, 2017	May CDFR

© MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May CDFR
XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May CDFR

TABLET;ORAL-21

LOESTRIN 21 1.5/30

+ @ TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jun DISC
LOESTRIN 21 1/20					

+ @ TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jul DISC
LOESTRIN FE 1.5/30					

+ @ TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jun DISC
MICROGESTIN 1.5/30					

© MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan DISC
MICROGESTIN 1/20					

© MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Jan DISC

TABLET;ORAL-28

JUNEL FE 1.5/30

AB	! BARR	0.03MG;1.5MG	A076064	001	Sep 18, 2003	Jun CHRS
	LOESTRIN FE 1/20					

+ @ TEVA BRANDED PHARM	0.02MG;1MG	N017354	001		Jun DISC
MICROGESTIN FE 1.5/30					

© MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan DISC
MICROGESTIN FE 1/20					

© MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan DISC

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

© MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Jan DISC
----------------	-----------------------------------	---------	-----	--------------	----------

AB	MYLAN	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CMFD
----	-------	-----------------------------------	---------	-----	--------------	----------

AB		0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CAHN
----	--	-----------------------------------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

FINZALA

AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jan CMFD
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					

© AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan DISC
-----------------	------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

TRI-LO-LINYAH

>A> AB	NOVAST LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A090541	001	Sep 02, 2022	Aug NEWA
--------	-------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

+ @ CADENCE HEALTH	0.03MG;0.3MG	N017612	001		Apr CRLD
--------------------	--------------	---------	-----	--	----------

TABLET;ORAL-28

CRYSELLE

AB	! DURAMED PHARMS BARR	0.03MG;0.3MG	A075840	002	Nov 30, 2001	Apr CHRS
	LO/OVRAL-28					

+ @ WYETH PHARMS	0.03MG;0.3MG	N017802	001		Apr CRLD
------------------	--------------	---------	-----	--	----------

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

@ ORGANON

NEXPLANON

+! ORGANON

68MG/IMPLANT

N021529 001 Jul 17, 2006 Jan CAHN

68MG/IMPLANT

N021529 002 May 31, 2011 Jan CAHN

ETRAVIRINE

TABLET; ORAL

ETRAVIRINE

AB CARNEGIE

100MG

A215402 001 Apr 13, 2022 Apr NEWA

AB

200MG

A215402 002 Apr 13, 2022 Apr NEWA

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB EUGIA PHARMA

25MG

A216454 001 May 20, 2022 May NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB HETERO LABS LTD III

10MG

A208332 001 Jun 12, 2017 Apr DISC

10MG

A210859 001 Jul 26, 2022 Jul NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

@ CIPLA

125MG

A078278 001 Mar 21, 2011 Mar DISC

@

250MG

A078278 002 Mar 21, 2011 Mar DISC

@

500MG

A078278 003 Mar 21, 2011 Mar DISC

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

AB AMNEALS PHARMS

40MG/5ML

A216427 001 Aug 04, 2022 Jul NEWA

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

@ AKORN

10MG/ML

A076324 001 Nov 27, 2002 Feb CAHN

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

@ AKORN

10MG/ML

A076322 001 Nov 27, 2002 Feb CAHN

TABLET; ORAL

FAMOTIDINE

AB ZYDUS PHARMS

20MG

A216441 001 Jun 03, 2022 May NEWA

AB

40MG

A216441 002 Jun 03, 2022 May NEWA

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB PRINSTON INC

40MG

A206266 001 Mar 28, 2022 Mar NEWA

AB

80MG

A206266 002 Mar 28, 2022 Mar NEWA

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

@ ATLANTIDE

2.5MG

A091484 001 Aug 15, 2012 Apr CAHN

@

5MG

A091484 002 Aug 15, 2012 Apr CAHN

@

10MG

A091484 003 Aug 15, 2012 Apr CAHN

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

+ @ LUPIN

30MG

N021695 004 Oct 18, 2013 Jul DISC

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB RISING

EQ 400MG BASE

A214475 001 Jul 18, 2022 Jul NFTG

NALFON

AB +! XSPIRE PHARMA

EQ 400MG BASE

N017604 004 Jul 21, 2009 Jul CFTG

TABLET;ORAL

FENOPROFEN CALCIUM
@ STRIDES PHARMA

EQ 600MG BASE

A072429 001 Aug 17, 1988 Jul CAHN

FENTANYL

>D>	SPRAY; SUBLINGUAL							
>D>	SUBSYS							
>D>	+ BTCP PHARMA	0.1MG			N202788	001	Jan 04, 2012	Aug DISC
>A>	+ @	0.1MG			N202788	001	Jan 04, 2012	Aug DISC
>D>	+	0.2MG			N202788	002	Jan 04, 2012	Aug DISC
>A>	+ @	0.2MG			N202788	002	Jan 04, 2012	Aug DISC
>D>	+!	0.4MG			N202788	003	Jan 04, 2012	Aug DISC
>A>	+ @	0.4MG			N202788	003	Jan 04, 2012	Aug DISC
>D>	+	0.6MG			N202788	004	Jan 04, 2012	Aug DISC
>A>	+ @	0.6MG			N202788	004	Jan 04, 2012	Aug DISC
>D>	+	0.8MG			N202788	005	Jan 04, 2012	Aug DISC
>A>	+ @	0.8MG			N202788	005	Jan 04, 2012	Aug DISC
>D>	+	1.2MG			N202788	006	Aug 30, 2012	Aug DISC
>A>	+ @	1.2MG			N202788	006	Aug 30, 2012	Aug DISC
>D>	+	1.6MG			N202788	007	Aug 30, 2012	Aug DISC
>A>	+ @	1.6MG			N202788	007	Aug 30, 2012	Aug DISC

FENTANYL CITRATE

	FILM;BUCCAL							
	ONSOLIS							
>A>	@ ADALVO	EQ 0.2MG BASE			N022266	001	Jul 16, 2009	Aug CAHN
>A>	@	EQ 0.4MG BASE			N022266	002	Jul 16, 2009	Aug CAHN
>A>	@	EQ 0.6MG BASE			N022266	003	Jul 16, 2009	Aug CAHN
>A>	@	EQ 0.8MG BASE			N022266	004	Jul 16, 2009	Aug CAHN
>A>	@	EQ 1.2MG BASE			N022266	005	Jul 16, 2009	Aug CAHN
>D>	@ BDSI	EQ 0.2MG BASE			N022266	001	Jul 16, 2009	Aug CAHN
>D>	@	EQ 0.4MG BASE			N022266	002	Jul 16, 2009	Aug CAHN
>D>	@	EQ 0.6MG BASE			N022266	003	Jul 16, 2009	Aug CAHN
>D>	@	EQ 0.8MG BASE			N022266	004	Jul 16, 2009	Aug CAHN
>D>	@	EQ 1.2MG BASE			N022266	005	Jul 16, 2009	Aug CAHN
>D>	SPRAY, METERED;NASAL							
>D>	LAZANDA							
>D>	+ BTCP PHARMA	EQ 0.1MG BASE			N022569	001	Jun 30, 2011	Aug DISC
>A>	+ @	EQ 0.1MG BASE			N022569	001	Jun 30, 2011	Aug DISC
>D>	+!	EQ 0.4MG BASE			N022569	002	Jun 30, 2011	Aug DISC
>A>	+ @	EQ 0.4MG BASE			N022569	002	Jun 30, 2011	Aug DISC
	TABLET;BUCCAL, SUBLINGUAL							
	FENTANYL CITRATE							
>A> AB	MAYNE PHARMA	EQ 0.1MG BASE			A206329	001	Aug 22, 2022	Aug NEWA
>A> AB		EQ 0.2MG BASE			A206329	002	Aug 22, 2022	Aug NEWA
>A>		EQ 0.3MG BASE			A206329	003	Aug 22, 2022	Aug NEWA
>A> AB		EQ 0.4MG BASE			A206329	004	Aug 22, 2022	Aug NEWA
>A> AB		EQ 0.6MG BASE			A206329	005	Aug 22, 2022	Aug NEWA
>A> AB		EQ 0.8MG BASE			A206329	006	Aug 22, 2022	Aug NEWA
	FENTORA							
>D>	+ CEPHALON	EQ 0.1MG BASE			N021947	001	Sep 25, 2006	Aug CTEC
>A> AB	+	EQ 0.1MG BASE			N021947	001	Sep 25, 2006	Aug CTEC
>D>	+	EQ 0.2MG BASE			N021947	002	Sep 25, 2006	Aug CTEC
>A> AB	+	EQ 0.2MG BASE			N021947	002	Sep 25, 2006	Aug CTEC
>D>	+!	EQ 0.4MG BASE			N021947	003	Sep 25, 2006	Aug CTEC
>A> AB	+!	EQ 0.4MG BASE			N021947	003	Sep 25, 2006	Aug CTEC
>D>	+	EQ 0.6MG BASE			N021947	004	Sep 25, 2006	Aug CTEC
>A> AB	+	EQ 0.6MG BASE			N021947	004	Sep 25, 2006	Aug CTEC
>D>	+	EQ 0.8MG BASE			N021947	005	Sep 25, 2006	Aug CTEC
>A> AB	+	EQ 0.8MG BASE			N021947	005	Sep 25, 2006	Aug CTEC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS
INJECTAFER
+! AM REGENT

100MG IRON/2ML (50MG IRON/ML)

N203565 004 Feb 04, 2022 Feb NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May CMFD
AB		8MG	A204827	002	Dec 10, 2015	May CMFD
AB	DR REDDYS	4MG	A204975	001	Aug 13, 2019	Jun CMFD
AB		8MG	A204975	002	Aug 13, 2019	Jun CMFD

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

@ CHATTEM SANOFI 60MG
@ 60MGN020625 001 Jul 25, 1996 Jan CAHN
N020625 001 Jul 25, 1996 Jan CAHNFINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

>D>	@ DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Aug CMFD	
>A> AB	AB	HETERO LABS LTD V	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Aug CMFD
>D>	@ MYLAN	EQ 0.5MG BASE	A207933	001	May 18, 2020	Jul CMFD	
>A> AB		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Aug CMFD	
	@	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Aug CMFD	
	AB	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb DISC	
>A> AB	PRINSTON INC	EQ 0.5MG BASE	A208003	001	Sep 07, 2022	Aug NEWA	
>D>	@ SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug CMFD	
>A> AB	@ TEVA PHARMS USA GILENYA	EQ 0.25MG BASE	A208014	001	Dec 04, 2019	Aug CMFD	
	+ NOVARTIS	EQ 0.25MG BASE	A212152	001	Nov 12, 2021	Jun DISC	
			N022527	002	May 11, 2018	Jun CTEC	

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

@ CHARTWELL	50MG	A079164	001	Jul 09, 2009	Feb CAHN	
@	100MG	A079164	002	Jul 09, 2009	Feb CAHN	
@	150MG	A079164	003	Jul 09, 2009	Feb CAHN	
>A> AB	YICHANG HUMANWELL	50MG	A215599	001	Sep 08, 2022	Aug NEWA
>A> AB		100MG	A215599	002	Sep 08, 2022	Aug NEWA
>A> AB		150MG	A215599	003	Sep 08, 2022	Aug NEWA

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

AB	THINQ PHARM-CRO PVT	50MG	A076957	001	Sep 28, 2005	Jun CAHN
AB		100MG	A076957	002	Sep 28, 2005	Jun CAHN
AB		150MG	A076957	004	Feb 27, 2017	Jun CAHN
AB		200MG	A076957	003	Sep 28, 2005	Jun CAHN

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

AB	STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Feb CMFD
AB		500MG	A212632	002	Apr 17, 2020	Feb CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

>D> AP	CUSTOPHARM INC	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN
>A> AP	HIKMA	50MG/VIAL	A076349	001	Aug 28, 2003	Aug CAHN

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB	NOVITIUM PHARMA	0.1MG	A215279	001	May 31, 2022	May NEWA
----	-----------------	-------	---------	-----	--------------	----------

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	@ APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	May DISC
AB	! BAUSCH	0.025MG/SPRAY	A074805	001	Feb 20, 2002	Jun CAHN
AB	RICONPHARMA LLC	0.025MG/SPRAY	A207802	001	Jun 16, 2022	Jun NEWA

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

@ AMNEAL 0.01%
@ 0.01%A201759 001 Oct 17, 2011 Jul DISC
A201764 001 Oct 17, 2011 Jul DISC

OIL/DROPS;OTIC
 FLUOCINOLONE ACETONIDE
 @ AMNEAL 0.01% A091306 001 Oct 17, 2011 Jul DISC
 SOLUTION;TOPICAL
 FLUOCINOLONE ACETONIDE
 @ PAI HOLDINGS PHARM 0.01% A088312 001 Jan 27, 1984 Apr CAHN

FLUOCINONIDE

CREAM;TOPICAL
 FLUOCINONIDE
 @ ENCUBE 0.05% A211410 001 Oct 16, 2018 Jul CAHN
>D> LIDEX-E
>D> AB2 + ALVOGEN 0.05% N016908 003 Aug DISC
>A> + @ 0.05% N016908 003 Aug DISC

FLUOROMETHOLONE

>D> OINTMENT;OPHTHALMIC
>D> FML
>D> +! ALLERGAN 0.1% N017760 001 Sep 04, 1985 Aug DISC
>A> + @ 0.1% N017760 001 Sep 04, 1985 Aug DISC

FLUOROURACIL

CREAM;TOPICAL
 FLUOROPLEX
 + @ CHARTWELL RX 1% N016988 001 Jul CAHN
 INJECTABLE;INJECTION
 FLUOROURACIL
 @ EUGIA PHARMA SPECLTS 500MG/10ML (50MG/ML) A202668 001 Jul 17, 2012 Mar CAHN
 @ 1GM/20ML (50MG/ML) A202668 002 Jul 17, 2012 Mar CAHN
 @ 2.5GM/50ML (50MG/ML) A202669 001 Jul 17, 2012 Mar CAHN
 @ 5GM/100ML (50MG/ML) A202669 002 Jul 17, 2012 Mar CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL
 FLUOXETINE HYDROCHLORIDE
 AB1 MICRO LABS EQ 10MG BASE A216232 001 Mar 29, 2022 Mar NEWA
 AB1 EQ 20MG BASE A216232 002 Mar 29, 2022 Mar NEWA
 AB EQ 40MG BASE A216232 003 Mar 29, 2022 Mar NEWA

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL
 FLUPHENAZINE HYDROCHLORIDE
 AB APOTEX 1MG A216649 001 Jul 15, 2022 Jul NEWA
 AB 2.5MG A216649 002 Jul 15, 2022 Jul NEWA
 AB 5MG A216649 003 Jul 15, 2022 Jul NEWA
 AB 10MG A216649 004 Jul 15, 2022 Jul NEWA
 AB PRASCO 1MG A089804 002 Aug 12, 1988 Jun CMFD
 @ 1MG A089804 002 Aug 12, 1988 Mar CAHN
 AB 2.5MG A089804 003 Aug 12, 1988 Jun CMFD
 @ 2.5MG A089804 003 Aug 12, 1988 Mar CAHN
 AB 5MG A089804 004 Aug 12, 1988 Jun CMFD
 @ 5MG A089804 004 Aug 12, 1988 Mar CAHN
 AB 10MG A089804 001 Aug 12, 1988 Jun CMFD
 @ 10MG A089804 001 Aug 12, 1988 Mar CAHN
 AB TARO PHARM IND LTD 1MG A215674 001 Apr 14, 2022 Apr NEWA
 AB 2.5MG A215674 002 Apr 14, 2022 Apr NEWA
 AB 5MG A215674 003 Apr 14, 2022 Apr NEWA
 AB 10MG A215674 004 Apr 14, 2022 Apr NEWA
 AB TWI PHARMS 2.5MG A215848 001 Apr 01, 2022 Mar NEWA
 AB 5MG A215848 002 Apr 01, 2022 Mar NEWA
 AB 10MG A215848 003 Apr 01, 2022 Mar NEWA

FLURANDRENOLIDE

CREAM;TOPICAL
 CORDRAN SP
 +! ALMIRALL 0.05% N012806 002 Feb CTEC
 FLURANDRENOLIDE
 @ CINTEX SVCS 0.05% A205342 001 Apr 13, 2016 Feb DISC
 LOTION;TOPICAL
 FLURANDRENOLIDE
 @ CINTEX SVCS 0.05% A205343 001 Dec 22, 2016 Feb DISC

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

RISING	15MG	A070345	002	Nov 27, 1985	Apr CAHN
!	30MG	A070345	001	Nov 27, 1985	Apr CAHN

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ CHARTWELL RX	125MG	A075818	001	Sep 18, 2001	Jan CAHN
----------------	-------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

LOTION;TOPICAL

CUTIVATE

+ @ FOUGERA PHARMS	0.05%	N021152	001	Mar 31, 2005	Mar DISC
+	0.05%	N021152	001	Mar 31, 2005	Mar CHRS

AB	FLUTICASONE PROPIONATE					
AB	! GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Mar CHRS
	POWDER;INHALATION					
	ARMONAIR DIGIHALER					
	+ @ TEVA PHARM	0.03MG/INH	N208798	008	Apr 08, 2022	Apr NEWA

FLUVOXAMINE MALEATECAPSULE, EXTENDED RELEASE;ORAL
FLUVOXAMINE MALEATE

AB	BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb CMFD
	TABLET;ORAL					
	FLUVOXAMINE MALEATE					
>A>	@ CHARTWELL RX	25MG	A075900	001	Feb 23, 2006	Aug CAHN
>A>	@	50MG	A075900	002	Feb 23, 2006	Aug CAHN
>A>	@	100MG	A075900	003	Feb 23, 2006	Aug CAHN
>D>	@ PHARMA LIFE	25MG	A075900	001	Feb 23, 2006	Aug CAHN
>D>	@	50MG	A075900	002	Feb 23, 2006	Aug CAHN
>D>	@	100MG	A075900	003	Feb 23, 2006	Aug CAHN

FORMOTEROL FUMARATESOLUTION;INHALATION
FORMOTEROL FUMARATE

>A> AN	LUPIN	0.02MG/2ML	A215053	001	Aug 22, 2022	Aug NEWA
--------	-------	------------	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINEPOWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

@ ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Mar CAHN
@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Mar CAHN
@ PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Feb DISC
@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Feb DISC

FOSDENOPTERIN HYDROBROMIDEPOWDER;INTRAVENOUS
NULIBRY

+! SENTYNL THERAPS INC	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Mar CAHN
------------------------	--------------------	---------	-----	--------------	----------

FOSFOMYCIN TROMETHAMINEFOR SOLUTION;ORAL
FOSFOMYCIN TROMETHAMINE

AA	CIPLA	EQ 3GM BASE/PACKET	A211881	001	Jan 26, 2022	Jan NEWA
----	-------	--------------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUMINJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

AP	ATLANTIDE	EQ 50MG PHENYTOIN NA/ML	A078137	001	Aug 06, 2007	Apr CAHN
----	-----------	-------------------------	---------	-----	--------------	----------

FROVATRIPTAN SUCCINATETABLET;ORAL
FROVATRIPTAN SUCCINATE

AB	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	May CAHN
AB	ZENARA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Mar NEWA

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FULVESTRANT

AO	@ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
AO	JIANGSU HANSOH PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
AO	ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
AP	MEITHEAL	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN
	SOLUTION; ORAL					
	FUROSEMIDE					
!	HIKMA	10MG/ML	A070434	001	Apr 22, 1987	May CTEC
@	WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	May DISC
	TABLET; ORAL					
	FUROSEMIDE					
@	EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984	Mar CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

@	CHARTWELL RX	100MG	A091008	001	Oct 26, 2017	Jun CAHN
@		300MG	A091008	002	Oct 26, 2017	Jun CAHN
@		400MG	A091008	003	Oct 26, 2017	Jun CAHN
	NEURONTIN					
AB	+ VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb CAHN
AB	+	300MG	N020235	002	Dec 30, 1993	Feb CAHN
AB	+!	400MG	N020235	003	Dec 30, 1993	Feb CAHN
	SOLUTION; ORAL					
	GABAPENTIN					
AA	BELCHER	250MG/5ML	A091286	001	Mar 14, 2016	Jun CAHN
@	PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN
@	VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN
	NEURONTIN					
AA	+! VIATRIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb CAHN
	TABLET; ORAL					
	NEURONTIN					
AB	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb CAHN
AB	+!	800MG	N020882	002	Oct 09, 1998	Feb CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

+	AZURITY	300MG	N022399	002	Dec 13, 2011	Mar CAHN
+		600MG	N022399	001	Apr 06, 2011	Mar CAHN

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

GADOTERATE MEGLUMINE

AP	HENGRIU PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Jun CAHN
AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Jun CAHN
AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Jun CAHN
AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Jun CAHN
AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Jun CAHN
AP	JIANGSU HENGRIU MED	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Apr NEWA
AP		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Apr NEWA
AP		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Apr NEWA
AP		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Apr NEWA
AP		37.69GM/100ML (376.9MG/ML)	A215982	001	Apr 15, 2022	Apr NEWA

GALLIUM GA-68 GOZETOTIDE

POWDER; INTRAVENOUS

ILLUCIX

+	TELIX	N/A	N214032	001	Dec 17, 2021	Mar CPOT
+	LOCAMETZ					
+	AAA USA NOVARTIS	N/A	N215841	001	Mar 23, 2022	Mar NEWA

SOLUTION; INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

+!	UNIV CA LOS ANGELES	0.5-5mCi/mL	N212642	001	Dec 01, 2020	Jul CPOT
+!		30ML (0.5-5mCi/mL)	N212642	001	Dec 01, 2020	Jun CTNA
+!		30ML (0.5-5mCi/mL)	N212642	001	Dec 01, 2020	Jun CAIN
+!	UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643	001	Dec 01, 2020	Jul CPOT
+!		20ML (0.5-5mCi/mL)	N212643	001	Dec 01, 2020	Jun CTNA
+!		20ML (0.5-5mCi/mL)	N212643	001	Dec 01, 2020	Jun CAIN

GANAXOLONE

SUSPENSION; ORAL

ZTALMY

+!	MARINUS	50MG/ML	N215904	001	Jun 01, 2022	Jun NEWA
----	---------	---------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

@ STERISCIENCE

EQ 500MG BASE/VIAL

A204560 001 Nov 17, 2017 Feb CAHN

GANIRELIX ACETATE

INJECTABLE; INJECTION

FYREMADEL

AP	SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	May CTNA
AP	AMPHASTAR PHARMS INC	250MCG/0.5ML	A212613	001	Apr 07, 2022	Apr NEWA
AP	HONG KONG	250MCG/0.5ML	A214996	001	Jun 06, 2022	May NEWA

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

@ RISING

0.5%

A206446 001 Jun 08, 2018 Jun CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	TEYRO LABS	EQ 200MG BASE/VIAL	A078759	001	Jul 25, 2011	Apr CAHN
AP		EQ 1GM BASE/VIAL	A078759	002	Jul 25, 2011	Apr CAHN

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

@ CHARTWELL RX

600MG

A074615 001 Sep 29, 1995 Feb CAHN

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ @ LG CHEM LTD

EQ 320MG BASE

N021158 001 Apr 04, 2003 Jan DISC

GEMIFLOXACIN MESYLATE

EQ 320MG BASE

A090466 001 Jun 15, 2015 Jan DISC

@ ORBION PHARMS

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

>D> AT	AKORN	EQ 0.3% BASE	A062635	001	Jan 08, 1987	Aug DISC
>A>	@	EQ 0.3% BASE	A062635	001	Jan 08, 1987	Aug DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	! APOTEX	10MG	A075795	002	Jun 13, 2001	May CHRS
AB	AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb CAHN
AB		10MG	A074226	002	May 10, 1994	Feb CAHN
	GLUCOTROL					
+ @ PFIZER		5MG	N017783	001	May 08, 1984	May DISC
+ @		10MG	N017783	002	May 08, 1984	May DISC

GLYBURIDE

TABLET;ORAL

GLYBURIDE

@ CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016	Jul CAHN
@	2.5MG	A203581	002	Apr 14, 2016	Jul CAHN
@	5MG	A203581	003	Apr 14, 2016	Jul CAHN
@ SUNNY	1.25MG	A203581	001	Apr 14, 2016	Mar DISC
@	2.5MG	A203581	002	Apr 14, 2016	Mar DISC
@	5MG	A203581	003	Apr 14, 2016	Mar DISC
GLYBURIDE (MICRONIZED)					
@ CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb CAHN
@	3MG	A075174	002	Jun 22, 1998	Feb CAHN

GLCOPYRROLATE

INJECTABLE;INJECTION

GLCOPYRROLATE

@ EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018	Jul DISC
@ ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC
SOLUTION;INTRAMUSCULAR, INTRAVENOUS					
GLCOPYRROLATE					

+! FRESENIUS KABI USA 0.6MG/3ML (0.2MG/ML) N214919 001 Apr 21, 2022 Apr NEWA

SOLUTION;ORAL

GLCOPYRROLATE

AA ANNORA PHARMA	1MG/5ML	A213698	001	Jul 05, 2022	Jun NEWA
AA SUVEN PHARMS	1MG/5ML	A212467	001	Jul 05, 2022	Jun NEWA
TABLET;ORAL					
GLCOPYRROLATE					
@ CHARTWELL RX	1MG	A040568	001	Dec 22, 2004	Jul CAHN
@	2MG	A040568	002	Dec 22, 2004	Jul CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

@ AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009	Jul DISC
AP AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
AP	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
AP	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
@ EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jul DISC
@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jul DISC

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB TWI PHARMS	EQ 1MG BASE	A216399	001	Jun 08, 2022	May NEWA
AB	EQ 2MG BASE	A216399	002	Jun 08, 2022	May NEWA
TABLET, EXTENDED RELEASE;ORAL					
GUANFACINE HYDROCHLORIDE					
AB YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May CMFD
AB	EQ 2MG BASE	A213428	002	Nov 25, 2020	May CMFD
AB	EQ 3MG BASE	A213428	003	Nov 25, 2020	May CMFD
AB	EQ 4MG BASE	A213428	004	Nov 25, 2020	May CMFD

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB ACTAVIS GROUP	0.5MG	A200854	001	Jul 01, 2022	Jun NEWA
AB	1MG	A200854	002	Jul 01, 2022	Jun NEWA
AB	2MG	A200854	003	Jul 01, 2022	Jun NEWA
AB	5MG	A200854	004	Jul 01, 2022	Jun NEWA
AB	10MG	A200854	005	Jul 01, 2022	Jun NEWA
AB	20MG	A200854	006	Jul 01, 2022	Jun NEWA
AB SANDOZ	0.5MG	A071209	002	Nov 17, 1986	Mar CMS1
AB	1MG	A071209	003	Nov 17, 1986	Mar CMS1
@	2MG	A071209	004	Nov 17, 1986	Mar CMS1

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

>D>	AP	AKORN	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug DISC
>A>		@	EQ 5MG BASE/ML	A204849	001	Sep 06, 2017	Aug DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

+ @ HIKMA	1,000 UNITS/ML	N017007	001	Jul CAHN		
+ @	2,500 UNITS/ML	N017007	007	Jul CAHN		
+ @	5,000 UNITS/ML	N017007	002	Jul CAHN		
+ @	5,000 UNITS/0.5ML	N017007	010	Jul CAHN		
+ @	7,500 UNITS/ML	N017007	003	Jul CAHN		
+ @	10,000 UNITS/ML	N017007	004	Jul CAHN		
+ @	15,000 UNITS/ML	N017007	005	Jul CAHN		
+ @	20,000 UNITS/ML	N017007	006	Jul CAHN		
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
+! B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992	Mar CTEC	
@ HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989	Mar DISC	
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
@ HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989	Mar DISC	
HEPARIN SODIUM PRESERVATIVE FREE						
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jul CMFD

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

AB	+! AZURITY	37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CFTG
	+!	37.5MG;20MG	N020727	001	Jun 23, 2005	Mar CAHN
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
AB	RICONPHARMA LLC	37.5MG;20MG	A215586	001	Apr 06, 2022	Mar NFTG

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

@ CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb CAHN
@	50MG	A084912	001		Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987	Feb CAHN
@	25MG;80MG	A071061	001	Aug 26, 1987	Jan CAHN
@ RISING	25MG;40MG	A070947	002	Mar 04, 1987	Jul CAHN
@	25MG;80MG	A070947	001	Apr 01, 1987	Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun CTNA
@	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
AB	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May CTNA
@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun CTNA
@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
AB	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May CTNA
@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun CTNA
@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC
AB	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May CTNA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996	Jun DISC	
TABLET; ORAL						
MAXZIDE						
AB	+! AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984	Feb CAHN
MAXZIDE-25						
AB	+ AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988	Feb CAHN

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE
 AB RUBICON 25MG;37.5MG
 AB 50MG;75MG

A216211 001 Feb 23, 2022 Feb NEWA
 A216211 002 Feb 23, 2022 Feb NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL
 HYDROCODONE BITARTRATE

AB ALVOGEN	20MG	A208269	001	Mar 01, 2021	May CAHN
AB	30MG	A208269	002	Mar 01, 2021	May CAHN
AB	40MG	A208269	003	Mar 01, 2021	May CAHN
AB	60MG	A208269	004	Mar 01, 2021	May CAHN
AB	80MG	A208269	005	Mar 01, 2021	May CAHN
AB	100MG	A208269	006	Mar 01, 2021	May CAHN
AB	120MG	A208269	007	Mar 01, 2021	May CAHN

HYDROCORTISONE

CREAM;TOPICAL
 HYDROCORTISONE

@ ENCUBE	2.5%	A203810	001	Jul 23, 2018	Jul CAHN
@ LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	Jun DISC

LOTION;TOPICAL
 ALA-SCALP

DERM RX	2%	A083231	001		Jun CAHN
HYDROCORTISONE		A040417	001	Jul 30, 2003	Jun DISC
@ LANNETT CO INC	2.5%				

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION
 HYDROMORPHONE HYDROCHLORIDE

HOSPIRA INC 0.5MG/0.5ML

N200403 004 Jun 13, 2022 Jun NEWA

TABLET;ORAL
 HYDROMORPHONE HYDROCHLORIDE

>D> AB HIKMA	4MG	A074597	003	May 29, 2009	Aug DISC
>A> @	4MG	A074597	003	May 29, 2009	Aug DISC
>D> AB	8MG	A074597	001	Jul 29, 1998	Aug DISC
>A> @	8MG	A074597	001	Jul 29, 1998	Aug DISC

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
 CYANOKIT

@ BTG INTL	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Mar CAHN
+!	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Mar CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
 HYDROXYCHLOROQUINE SULFATE

! ACCORD HLTHCARE	400MG	A213342	004	Aug 18, 2021	Jan CHRS
!	400MG	A213342	004	Aug 18, 2021	Jan CHRS
AB AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May CAHN
+ NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan NEWA
+!	300MG	N214581	002	Jan 14, 2022	Jan NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL
 HYDROXYZINE HYDROCHLORIDE

>D> AA ! AKORN	10MG/5ML	A040010	001	Oct 28, 1994	Aug DISC
>A> @	10MG/5ML	A040010	001	Oct 28, 1994	Aug DISC
+! PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Jan CAHN

TABLET;ORAL
 HYDROXYZINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May CMFD
AB	25MG	A087871	003	Dec 20, 1982	May CMFD
AB	50MG	A087871	001	Dec 20, 1982	May CMFD

IBRUTINIB

>A> SUSPENSION;ORAL					
>A> IMBRUVICA					
>A> +! PHARMACYCLICS INC	70MG/ML	N217003	001	Aug 24, 2022	Aug NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AB	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May CTEC
AB	STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	May NEWA
	TABLET;ORAL					
	IBUPROFEN					
	@ SUNSHINE	400MG	A204062	001	Sep 10, 2018	Mar CAHN
	@	600MG	A204062	002	Sep 10, 2018	Mar CAHN
	@	800MG	A204062	003	Sep 10, 2018	Mar CAHN
AB	YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar NEWA
AB		600MG	A215318	002	Mar 30, 2022	Mar NEWA
AB		800MG	A215318	003	Mar 30, 2022	Mar NEWA

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	+!	TAKEDA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CAHN
----	----	-------------------	------------------------------------	---------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB	TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Jul CMFD
----	-----------------	-------	---------	-----	--------------	----------

ILOPERIDONE

TABLET;ORAL

FANAPT

AB	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jul CTEC
AB	+!		1MG	N022192	001	May 06, 2009	Apr CTEC
	+		2MG	N022192	002	May 06, 2009	Jul CTEC
AB	+		2MG	N022192	002	May 06, 2009	Apr CTEC
	+		4MG	N022192	003	May 06, 2009	Jul CTEC
AB	+		4MG	N022192	003	May 06, 2009	Apr CTEC
	+		6MG	N022192	004	May 06, 2009	Jul CTEC
AB	+		6MG	N022192	004	May 06, 2009	Apr CTEC
	+		8MG	N022192	005	May 06, 2009	Jul CTEC
AB	+		8MG	N022192	005	May 06, 2009	Apr CTEC
	+		10MG	N022192	006	May 06, 2009	Jul CTEC
AB	+		10MG	N022192	006	May 06, 2009	Apr CTEC
	+		12MG	N022192	007	May 06, 2009	Jul CTEC
AB	+		12MG	N022192	007	May 06, 2009	Apr CTEC
	ILOPERIDONE						
	@ LUPIN LTD	1MG	A206890	001	May 05, 2022	Jul DISC	
AB		1MG	A206890	001	May 05, 2022	Apr NEWA	
	@	2MG	A206890	002	May 05, 2022	Jul DISC	
AB		2MG	A206890	002	May 05, 2022	Apr NEWA	
	@	4MG	A206890	003	May 05, 2022	Jul DISC	
AB		4MG	A206890	003	May 05, 2022	Apr NEWA	
	@	6MG	A206890	004	May 05, 2022	Jul DISC	
AB		6MG	A206890	004	May 05, 2022	Apr NEWA	
	@	8MG	A206890	005	May 05, 2022	Jul DISC	
AB		8MG	A206890	005	May 05, 2022	Apr NEWA	
	@	10MG	A206890	006	May 05, 2022	Jul DISC	
AB		10MG	A206890	006	May 05, 2022	Apr NEWA	
	@	12MG	A206890	007	May 05, 2022	Jul DISC	
AB		12MG	A206890	007	May 05, 2022	Apr NEWA	

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB	QILU PHARM HAINAN	EQ 100MG BASE	A212135	001	Jun 21, 2022	Jun NEWA
AB		EQ 400MG BASE	A212135	002	Jun 21, 2022	Jun NEWA

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

@ CHARTWELL RX

1.25MG

@

2.5MG

A074594 001 May 23, 1996 Feb CAHN

A074594 002 May 23, 1996 Feb CAHN

INDIGOTINDISULFONATE SODIUM

SOLUTION; INTRAVENOUS

BLUDIGO

+! PROVEPHARM SAS

40MG/5ML (8MG/ML)

N216264 001 Jul 08, 2022 Jul NEWA

IODIXANOL

INJECTABLE; INJECTION

IODIXANOL

AP	HENGRIU PHARMA	55%	A214271	001	May 19, 2022	May NFTG
AP		65.2%	A214271	002	May 19, 2022	May NFTG
	VISIPAQUE 270					
AP	+! GE HEALTHCARE	55%	N020351	001	Mar 22, 1996	May CFTG
	VISIPAQUE 320					
AP	+! GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996	May CFTG

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

AP	+! GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011	Mar CFTG
AP	CURIUM	5mCi/2.5ML (2mCi/ML)	A213792	001	Mar 30, 2022	Mar NFTG

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

@ BAUSCH

0.02%

A075835 001 Oct 15, 2001 Jun CAHN

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

>A> AB	AMNEAL	0.021MG/SPRAY	A215104	001	Aug 16, 2022	Aug NEWA
>A> AB		0.042MG/SPRAY	A215105	001	Aug 16, 2022	Aug NEWA
AB	BAUSCH	0.021MG/SPRAY	A076025	001	Mar 31, 2003	Jun CAHN
AB		0.042MG/SPRAY	A076103	001	Mar 31, 2003	Jun CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	EUGIA PHARMA	500MG/25ML (20MG/ML)	A213278	004	Apr 11, 2022	Apr NEWA
----	--------------	----------------------	---------	-----	--------------	----------

ISONIAZID

SYRUP; ORAL

ISONIAZID

@ CHARTWELL RX

50MG/5ML

A081118 001 Jul 21, 1997 Mar CAHN

TABLET; ORAL

ISONIAZID

+ @ EPIC PHARMA LLC

100MG

N008678 002

Jul CAHN

+ @

300MG

N008678 003

Jul CAHN

AA	MIKART	100MG	A040090	001	Jun 26, 1997	Mar CAHN
AA		300MG	A040090	002	Jun 26, 1997	Mar CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

>A> AP	MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Aug NEWA
--------	----------------	----------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

AB	RUBICON	5MG	A215723	001	Jul 08, 2022	Jul NEWA
AB		10MG	A215723	002	Jul 08, 2022	Jul NEWA
AB		20MG	A215723	003	Jul 08, 2022	Jul NEWA
AB		30MG	A215723	004	Jul 08, 2022	Jul NEWA
AB		40MG	A215723	005	Jul 08, 2022	Jul NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	SHANDONG	120MG	A214115	001	Apr 29, 2022	Apr NEWA
AB	ZYDUS PHARMS	30MG	A075395	001	Mar 16, 2000	Mar CAHN
AB		60MG	A075395	002	Mar 16, 2000	Mar CAHN
AB		120MG	A075395	003	Mar 16, 2000	Mar CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION
 ISOSULFAN BLUE
 @ EUGIA PHARMA 1% A206831 001 Feb 02, 2016 Jul DISC

ITRACONAZOLE

CAPSULE; ORAL
 ITRACONAZOLE
 @ JUBILANT GENERICS 100MG A203445 001 Feb 23, 2017 May DISC

IVABRADINE HYDROCHLORIDE

TABLET; ORAL
 CORLANOR
 + AMGEN INC EQ 5MG BASE N206143 001 Apr 15, 2015 Jan CTEC
 +! EQ 7.5MG BASE N206143 002 Apr 15, 2015 Jan CTEC
 IVABRADINE HYDROCHLORIDE
 @ CENTAUR PHARMS PVT EQ 5MG BASE A214051 001 Dec 30, 2021 Jan DISC
 @ EQ 7.5MG BASE A214051 002 Dec 30, 2021 Jan DISC

IVERMECTIN

CREAM; TOPICAL
 IVERMECTIN
 AB ZYDUS 1% A215210 001 Aug 02, 2022 Jul NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
 KETOROLAC TROMETHAMINE
 @ STERISCIENCE 15MG/ML A078299 001 Jul 16, 2007 Feb CAHN
 @ 15MG/ML A201155 001 Aug 04, 2014 Feb CAHN
 @ 30MG/ML A078299 002 Jul 16, 2007 Feb CAHN
 @ 30MG/ML A201155 002 Aug 04, 2014 Feb CAHN
 SOLUTION/DROPS; OPHTHALMIC
 KETOROLAC TROMETHAMINE
 @ AKORN 0.4% A078399 001 Nov 05, 2009 Jun DISC
 TABLET; ORAL
 KETOROLAC TROMETHAMINE
 AB HAVIX 10MG A215788 001 Mar 23, 2022 Mar NEWA
 >A> AB HETERO LABS LTD III 10MG A216651 001 Aug 25, 2022 Aug NEWA
 AB SENORES PHARMS 10MG A215788 001 Mar 23, 2022 Mar CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION
 OMIDRIA
 AT +! RAYNER SURGICAL EQ 0.3% BASE; EQ 1% BASE N205388 001 May 30, 2014 Feb CAHN

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS; OPHTHALMIC
 ACUVUE THERAVISION WITH KETOTIFEN
 +! JOHNSON JOHNSON VISN EQ 19MCG BASE N022388 001 Feb 25, 2022 Feb NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION
 LABETALOL HYDROCHLORIDE
 @ STERISCIENCE 5MG/ML A079134 001 Feb 03, 2010 Feb CAHN
 SOLUTION; INTRAVENOUS
 LABETALOL HYDROCHLORIDE
 >A> +! HIKMA 10MG/2ML (5MG/ML) N213330 005 Mar 18, 2022 Aug NEWA
 TABLET; ORAL
 LABETALOL HYDROCHLORIDE
 AB UNICHEM 100MG A212719 001 Aug 08, 2022 Jul NEWA
 AB 200MG A212719 002 Aug 08, 2022 Jul NEWA
 AB 300MG A212719 003 Aug 08, 2022 Jul NEWA

LACOSAMIDE

SOLUTION; INTRAVENOUS
 LACOSAMIDE
 AP FRESENIUS KABI USA 200MG/20ML (10MG/ML) A214677 001 May 03, 2022 Apr NEWA
 AP INDOCO 200MG/20ML (10MG/ML) A214301 001 Apr 07, 2022 Apr NFTG
 AP ZYDUS PHARMS 200MG/20ML (10MG/ML) A209465 001 Jun 29, 2022 Jun NEWA

SOLUTION; INTRAVENOUS

VIMPAT

AP	+! UCB INC	200MG/20ML (10MG/ML)	N 022254	001	Oct 28, 2008	Apr CFTG
	SOLUTION; ORAL					
	LACOSAMIDE					
AA	ALKEM LABS LTD	10MG/ML	A 214672	001	May 19, 2022	May NFTG
AA	HETERO LABS LTD III	10MG/ML	A 209301	001	May 31, 2022	May NEWA
>A> AA	NOVITIUM PHARMA	10MG/ML	A 216151	001	Aug 26, 2022	Aug NEWA
	VIMPAT					
AA	+! UCB INC	10MG/ML	N 022255	001	Apr 20, 2010	May CFTG
	TABLET; ORAL					
	LACOSAMIDE					
AB	ACCORD HLTHCARE	50MG	A 205011	001	Jul 12, 2022	Jul NEWA
AB		100MG	A 205011	002	Jul 12, 2022	Jul NEWA
AB		150MG	A 205011	003	Jul 12, 2022	Jul NEWA
AB		200MG	A 205011	004	Jul 12, 2022	Jul NEWA
AB	ALEMBIC PHARMS LTD	50MG	A 204974	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 204974	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 204974	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 204974	004	Mar 17, 2022	Mar NFTG
AB	ALKEM LABS LTD	50MG	A 214695	001	Mar 31, 2022	Mar NEWA
AB		100MG	A 214695	002	Mar 31, 2022	Mar NEWA
AB		150MG	A 214695	003	Mar 31, 2022	Mar NEWA
AB		200MG	A 214695	004	Mar 31, 2022	Mar NEWA
AB	AMNEAL PHARMS	50MG	A 204857	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 204857	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 204857	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 204857	004	Mar 17, 2022	Mar NFTG
AB	GLENMARK PHARMS LTD	50MG	A 205006	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 205006	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 205006	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 205006	004	Mar 17, 2022	Mar NFTG
AB	HETERO LABS LTD V	50MG	A 204787	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 204787	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 204787	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 204787	004	Mar 17, 2022	Mar NFTG
AB	INDOCO	50MG	A 208308	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 208308	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 208308	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 208308	004	Mar 17, 2022	Mar NFTG
AB	MSN LABS PVT LTD	50MG	A 204921	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 204921	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 204921	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 204921	004	Mar 17, 2022	Mar NFTG
AB	SCIEGEN PHARMS INC	50MG	A 205237	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 205237	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 205237	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 205237	004	Mar 17, 2022	Mar NFTG
AB	SUN PHARM	50MG	A 205031	001	Mar 17, 2022	Mar NFTG
AB		100MG	A 205031	002	Mar 17, 2022	Mar NFTG
AB		150MG	A 205031	003	Mar 17, 2022	Mar NFTG
AB		200MG	A 205031	004	Mar 17, 2022	Mar NFTG
	VIMPAT					
AB	+ UCB INC	50MG	N 022253	001	Oct 28, 2008	Mar CFTG
AB	+	100MG	N 022253	002	Oct 28, 2008	Mar CFTG
AB	+	150MG	N 022253	003	Oct 28, 2008	Mar CFTG
AB	+!	200MG	N 022253	004	Oct 28, 2008	Mar CFTG

LACTULOSE

SOLUTION; ORAL

LACTULOSE

@ TORRENT

10GM/15ML

A 207786

001

Jun 11, 2018

Jun

DISC

SOLUTION; ORAL, RECTAL

LACTULOSE

@ TORRENT

10GM/15ML

A 203762

001

Mar 27, 2015

Jun

DISC

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

@ CHARTWELL RX

150MG; 300MG

A 079081

001

May 25, 2011

Mar

CAHN

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

>D>	AB	TORRENT	200MG	A203370	004	Dec 23, 2013	Aug DISC
>A>	@		200MG	A203370	004	Dec 23, 2013	Aug DISC
TABLET, FOR SUSPENSION;ORAL							
LAMICTAL CD							
AB	+	GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Jan CDFR
AB	+		5MG	N020764	001	Aug 24, 1998	Jan CDFR
AB	+!		25MG	N020764	002	Aug 24, 1998	Jan CDFR
	@		100MG	N020764	003	Aug 24, 1998	Jan CDFR
LAMOTRIGINE							
AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	Jan CDFR
AB			25MG	A201168	002	Jun 12, 2014	Jan CDFR
AB		AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009	Jan CDFR
AB			25MG	A090401	003	Nov 04, 2009	Jan CDFR
AB		DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009	Jan CDFR
AB			25MG	A076701	002	Jan 22, 2009	Jan CDFR
AB		GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	Jan CDFR
AB			25MG	A079099	002	Feb 19, 2009	Jan CDFR
	@	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jan CDFR
	@		25MG	A200220	002	Feb 28, 2011	Jan CDFR
	@	MYLAN	5MG	A076630	001	Jan 22, 2009	Jan CDFR
	@		25MG	A076630	002	Jan 22, 2009	Jan CDFR
	@	SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan CDFR
	@		25MG	A078409	003	Jan 22, 2009	Jan CDFR
AB		TARO	5MG	A079204	001	Feb 04, 2009	Jan CDFR
AB			25MG	A079204	002	Feb 04, 2009	Jan CDFR
	@	TEVA	5MG	A076420	001	Jun 21, 2006	Jan CDFR
	@		25MG	A076420	002	Jun 21, 2006	Jan CDFR
AB		WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan CDFR
AB			5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB			25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB		ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB			25MG	A078009	003	Jan 22, 2009	Jan CDFR
TABLET, ORALLY DISINTEGRATING;ORAL							
LAMOTRIGINE							
AB		AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB			50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB			100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB			200MG	A214124	004	Feb 03, 2022	Jan NEWA
	@	IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jun DISC
	@		50MG	A200828	002	Jul 15, 2013	Jun DISC
	@		100MG	A200828	003	Jul 15, 2013	Jun DISC
	@		200MG	A200828	004	Jul 15, 2013	Jun DISC

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB	ATLANTIDE	15MG	A202176	001	Sep 14, 2012	Apr CAHN
AB		30MG	A202176	002	Sep 14, 2012	Apr CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD
AB	WANBANG BIOPHARMS	10MG	A077087	001	Sep 13, 2005	Jun CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

>A> AB	APOTEX	5MG	A211022	001	Aug 30,	2022	Aug	NEWA
>A> AB		10MG	A211022	002	Aug 30,	2022	Aug	NEWA
>A> AB		15MG	A211022	003	Aug 30,	2022	Aug	NEWA
>A> AB		25MG	A211022	004	Aug 30,	2022	Aug	NEWA
>A> AB	CIPPLA	5MG	A210435	001	Sep 06,	2022	Aug	NEWA
>A> AB		10MG	A210435	002	Sep 06,	2022	Aug	NEWA
>A> AB		15MG	A210435	003	Sep 06,	2022	Aug	NEWA
>A> AB		25MG	A210435	004	Sep 06,	2022	Aug	NEWA
>A> AB	DR REDDYS	5MG	A209348	003	Aug 30,	2022	Aug	NEWA
>A> AB		10MG	A209348	004	Aug 30,	2022	Aug	NEWA
>A> AB		15MG	A209348	005	Aug 30,	2022	Aug	NEWA
>A> AB		25MG	A209348	006	Aug 30,	2022	Aug	NEWA
>A> AB	LOTUS PHARM CO LTD	5MG	A210480	001	Aug 31,	2022	Aug	NEWA
>A> AB		10MG	A210480	002	Aug 31,	2022	Aug	NEWA
>A> AB		15MG	A210480	003	Aug 31,	2022	Aug	NEWA
>A> AB		25MG	A210480	004	Aug 31,	2022	Aug	NEWA
>A> AB	MYLAN	5MG	A213912	001	Aug 30,	2022	Aug	NEWA
>A> AB		10MG	A213912	002	Aug 30,	2022	Aug	NEWA
>A> AB		15MG	A213912	003	Aug 30,	2022	Aug	NEWA
>A> AB		25MG	A213912	004	Aug 30,	2022	Aug	NEWA

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LUTRATE DEPOT KIT

+! GP-PHARM SA 22.5MG/VIAL

N205054 001 Aug 28, 2018 May CMFD

+! INVAGEN PHARMS 22.5MG/VIAL

N205054 001 Aug 28, 2018 Jun CAHN

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP EUGIA PHARMA 1MG/0.2ML

A212963 001 Jun 06, 2022 May NEWA

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

+! ACCORD EQ 42MG BASE

N211488 001 May 25, 2021 Jan CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

AP PRINSTON INC 500MG/5ML (100MG/ML)

A209474 001 Mar 28, 2022 Mar NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA AIPING PHARM INC 100MG/ML
AA BELCHER 100MG/ML
AA MSN 100MG/ML
@ WOCKHARDT BIO AG 100MG/MLA090079 001 Apr 11, 2012 Jun CAHN
A090461 001 Sep 30, 2010 Jun CAHN
A214757 001 Jul 15, 2022 Jul NEWA
A090028 001 Mar 03, 2010 Apr DISC

TABLET;ORAL

LEVETIRACETAM

AB ALKEM LABS LTD 250MG

A216375 001 May 27, 2022 May NEWA

AB 500MG

A216375 002 May 27, 2022 May NEWA

AB 750MG

A216375 003 May 27, 2022 May NEWA

AB 1GM

A216375 004 May 27, 2022 May NEWA

AB SCIEGEN PHARMS INC 250MG

A215069 003 May 27, 2022 May NEWA

AB 500MG

A215069 004 May 27, 2022 May NEWA

AB 750MG

A215069 001 Jun 11, 2021 Jun CMFD

@ 750MG

A215069 001 Jun 11, 2021 Apr DISC

AB 1GM

A215069 002 Jun 11, 2021 Jun CMFD

@ 1GM

A215069 002 Jun 11, 2021 Apr DISC

@ SECAN PHARMS 500MG

A205102 004 Dec 16, 2015 Jan DISC

@ 1GM

A205102 003 Dec 16, 2015 Jan DISC

AB STALLION LABS 250MG

A079042 001 Jan 15, 2009 Mar CAHN

AB 500MG

A079042 002 Jan 15, 2009 Mar CAHN

AB 750MG

A079042 003 Jan 15, 2009 Mar CAHN

AB 1GM

A079042 004 Jan 15, 2009 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

>A> AB AIPING PHARM INC 500MG

A204754 001 Aug 26, 2016 Aug CAHN

>A> AB 750MG

A204754 002 Aug 26, 2016 Aug CAHN

>D> AB GENUS LIFESCIENCES 500MG

A204754 001 Aug 26, 2016 Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

>D> AB 750MG A204754 002 Aug 26, 2016 Aug CAHN

LEVOSETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
LEVOSETIRIZINE DIHYDROCHLORIDE

AA CHARTWELL MOLECULAR 2.5MG/5ML

A204599 001 May 15, 2017 Jun CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVOFLOXACIN

AP ! AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001 Jun 20, 2011 Jul CHRS
AP ! @ EUGIA PHARMA	EQ 750MG/30ML (EQ 25MG/ML)	A091644 002 Jun 20, 2011 Jul CHRS
@	EQ 500MG/20ML (EQ 25MG/ML)	A202328 001 Jan 24, 2013 Jul DISC
@	EQ 750MG/30ML (EQ 25MG/ML)	A202328 002 Jan 24, 2013 Jul DISC
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER		
@ EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919 001 Feb 10, 2016 Jul DISC
@	EQ 500MG/100ML (EQ 5MG/ML)	A206919 002 Feb 10, 2016 Jul DISC
@	EQ 750MG/150ML (EQ 5MG/ML)	A206919 003 Feb 10, 2016 Jul DISC

TABLET;ORAL

LEVOFLOXACIN

AB CHARTWELL MOLECULAR	250MG	A076890 001 Mar 30, 2012 Mar CAHN
AB	500MG	A076890 002 Mar 30, 2012 Mar CAHN
AB	750MG	A076890 003 Mar 30, 2012 Mar CAHN

LEVOLEUCOVORIN

POWDER;INTRAVENOUS
KHPZORY

+! ACROTECH BIOPHARMA	175MG/VIAL	N211226 001 Oct 19, 2018 Jul CAHN
+!	300MG/VIAL	N211226 002 Oct 19, 2018 Jul CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

@ HIKMA	EQ 50MG BASE/VIAL	A206263 001 Jun 16, 2016 Jul DISC
---------	-------------------	-----------------------------------

SOLUTION;INTRAVENOUS
LEVOLEUCOVORIN CALCIUM

@ PAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797 001 Nov 02, 2021 Feb DISC
----------	--	-----------------------------------

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

@ L PERRIGO CO	0.75MG	A090740 001 Dec 30, 2010 May DISC
----------------	--------	-----------------------------------

LEVOOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOOTHYROXINE SODIUM

@ TEVA PHARMS USA INC	0.112MG	A211369 003 Apr 16, 2021 Jan DISC
TIROSINT		
+ INSTITUT BIOCHIMIQUE	0.0375MG	N021924 014 Jun 22, 2022 Jun NEWA
+	0.044MG	N021924 015 Jun 22, 2022 Jun NEWA
+	0.0625MG	N021924 016 Jun 22, 2022 Jun NEWA
+	0.112MG	N021924 008 Oct 02, 2009 Jan CTEC

SOLUTION;INTRAVENOUS
LEVOOTHYROXINE SODIUM

>D> +! CUSTOPHARM INC	100MCG/ML	N214253 001 May 17, 2021 Aug CAHN
>A> +! HIKMA	100MCG/ML	N214253 001 May 17, 2021 Aug CAHN

SOLUTION;ORAL

ERMEZA

+! MYLAN THYQUIDITY	150MCG/5ML	N215809 001 Apr 29, 2022 Apr NEWA
+! AZURITY	100MCG/5ML	N214047 001 Nov 30, 2020 Jul CAHN

LEVOOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

>D> AB1, AB3, AB4 GENUS LIFESCIENCES	0.025MG	N021137 001 Jun 06, 2003 Aug CTEC
--------------------------------------	---------	-----------------------------------

TABLET;ORAL
LEVOLET

>A>	AB1, AB2, AB3, AB4	0.025MG	N 021137 001 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.025MG	N 021137 001 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.05MG	N 021137 002 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.05MG	N 021137 002 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.05MG	N 021137 002 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.075MG	N 021137 003 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.075MG	N 021137 003 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.075MG	N 021137 003 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.088MG	N 021137 004 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.088MG	N 021137 004 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.088MG	N 021137 004 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.1MG	N 021137 005 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.1MG	N 021137 005 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.1MG	N 021137 005 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.112MG	N 021137 006 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.112MG	N 021137 006 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.112MG	N 021137 006 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.125MG	N 021137 007 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.125MG	N 021137 007 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.125MG	N 021137 007 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.137MG	N 021137 008 Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.137MG	N 021137 008 Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.137MG	N 021137 008 Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.15MG	N 021137 009 Jun 06, 2003	Aug CTEC

TABLET;ORAL LEVOLET						
>A>	AB1, AB2, AB3, AB4	0.15MG	N 021137	009	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.15MG	N 021137	009	Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.175MG	N 021137	010	Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.175MG	N 021137	010	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.175MG	N 021137	010	Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.2MG	N 021137	011	Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.2MG	N 021137	011	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.2MG	N 021137	011	Jun 06, 2003	Jan CMFD
>D>	AB1, AB3, AB4	0.3MG	N 021137	012	Jun 06, 2003	Aug CTEC
>A>	AB1, AB2, AB3, AB4	0.3MG	N 021137	012	Jun 06, 2003	Aug CTEC
	AB1, AB3, AB4	0.3MG	N 021137	012	Jun 06, 2003	Jan CMFD
LEVOTHYROXINE SODIUM						
AB1,	WATSON LABS TEVA	0.025MG	A 207588	001	May 10, 2022	Apr NEWA
AB2,		0.05MG	A 207588	002	May 10, 2022	Apr NEWA
AB1,		0.075MG	A 207588	003	May 10, 2022	Apr NEWA
AB2,		0.088MG	A 207588	004	May 10, 2022	Apr NEWA
AB1,		0.1MG	A 207588	005	May 10, 2022	Apr NEWA
AB2,		0.112MG	A 207588	006	May 10, 2022	Apr NEWA
AB1,		0.125MG	A 207588	007	May 10, 2022	Apr NEWA
AB2,		0.137MG	A 207588	008	May 10, 2022	Apr NEWA
AB1,		0.15MG	A 207588	009	May 10, 2022	Apr NEWA
AB2,		0.175MG	A 207588	010	May 10, 2022	Apr NEWA
AB1,		0.2MG	A 207588	011	May 10, 2022	Apr NEWA
AB2,		0.3MG	A 207588	012	May 10, 2022	Apr NEWA
THYRO-TABS						
AB1, +	ALVOGEN	0.025MG	N 021116	001	Oct 24, 2002	Apr CTEC
AB2,		0.05MG	N 021116	002	Oct 24, 2002	Apr CTEC
AB3,		0.075MG	N 021116	003	Oct 24, 2002	Apr CTEC
AB4		0.088MG	N 021116	010	Oct 24, 2002	Apr CTEC

TABLET;ORAL
THYRO-TABS

AB1, +	0.1MG	N 021116 004 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.112MG	N 021116 011 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.125MG	N 021116 005 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.137MG	N 021116 012 Dec 07, 2004	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.15MG	N 021116 006 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.175MG	N 021116 007 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.2MG	N 021116 008 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			
AB1, +	0.3MG	N 021116 009 Oct 24, 2002	Apr CTEC
AB2,			
AB3,			
AB4			

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC
AKTEN

+! THEA PHARMA	3.5%	N 022221 001 Oct 07, 2008	Apr CAHN
INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE			
AP AFAXYS	1%	A 215132 001 Jun 09, 2022	Jun NEWA
AP SINTETICA SA	4%	A 214269 001 May 05, 2022	Apr NEWA
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
AP ! HOSPIRA	4%	A 088295 001 May 17, 1984	Apr CTEC
INJECTABLE;SPINAL LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%			
+! HOSPIRA	5%	A 083914 001	Jul CRLD
SOLUTION;TOPICAL LIDOCAINE HYDROCHLORIDE			
AT NOVITIUM PHARMA	4%	A 216250 001 Mar 23, 2022	Mar NEWA

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
EMLA

+ @ TEVA BRANDED PHARM	2.5%;2.5%	N 019941 001 Dec 30, 1992	Jul DISC
LIDOCAINE AND PRILOCAINE			
@ ACRUX DDS PTY	2.5%;2.5%	A 212482 001 Jul 27, 2021	Jan DISC
AB ! AKORN	2.5%;2.5%	A 076290 001 Sep 25, 2003	Jul CHRS
AB ALEOR DERMACEUTICALS	2.5%;2.5%	A 213923 001 Apr 08, 2022	Apr NEWA
@ PADAGIS US	2.5%;2.5%	A 212482 001 Jul 27, 2021	Jun CAHN

LINDANE

SHAMPOO;TOPICAL
LINDANE

@ WOCKHARDT BIO AG	1%	A 088191 001 Sep 18, 1984	Jul DISC
--------------------	----	---------------------------	----------

LINEZOLID

SOLUTION;INTRAVENOUS
LINEZOLID

>A> AP HIKMA	600MG/300ML (2MG/ML)	A 206454 001 Aug 22, 2022	Aug NEWA
@ HOSPIRA	600MG/300ML (2MG/ML)	A 205442 001 Jul 07, 2015	May DISC
TABLET;ORAL LINEZOLID			
@ AMNEAL PHARMS	600MG	A 204536 001 Dec 21, 2015	Jul DISC

LISINOPRIL

TABLET;ORAL

LISINOPRIL

@	GRAVITI PHARMS	2.5MG	A075999	001	Jul 01, 2002	Apr CAHN
@		5MG	A075999	002	Jul 01, 2002	Apr CAHN
@		10MG	A075999	003	Jul 01, 2002	Apr CAHN
@		20MG	A075999	004	Jul 01, 2002	Apr CAHN
@		30MG	A075999	005	Jul 01, 2002	Apr CAHN
@		40MG	A075999	006	Jul 01, 2002	Apr CAHN
@	STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002	Jan CAHN
@		5MG	A076071	002	Jul 01, 2002	Jan CAHN
@		10MG	A076071	003	Jul 01, 2002	Jan CAHN
@		20MG	A076071	004	Jul 01, 2002	Jan CAHN
@		30MG	A076071	005	Jul 01, 2002	Jan CAHN
@		40MG	A076071	006	Jul 01, 2002	Jan CAHN
	PRINIVIL					
@	MERCK	5MG	N019558	001	Dec 29, 1987	Mar DISC
@		40MG	N019558	004	Oct 25, 1988	Mar DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

+	@	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001	Apr DISC
!	PAJ HOLDINGS PHARM		EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986
!	WOCKHARDT BIO AG		EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986
AA	!		EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

@	CHARTWELL RX	2MG	A072993	001	Aug 28, 1992	Mar CAHN
---	--------------	-----	---------	-----	--------------	----------

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	LAURUS	100MG;25MG	A213857	001	Mar 21, 2022	Mar NEWA
AB		200MG;50MG	A213857	002	Mar 21, 2022	Mar NEWA

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

+	ALMATICHA	1.5MG	N214826	004	Feb 16, 2022	Feb NEWA
	CONCENTRATE;ORAL					
	LORAZEPAM					

@ LANNETT CO INC 2MG/ML

A079244 001 Apr 28, 2009 Jun DISC

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

@ HIKMA 25MG A077459 001 Oct 06, 2010 Jul DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

EYSUVIS

>A>	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020	Aug CAHN
>D>	+!	KALA PHARMS INC	0.25%	N210933	001	Oct 26, 2020	Aug CAHN
		INVELTYS					
>A>	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018	Aug CAHN
>D>	+!	KALA PHARMS INC	1%	N210565	001	Aug 22, 2018	Aug CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

>D> AB	BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Aug CAHN
>D> AB		20MG	A075300	002	Dec 17, 2001	Aug CAHN
>D> AB		40MG	A075300	003	Dec 17, 2001	Aug CAHN
>A> AB	CHARTWELL RX	10MG	A075300	001	Dec 17, 2001	Aug CAHN
>A> AB		20MG	A075300	002	Dec 17, 2001	Aug CAHN
>A> AB		40MG	A075300	003	Dec 17, 2001	Aug CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

@	AMNEAL	8MCG	A209450	001	Nov 30, 2021	May DISC
@		24MCG	A209450	002	Nov 30, 2021	May DISC
AB	ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022	Jun NEWA
AB		24MCG	A201442	002	Jun 27, 2022	Jun NEWA
AB	DR REDDYS	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB		24MCG	A206994	002	Feb 08, 2022	Jan NEWA
>D>	TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Aug DISC
>A>	@	8MCG	A209920	001	Jan 18, 2022	Aug DISC
AB		8MCG	A209920	001	Jan 18, 2022	Jan NEWA
>D>	AB	24MCG	A209920	002	Jan 18, 2022	Aug DISC
>A>	@	24MCG	A209920	002	Jan 18, 2022	Aug DISC
AB		24MCG	A209920	002	Jan 18, 2022	Jan NEWA

LUMATEPERONE TOSYLATE

CAPSULE;ORAL

CAPLYTA

+ INTRA-CELLULAR

EQ 10.5MG BASE

N209500

002 Apr 22, 2022

May NEWA

+ EQ 21MG BASE

N209500

003 Apr 22, 2022

May NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

>D>	@ INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Aug CMFD
>A> AB		20MG	A208028	001	Jan 03, 2019	Aug CMFD
>D>	@	40MG	A208028	002	Jan 03, 2019	Aug CMFD
>A> AB		40MG	A208028	002	Jan 03, 2019	Aug CMFD
>D>	@	60MG	A208028	003	Jan 03, 2019	Aug CMFD
>A> AB		60MG	A208028	003	Jan 03, 2019	Aug CMFD
>D>	@	80MG	A208028	004	Jan 03, 2019	Aug CMFD
>A> AB		80MG	A208028	004	Jan 03, 2019	Aug CMFD
>D>	@	120MG	A208028	005	Jan 03, 2019	Aug CMFD
>A> AB		120MG	A208028	005	Jan 03, 2019	Aug CMFD

LUTETIUM LU 177 DOTATATE

SOLUTION;INTRAVENOUS

LUTATHERA

+! AAA USA INC

10mCi/ML

N208700

001 Jan 26, 2018

Jun CAIN

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION;INTRAVENOUS

PLUVICTO

+! AAA USA NOVARTIS

27mCi/ML

N215833

001 Mar 23, 2022

Mar NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	! PAR FORM	5%	A201511	001	Feb 12, 2013	Feb CHRS
	SULFAMYLYON		N019832	003	Jun 05, 1998	Feb DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun NFTG
	MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4					

AP	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Jun CTNA
	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML					

AP	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Jun CFTG
	PLASMA-LYTE A IN PLASTIC CONTAINER					

AP	+! BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	May CFTG
	PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER					

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	@ MILLA PHARMS	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jul DISC
		2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jun CAHN
AP	@	4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jul DISC
		4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jun CAHN
AP	@	4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jul DISC
		4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jun CAHN

MARAVIROC

TABLET; ORAL

MARAVIROC

AB	HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan NFTG
AB		300MG	A203347	002	Feb 07, 2022	Jan NFTG
	SELZENTRY					
AB	+ VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan CFTG
AB	+!	300MG	N022128	002	Aug 06, 2007	Jan CFTG

MAVACAMTEN

CAPSULE; ORAL

CAMZYOS

+	MYOKARDIA	2.5MG	N214998	001	Apr 28, 2022	Apr NEWA
+		5MG	N214998	002	Apr 28, 2022	Apr NEWA
+		10MG	N214998	003	Apr 28, 2022	Apr NEWA
+!		15MG	N214998	004	Apr 28, 2022	Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	APNAR PHARMA LP	12.5MG	A087128	002		Apr CAHN
AA		25MG	A087128	001		Apr CAHN
AA	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb NEWA
AA		25MG	A200432	002	Feb 17, 2022	Feb NEWA
AA		50MG	A200432	003	Feb 17, 2022	Feb NEWA
>A> AA	LUPIN LTD	12.5MG	A203003	001	Aug 11, 2022	Aug NEWA
>A> AA		25MG	A203003	002	Aug 11, 2022	Aug NEWA
>A> AA		50MG	A203003	003	Aug 11, 2022	Aug NEWA

TABLET, CHEWABLE; ORAL

MECLIZINE HYDROCHLORIDE

AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb NEWA
----	----------------	------	---------	-----	--------------	----------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>A> AB	EUGIA PHARMA	150MG/ML	A212824	001	Aug 22, 2022	Aug NEWA
>A> AB		150MG/ML	A212844	001	Aug 31, 2022	Aug NEWA
	@ SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Jul DISC
	@	150MG/ML	A210761	001	Apr 24, 2019	Jul DISC

MELOXICAM

CAPSULE; ORAL

VIVLODEX

+	@ ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar CAHN
+	@	10MG	N207233	002	Oct 22, 2015	Mar CAHN

SUSPENSION; ORAL

MELOXICAM

+	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	May CTNA
+		7.5MG/5ML	N021530	001	Jun 01, 2004	May CMFD

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

	@ ANI PHARMS	14MG	A205365	002	Feb 28, 2020	Apr DISC
--	--------------	------	---------	-----	--------------	----------

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

AB	ALLIED	5MG	A209527	001	May 07, 2018	Feb CAHN
AB		10MG	A209527	002	May 07, 2018	Feb CAHN
>A> AB	ESKAYEF	5MG	A209527	001	May 07, 2018	Aug CAHN
>A> AB		10MG	A209527	002	May 07, 2018	Aug CAHN
>D> AB	RENATA	5MG	A209527	001	May 07, 2018	Aug CAHN

TABLET;ORAL
MEMANTINE HYDROCHLORIDE

AB		5MG	A209527	001	May 07, 2018	Jul CAHN
>D> AB		10MG	A209527	002	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Jul CAHN
@ RISING		5MG	A079225	001	Jan 30, 2015	Jan CAHN
@		10MG	A079225	002	Jan 30, 2015	Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL
MEPERIDINE HYDROCHLORIDE

@ GENUS	50MG	A040893	001	Jun 24, 2009	Apr CAHN
@	75MG	A040893	002	Jun 24, 2009	Apr CAHN
@	100MG	A040893	003	Jun 24, 2009	Apr CAHN
@	150MG	A040893	004	Jun 24, 2009	Apr CAHN
@ MIKART	50MG	A040893	001	Jun 24, 2009	Mar CAHN
@	75MG	A040893	002	Jun 24, 2009	Mar CAHN
@	100MG	A040893	003	Jun 24, 2009	Mar CAHN
@	150MG	A040893	004	Jun 24, 2009	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTION

MEPERGAN

@ HIKMA 25MG/ML;25MG/ML

N011730 001

Jul CAHN

MEROPENEMINJECTABLE; INJECTION

MEROOPENEM

>A> AP	STERISCIENCE	500MG/VIAL	A216154	001	Aug 18, 2022	Aug NEWA
>A> AP		1GM/VIAL	A216154	002	Aug 18, 2022	Aug NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL
MESALAMINE

AB	SUN PHARM	500MG	A214585	001	May 11, 2022	Apr NFTG
AB	TEVA PHARMS USA	375MG	A209970	001	May 06, 2022	Apr NEWA
	PENTASA					
AB	+! TAKEDA PHARMS USA	500MG	N020049	002	Jul 08, 2004	Apr CFTG
	TABLET, DELAYED RELEASE;ORAL					
	ASACOL HD					
+ @ API		800MG	N021830	001	May 29, 2008	May DISC
	MESALAMINE					
!	ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	May CTEC
AB	!	800MG	A203286	001	Jul 21, 2017	May CHRS

METFORMIN HYDROCHLORIDESOLUTION;ORAL

METFORMIN HYDROCHLORIDE

>A> AB	VISTAPHARM	500MG/5ML	A212677	001	Aug 19, 2022	Aug NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	METFORMIN HYDROCHLORIDE					
AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb CTEC
AB		750MG	A078596	002	Jan 03, 2008	Feb CTEC
@ AMTA		500MG	A213394	001	Aug 03, 2021	Jan DISC
@		1GM	A213394	002	Aug 03, 2021	Jan DISC
AB3	PRINSTON INC	500MG	A212681	001	Jun 09, 2022	Jun NEWA
AB3		1GM	A212681	002	Jun 09, 2022	Jun NEWA
AB2	SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb NEWA
AB2		1GM	A214629	002	Feb 22, 2022	Feb NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDETABLET;ORAL

ACTOPLUS MET

+ @ TAKEDA PHARMS USA 500MG;EQ 15MG BASE

N021842 001 Aug 29, 2005

May DISC

METHADONE HYDROCHLORIDETABLET;ORAL

METHADONE HYDROCHLORIDE

@ NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
@	10MG	A210484	002	Aug 02, 2018	Feb DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

>A>	AA	+!	KEY THERAP	5MG	N005378	002	Aug CAHN
>D>	AA	+!	RECORDATI RARE	5MG	N005378	002	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL							
			DESOXYN				
>A>		@	KEY THERAP	5MG	N005378	004	Aug CAHN
>A>		@		10MG	N005378	003	Aug CAHN
>A>		@		15MG	N005378	005	Aug CAHN
>D>		@	RECORDATI RARE	5MG	N005378	004	Aug CAHN
>D>		@		10MG	N005378	003	Aug CAHN
>D>		@		15MG	N005378	005	Aug CAHN

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018	Apr CAHN
AB			50MG	A207438	002	Oct 05, 2018	Apr CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+	VALIDUS PHARMS	1GM	N017681	001		Apr CMFD
----	---	----------------	-----	---------	-----	--	----------

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Jul NEWA
>A>	AP	HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Aug CAHN
>D>	AP	SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Aug CAHN
TABLET;ORAL							
		METHOCARBAMOL					
>A>		@ CHARTWELL MOLECULAR	500MG	A084756	002	Mar 31, 2003	Aug CAHN
>A>		@	750MG	A084756	001		Aug CAHN
>D>		@ LANNETT CO INC	500MG	A084756	002	Mar 31, 2003	Aug CAHN
>D>		@	750MG	A084756	001		Aug CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE LPF

+ @	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan CRLD
+ @		METHOTREXATE PRESERVATIVE FREE				
+ @	HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan CRLD

+ @		EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan CRLD
-----	--	---------------------------------------	---------	-----	--------------	----------

		METHOTREXATE SODIUM					
+ @	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan CRLD	
+ @		EQ 20MG BASE/VIAL	N011719	001		Jan CRLD	
+ @		EQ 25MG BASE/ML	N011719	005		Jan CRLD	
+ @		EQ 50MG BASE/VIAL	N011719	003		Jan CRLD	
+ @		EQ 100MG BASE/VIAL	N011719	006		Jan CRLD	
		METHOTREXATE SODIUM PRESERVATIVE FREE					
@	EUGIA PHARMA SPEC LTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN	
@		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN	
@		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN	
@		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN	
AP	HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan CHRS	
+ @	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan CRLD	
		MEXATE-AQ					
+ @	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan CRLD	

METHYLDOPA

TABLET;ORAL

METHYLDOPA

>D>		! ACCORD HLTHCARE	500MG	A070085	001	Oct 15, 1985	Aug DISC
>A>		@	500MG	A070085	001	Oct 15, 1985	Aug DISC

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL
DAYTRANA

AB	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
AB	+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
AB	+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
AB	+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG
		METHYLPHENIDATE					
AB		MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar NFTG
AB			15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar NFTG
AB			20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar NFTG
AB			30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar NFTG

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR

+ @	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Jul DISC
+ @		35MG	N212038	002	Feb 27, 2019	Jul DISC
+ @		45MG	N212038	003	Feb 27, 2019	Jul DISC
+ @		55MG	N212038	004	Feb 27, 2019	Jul DISC
+ @		70MG	N212038	005	Feb 27, 2019	Jul DISC
+ @		85MG	N212038	006	Feb 27, 2019	Jul DISC
		METADATE CD				

AB2	+	AYTU BIOPHARMA	10MG	N021259	003	May 27, 2003	May CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	May CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	May CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	May CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	May CAHN
AB2	+!		60MG	N021259	006	Feb 19, 2006	May CAHN

		MATERIAL NUMBER					
AB		ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb NEWA
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb CTEC
	@ RHODES PHARMS	18MG		A214111	001	May 31, 2022	Jun DISC
AB			18MG	A214111	001	May 31, 2022	May NEWA
	@	27MG		A214111	002	May 31, 2022	Jun DISC
AB			27MG	A214111	002	May 31, 2022	May NEWA
	@	36MG		A214111	003	May 31, 2022	Jun DISC
AB			36MG	A214111	003	May 31, 2022	May NEWA
	@	54MG		A214111	004	May 31, 2022	Jun DISC
AB			54MG	A214111	004	May 31, 2022	May NEWA
		RELEXXII					
	+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022	Jun NEWA
	+		27MG	N216117	002	Jun 23, 2022	Jun NEWA
	+		36MG	N216117	003	Jun 23, 2022	Jun NEWA
	+		45MG	N216117	004	Jun 23, 2022	Jun NEWA
	+		54MG	N216117	005	Jun 23, 2022	Jun NEWA
	+		63MG	N216117	006	Jun 23, 2022	Jun NEWA
	+!		72MG	N216117	007	Jun 23, 2022	Jun NEWA

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

@ AMNEAL	4MG	A207481	001	Sep 21, 2021	Mar DISC
@	8MG	A207481	002	Sep 21, 2021	Mar DISC
@	16MG	A207481	003	Sep 21, 2021	Mar DISC
@	32MG	A207481	004	Sep 21, 2021	Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION
DEPO-MEDROL

AB	+	PFIZER	40MG/ML	N011757	001		Jul CHRS
AB	+		80MG/ML	N011757	004		Jul CHRS
		METHYLPREDNISOLONE ACETATE					
AB	!	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul CHRS
AB	!		80MG/ML	A210043	002	May 20, 2019	Jul CHRS
	@ PAR STERILE PRODUCTS	40MG/ML		A214297	001	Jan 21, 2022	Jul DISC
AB			40MG/ML	A214297	001	Jan 21, 2022	Jan NEWA
AB			80MG/ML	A214297	002	Jan 21, 2022	Jan NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015	Jul DISC
@		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015	Jul DISC
@		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015	Jul DISC
@		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015	Jul DISC
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan CMFD
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan CMFD
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan CMFD
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan CMFD
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

AB	! IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb CTEC
AB	NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995	Mar CAHN
@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Mar CAHN
@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Mar CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

>D> AB	PRINSTON INC	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022	Aug DISC
>A>	@	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022	Aug DISC
>D> AB		EQ 200MG TARTRATE	A210597	002	Jan 04, 2022	Aug DISC
>A>	@	EQ 200MG TARTRATE	A210597	002	Jan 04, 2022	Aug DISC
AB	YICHANG HUMANWELL	EQ 25MG TARTRATE	A213854	004	Aug 01, 2022	Jul NEWA

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

@	STERISCIENCE	1MG/ML	A090317	001	Apr 19, 2010	Feb CAHN
TABLET; ORAL						
	METOPROLOL TARTRATE					
@	CHARTWELL RX	50MG	A073288	001	Mar 25, 1994	Mar CAHN
@		100MG	A073289	001	Mar 25, 1994	Mar CAHN

METRONIDAZOLE

CREAM; TOPICAL

NORITATE

+! BAUSCH 1%

GEL; VAGINAL

METRONIDAZOLE

AB	GLENMARK PHARMS LTD	0.75%	A215794	001	Jan 27, 2022	Jan NEWA
INJECTABLE; INJECTION						
	METRONIDAZOLE					
@	HIKMA	500MG/100ML	N018907	001	Mar 30, 1984	Jul CAHN
	METRONIDAZOLE IN PLASTIC CONTAINER					
@	RISING	500MG/100ML	A205531	001	May 09, 2017	Jan CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>A> AB	ZENARA	150MG	A215315	001	Aug 26, 2022	Aug NEWA
>A> AB		200MG	A215315	002	Aug 26, 2022	Aug NEWA
>A> AB		250MG	A215315	003	Aug 26, 2022	Aug NEWA

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+! MYLAN 0.25%; 81.35%; 15%

N021026 001 Feb 16, 2006 Jul CAIN

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+! EXELA PHARMA	50MG/50ML (1MG/ML)
+!	100MG/100ML (1MG/ML)

N215868	001	Jul 20, 2022	Jul NEWA
N215868	002	Jul 20, 2022	Jul NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@ STERISCIENCE EQ 1MG BASE/ML

A090315 001 Nov 29, 2010 Jan CAHN

@ EQ 5MG BASE/ML

A090315 002 Nov 29, 2010 Jan CAHN

MIDOZALAM HYDROCHLORIDE

@ STERISCIENCE EQ 1MG BASE/ML

A090316 001 May 04, 2011 Feb CAHN

@ EQ 5MG BASE/ML

A090316 002 May 04, 2011 Feb CAHN

SOLUTION; INTRAMUSCULAR

MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)

>A>	+! RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Aug NEWA
-----	------------------	--	---------	-----	--------------	----------

SEIZALAM

+! MMT EQ 50MG BASE/10ML (EQ 5MG BASE/ML) N209566 001 Sep 14, 2018 May CAHN

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

>D> AA	AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Aug DISC
--------	-------	----------------	---------	-----	--------------	----------

>A>	@	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Aug DISC
-----	---	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET; ORAL

MIGLITOL

>D> AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Aug CAHN
>D> AB		50MG	A203965	002	Feb 24, 2015	Aug CAHN
>D> AB		100MG	A203965	003	Feb 24, 2015	Aug CAHN
>A> AB	WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015	Aug CAHN
>A> AB		50MG	A203965	002	Feb 24, 2015	Aug CAHN
>A> AB		100MG	A203965	003	Feb 24, 2015	Aug CAHN

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB	BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Jan NEWA
----	--------------	-------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+! JOURNEY EQ 4% BASE

N212379 001 Oct 18, 2019 Jan CAHN

ZILXI

+! JOURNEY EQ 1.5% BASE

N213690 001 May 28, 2020 Jan CAHN

CAPSULE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	TORRENT	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

INJECTABLE; INJECTION

MINOCIN

+! REMPEX EQ 100MG BASE/VIAL

N050444 001 Jul CFTG

MINOCYCLINE HYDROCHLORIDE

AP	NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Jul 22, 2022	Jul NFTG
----	--------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BEXIMCO PHARMS USA	EQ 50MG BASE	A215466	001	May 27, 2022	May NEWA
AB		EQ 75MG BASE	A215466	002	May 27, 2022	May NEWA
AB		EQ 100MG BASE	A215466	003	May 27, 2022	May NEWA
AB	TORRENT	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
MIRTAZAPINE

AB	SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB		30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB		45MG	A205798	003	Jun 01, 2017	Jan CAHN

MISOPROSTOL

TABLET;ORAL
CYTOTEC
+ PFIZER 0.1MG
+! 0.2MG
MISOPROSTOL
ANI PHARMS 0.1MG
AB 0.2MG

N019268	003	Sep 21, 1990	Mar CTEC
N019268	001	Dec 27, 1988	Mar CTEC
A076095	001	Jul 10, 2002	Mar CMFD
A076095	002	Jul 10, 2002	Mar CMFD

MITAPIVAT SULFATE

TABLET;ORAL
PYRUKYND
+ AGIOS PHARMS INC EQ 5MG BASE
+ EQ 20MG BASE
+! EQ 50MG BASE

N216196	001	Feb 17, 2022	Feb NEWA
N216196	002	Feb 17, 2022	Feb NEWA
N216196	003	Feb 17, 2022	Feb NEWA

MITOMYCIN

INJECTABLE;INJECTION
MITOMYCIN
>A> AP HONG KONG 40MG/VIAL

A214504 001 Sep 06, 2022 Aug NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
RYALTRIS
+! GLENMARK SPECIALTY 0.025MG/SPRAY;0.665MG/SPRAY

N211746 001 Jan 13, 2022 Jan NEWA

MONTELUKAST SODIUM

GRANULE;ORAL
SINGULAIR
AB +! ORGANON EQ 4MG BASE/PACKET

N021409 001 Jul 26, 2002 Mar CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

@ IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Jul DISC
@	30MG	A200411	002	Apr 12, 2016	Jul DISC
@	40MG	A200411	007	Jul 25, 2018	Jul DISC
@	50MG	A200411	003	Apr 12, 2016	Jul DISC
@	60MG	A200411	004	Apr 12, 2016	Jul DISC
@	80MG	A200411	005	Apr 12, 2016	Jul DISC
@	100MG	A200411	006	Apr 12, 2016	Jul DISC
@ NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
@	30MG	A203158	002	Aug 04, 2021	Jan DISC
@	50MG	A203158	003	Aug 04, 2021	Jan DISC
@	60MG	A203158	004	Aug 04, 2021	Jan DISC
@	80MG	A203158	005	Aug 04, 2021	Jan DISC
@	100MG	A203158	006	Aug 04, 2021	Jan DISC
UPSHER SMITH LABS	20MG	A202104	002	Jun 03, 2013	Jul CTEC
	30MG	A202104	003	Jun 03, 2013	Jul CTEC
	50MG	A202104	004	Jun 03, 2013	Jul CTEC
	60MG	A202104	005	Jun 03, 2013	Jul CTEC
	80MG	A202104	006	Jun 03, 2013	Jul CTEC
!	100MG	A202104	007	Jun 03, 2013	Jul CTEC

INJECTABLE;INJECTION

MORPHINE SULFATE
+! HOSPIRA INC 50MG/ML
+ @ INTL MEDICATION SYS 50MG/ML
1MG/ML

N202515	006	Apr 29, 2021	May CMFD
N202515	006	Apr 29, 2021	Jan DISC
A202861	001	Apr 29, 2021	Jan CMFD

SOLUTION;ORAL

MORPHINE SULFATE
>D> AA TRIS PHARMA INC 20MG/5ML
>A> @ 20MG/5ML

A203519	001	May 18, 2016	Aug DISC
A203519	001	May 18, 2016	Aug DISC

	TABLET;ORAL MORPHINE SULFATE						
>A>	@ NOVAST LABS	15MG	A215584	001	Feb 07, 2022	Aug CAHN	
>A>	@	30MG	A215584	002	Feb 07, 2022	Aug CAHN	
>D>	@ RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Aug CAHN	
	@	15MG	A215584	001	Feb 07, 2022	Feb DISC	
AB		15MG	A215584	001	Feb 07, 2022	Jan NEWA	
>D>	@	30MG	A215584	002	Feb 07, 2022	Aug CAHN	
	@	30MG	A215584	002	Feb 07, 2022	Feb DISC	
AB		30MG	A215584	002	Feb 07, 2022	Jan NEWA	
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC MOXEZA							
AT2	+! IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN	
MOXIFLOXACIN HYDROCHLORIDE							
AT1	INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN	
<u>MUPIROCIN CALCIUM</u>							
CREAM;TOPICAL MUPIROCIN							
AB	PADAGIS ISRAEL	EQ 2% BASE	A212465	001	Aug 03, 2022	Jul NEWA	
<u>MYCOPHENOLATE MOFETIL</u>							
FOR SUSPENSION;ORAL MYCOPHENOLATE MOFETIL							
AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA	
TABLET;ORAL MYCOPHENOLATE MOFETIL							
AB	AMNEAL	500MG	A090606	001	Jul 16, 2010	Jun CMFD	
<u>NADOLOL</u>							
TABLET;ORAL NADOLOL							
AB	AUROBINDO PHARMA LTD	20MG	A201893	003	Jun 07, 2022	Jun NEWA	
<u>NAFCILLIN SODIUM</u>							
INJECTABLE;INJECTION NAFCILLIN SODIUM							
	@ STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN	
	@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN	
AP	WYTELLS PHARMA	EQ 1GM BASE/VIAL	A091613	001	Dec 26, 2012	Jul CAHN	
AP		EQ 2GM BASE/VIAL	A091613	002	Dec 26, 2012	Jul CAHN	
AP		EQ 10GM BASE/VIAL	A091614	001	Dec 26, 2012	Jul CAHN	
<u>NALMEFENE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION REVEX							
+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT	
+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT	
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS NALMEFENE HYDROCHLORIDE							
!	PURDUE PHARMA LP REVEX	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA	
+ @	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR	
+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR	
+ @	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jul CAHN	
+ @		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jul CAHN	
<u>NALOXONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION NALOXONE HYDROCHLORIDE							
AP	HIKMA	1MG/ML	A212300	001	Jun 10, 2022	Jun NEWA	
AP	MYLAN LABS LTD	1MG/ML	A213843	001	Jun 09, 2022	Jun NEWA	
AP	PAR STERILE PRODUCTS	1MG/ML	A215964	001	Jul 29, 2022	Jul NEWA	
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS NALOXONE HYDROCHLORIDE (AUTOINJECTOR)							
+ @	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	May DISC	
+ !		10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	Feb NEWA	

	SPRAY, METERED;NASAL NALOXONE HYDROCHLORIDE					
AB	PADAGIS ISRAEL	4MG/SPRAY		A211951	001	Jun 21, 2022 Jun NEWA
<u>NANDROLONE DECANOATE</u>						
	INJECTABLE;INJECTION DECA-DURABOLIN			N013132	001	Jun 12, 1986 Apr CAHN
	@ WOODWARD SPECL	50MG/ML		N013132	002	Jun 12, 1986 Apr CAHN
	@	100MG/ML		N013132	003	Jun 12, 1986 Apr CAHN
	+ @	200MG/ML				
<u>NAPROXEN</u>						
	SUSPENSION;ORAL NAPROXEN					
AB	HETERO LABS LTD III	25MG/ML		A215776	001	Jun 07, 2022 May NEWA
<u>NEBIVOLOL HYDROCHLORIDE</u>						
	TABLET;ORAL NEBIVOLOL HYDROCHLORIDE					
AB	AJANTA PHARMA LTD	EQ 2.5MG BASE		A213349	001	Mar 31, 2022 Mar NEWA
AB		EQ 5MG BASE		A213349	002	Mar 31, 2022 Mar NEWA
AB		EQ 10MG BASE		A213349	003	Mar 31, 2022 Mar NEWA
AB		EQ 20MG BASE		A213349	004	Mar 31, 2022 Mar NEWA
AB	PRINSTON INC	EQ 2.5MG BASE		A212682	001	Apr 07, 2022 Apr NEWA
AB		EQ 5MG BASE		A212682	002	Apr 07, 2022 Apr NEWA
AB		EQ 10MG BASE		A212682	003	Apr 07, 2022 Apr NEWA
AB		EQ 20MG BASE		A212682	004	Apr 07, 2022 Apr NEWA
AB	REYOUNG	EQ 2.5MG BASE		A212917	001	Dec 17, 2021 May CAHN
AB		EQ 5MG BASE		A212917	002	Dec 17, 2021 May CAHN
AB		EQ 10MG BASE		A212917	003	Dec 17, 2021 May CAHN
AB		EQ 20MG BASE		A212917	004	Dec 17, 2021 May CAHN
AB	UNICHEM	EQ 2.5MG BASE		A213830	001	Mar 15, 2022 Mar NEWA
AB		EQ 5MG BASE		A213830	002	Mar 15, 2022 Mar NEWA
AB		EQ 10MG BASE		A213830	003	Mar 15, 2022 Mar NEWA
AB		EQ 20MG BASE		A213830	004	Mar 15, 2022 Mar NEWA
<u>NEDOCROMIL SODIUM</u>						
	SOLUTION/DROPS;OPHTHALMIC ALOCRIL					
+!	ALLERGAN	2%		N021009	001	Dec 08, 1999 Jul CTEC
	NEDOCROMIL SODIUM					
@	AKORN	2%		A090638	001	Aug 22, 2012 Jul DISC
<u>NEOMYCIN SULFATE</u>						
	TABLET;ORAL NEOMYCIN SULFATE					
>A>	@ CHARTWELL MOLECULAR	500MG		A204435	001	Jun 10, 2016 Aug CAHN
>D>	@ LANNETT CO INC	500MG		A204435	001	Jun 10, 2016 Aug CAHN
<u>NEOSTIGMINE METHYLSULFATE</u>						
	SOLUTION;INTRAVENOUS NEOSTIGMINE METHYLSULFATE					
	@ AM REGENT	5MG/10ML (0.5MG/ML)		A209182	001	May 04, 2018 Apr DISC
	@	10MG/10ML (1MG/ML)		A209182	002	May 04, 2018 Apr DISC
AP	DR REDDYS	3MG/3ML (1MG/ML)		A216291	001	Jul 06, 2022 Jul CPOT
AP		3MG/ML (1MG/ML)		A216291	001	Jul 06, 2022 Jun NFTG
AP	+! FRESENIUS KABI USA	3MG/3ML (1MG/ML)		N203629	003	Sep 18, 2018 Jun CFTG
AP	HIKMA	3MG/3ML (1MG/ML)		A216206	001	Jul 13, 2022 Jul NEWA
<u>NIACIN</u>						
	TABLET, EXTENDED RELEASE;ORAL NIACIN					
	@ BEIJING	500MG		A214428	001	Nov 22, 2021 May DISC
	@	1GM		A214428	002	Nov 22, 2021 May DISC
AB	MACLEODS PHARMS LTD	500MG		A204934	001	Mar 03, 2022 Feb NEWA
AB		1GM		A204934	002	Mar 03, 2022 Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

+! HIKMA INTL PHARMS 25MG/10ML (2.5MG/ML)

N022276 001 Jul 24, 2008 Apr CAHN

INJECTABLE; INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+! HIKMA INTL PHARMS 20MG/200ML (0.1MG/ML)

N022276 002 Apr 07, 2016 Apr CAHN

+! 40MG/200ML (0.2MG/ML)

N022276 003 Apr 07, 2016 Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2	ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar NEWA
AB2		60MG	A216067	002	Mar 29, 2022	Mar NEWA
AB2		90MG	A216067	003	Mar 29, 2022	Mar NEWA
>D>	@ MYLAN	30MG	A201071	001	Dec 03, 2010	Aug CAHN
>D>	@	60MG	A201071	002	Dec 03, 2010	Aug CAHN
>D>	@	90MG	A201071	003	Dec 03, 2010	Aug CAHN
>A>	@ RISING	30MG	A201071	001	Dec 03, 2010	Aug CAHN
>A>	@	60MG	A201071	002	Dec 03, 2010	Aug CAHN
>A>	@	90MG	A201071	003	Dec 03, 2010	Aug CAHN

NIMODIPINE

SOLUTION; ORAL

NYMALIZE

+ @ AZURITY

+! 3MG/ML

N203340 001 May 10, 2013 Mar CAHN

+! 6MG/ML

N203340 002 Apr 08, 2020 Mar CAHN

NITISINONE

CAPSULE; ORAL

NITISINONE

AB	DIPHARMA	2MG	A212390	001	May 26, 2022	May NEWA
AB		5MG	A212390	002	May 26, 2022	May NEWA
AB		10MG	A212390	003	May 26, 2022	May NEWA
AB	MEDUNIK	2MG	A212390	001	May 26, 2022	Jun CAHN
AB		5MG	A212390	002	May 26, 2022	Jun CAHN
AB		10MG	A212390	003	May 26, 2022	Jun CAHN

NITRIC OXIDE

GAS; INHALATION

NOXIVENT

AA	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr CAHN
		800PPM	A207141	002	Oct 02, 2018	Apr CAHN

NITROFURANTOIN

SUSPENSION; ORAL

NITROFURANTOIN

@ AMNEAL PHARMS

25MG/5ML

A201679 001 May 11, 2011 Jul DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@ AUROBINDO PHARMA USA 100MG

A077025 001 Aug 18, 2004 Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jul NEWA
AB	INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

>D>	AB2	HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Aug CAHN
>D>	AB2		0.2MG/HR	A089884	001	Oct 30, 1998	Aug CAHN
>D>	AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Aug CAHN
>D>	AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Aug CAHN
>A>	AB2	ZYDUS PHARMS	0.1MG/HR	A089885	002	Oct 30, 2017	Aug CAHN
>A>	AB2		0.2MG/HR	A089884	001	Oct 30, 1998	Aug CAHN
>A>	AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Aug CAHN
>A>	AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Aug CAHN

TABLET; SUBLINGUAL

NITROGLYCERIN

>D>	AB	ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Aug DISC
>A>	@		0.3MG	A210153	001	Mar 08, 2022	Aug DISC
	AB		0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
>D>	AB		0.4MG	A210153	002	Mar 08, 2022	Aug DISC
>A>	@		0.4MG	A210153	002	Mar 08, 2022	Aug DISC
	AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
>D>	AB		0.6MG	A210153	003	Mar 08, 2022	Aug DISC
>A>	@		0.6MG	A210153	003	Mar 08, 2022	Aug DISC
	AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA
		NITROSTAT					
AB	+	VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
AB	+		0.4MG	N021134	002	May 01, 2000	Jan CAHN
AB	+		0.6MG	N021134	003	May 01, 2000	Jan CAHN

NIZATIDINE

SOLUTION; ORAL

NIZATIDINE

@ AMNEAL PHARMS

15MG/ML

A090576 001 Nov 18, 2009 Jun DISC

NOREpinephrine Bitartrate

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP ZYDUS PHARMS EQ 1MG BASE/ML A216341 001 Jul 19, 2022 Jul NEWA

Nortriptyline Hydrochloride

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 10MG BASE

A074835 001 Jun 30, 1997 Feb CAHN

@ EQ 25MG BASE

A074835 002 Jun 30, 1997 Feb CAHN

@ EQ 50MG BASE

A074835 003 Jun 30, 1997 Feb CAHN

@ EQ 75MG BASE

A074835 004 Jun 30, 1997 Feb CAHN

NYSTATIN

SUSPENSION; ORAL

NILSTAT

+ @ GLENMARK PHARMS LTD 100,000 UNITS/ML

N050299 001 Apr CAHN

NYSTATIN

>A> AA LEADING 100,000 UNITS/ML A214346 001 Mar 10, 2022 Aug CAHN
>D> AA MEDLEY PHARMS 100,000 UNITS/ML A214346 001 Mar 10, 2022 Aug CAHN
AA 100,000 UNITS/ML A214346 001 Mar 10, 2022 Feb NEWA
AA VISTAPHARM 100,000 UNITS/ML A064142 002 Mar 07, 2011 May CMS1NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT MACLEODS PHARMS LTD 100,000 UNITS/GM; 0.1% A214181 001 Jul 13, 2022 Jul NEWA

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT ALEOR DERMACEUTICALS 100,000 UNITS/GM; 0.1% A214186 001 Mar 04, 2022 Feb NEWA

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE; ORAL

MYCAPSSA

+! AMRYT EQ 20MG BASE

N208232 001 Jun 26, 2020 Jan CAHN

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP HERITAGE PHARMS EQ 0.05MG BASE/ML A204669 001 Dec 27, 2018 Apr CMFD
AP EQ 0.1MG BASE/ML A204669 002 Dec 27, 2018 Apr CMFD
AP EQ 0.2MG BASE/ML A203765 001 Sep 07, 2018 Apr CMFD
AP EQ 0.5MG BASE/ML A204669 003 Dec 27, 2018 Apr CMFD
AP EQ 1MG BASE/ML A203765 002 Sep 07, 2018 Apr CMFDOFLOXACIN

SOLUTION/DROPS; OTIC

OFLOXACIN

@ FDC LTD 0.3% A215038 001 Jan 19, 2022 Jun DISC
AT 0.3% A215038 001 Jan 19, 2022 Jan NEWA
AT MANKIND PHARMA 0.3% A216130 001 Jul 14, 2022 Jul NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15,	2016	Mar CAHN
AB		5MG	A203333	002	Mar 15,	2016	Mar CAHN
AB		7.5MG	A203333	003	Mar 15,	2016	Mar CAHN
AB		10MG	A203333	004	Mar 15,	2016	Mar CAHN
AB		15MG	A203333	005	Mar 15,	2016	Mar CAHN
AB		20MG	A203333	006	Mar 15,	2016	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16,	2016	Mar CAHN
AB		10MG	A203456	002	Mar 16,	2016	Mar CAHN
AB		15MG	A203456	003	Mar 16,	2016	Mar CAHN
AB		20MG	A203456	004	Mar 16,	2016	Mar CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07,	2014	Jun CAHN
----	-----	--	---------	-----	---------	------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

@	STRIDES PHARMA	10MG	A075876	001	May 29,	2003	Jan CAHN
@		20MG	A075876	002	May 29,	2003	Jan CAHN
@		40MG	A075876	003	Jan 21,	2009	Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

KONVOME

>A>	+!	AZURITY	2MG/ML; 84MG/ML	N213593	001	Aug 30,	2022	Aug NEWA
-----	----	---------	-----------------	---------	-----	---------	------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26,	2006	Apr CMFD
AB		8MG	A077406	004	Dec 26,	2006	Apr CMFD
		16MG	A077406	001	Dec 26,	2006	Apr CMFD
		24MG	A077406	002	Dec 26,	2006	Apr CMFD

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP	ATLANTIDE	EQ 2MG BASE/ML	A077577	001	Dec 26,	2006	Mar CAHN
@	EUGIA PHARMA	EQ 2MG BASE/ML	A202599	001	Dec 21,	2012	Jun DISC
@	STERISCIENCE	EQ 2MG BASE/ML	A078257	001	Apr 23,	2008	Feb CAHN
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	ATLANTIDE	EQ 2MG BASE/ML	A077716	001	Dec 26,	2006	Mar CAHN
@	EUGIA PHARMA	EQ 2MG BASE/ML	A202600	001	Dec 21,	2012	Jul DISC
@	STERISCIENCE	EQ 2MG BASE/ML	A078244	001	Apr 23,	2008	Feb CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	AUROBINDO PHARMA	EQ 24MG BASE	A078539	003	Jul 31,	2007	Feb DISC
@	CASI PHARMS INC	EQ 24MG BASE	A077517	003	Jun 25,	2007	Feb DISC
AB	CHARTWELL MOLECULES	EQ 4MG BASE	A077303	001	Jun 25,	2007	May CMFD
AB		EQ 8MG BASE	A077303	002	Jun 25,	2007	May CMFD
AB	!	EQ 24MG BASE	A077303	004	Jun 25,	2007	May CMFD
@	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26,	2006	Mar DISC
@		EQ 24MG BASE	A076183	001	Dec 26,	2006	Feb DISC
AB	GLENMARK GENERICS	EQ 8MG BASE	A077535	002	Jun 25,	2007	May CHRS
AB	!	EQ 8MG BASE	A077535	002	Jun 25,	2007	Feb CHRS
@		EQ 24MG BASE	A077535	003	Jun 25,	2007	Feb DISC
@	TEVA	EQ 4MG BASE	A076252	001	Jun 25,	2007	Feb DISC
@		EQ 8MG BASE	A076252	002	Jun 25,	2007	Feb DISC
@	ZOFRAN	EQ 24MG BASE	A076252	003	Jun 25,	2007	Feb DISC
+	@ NOVARTIS	EQ 4MG BASE	N020103	001	Dec 31,	1992	Feb DISC
+	@	EQ 8MG BASE	N020103	002	Dec 31,	1992	Feb DISC
+	@	EQ 24MG BASE	N020103	003	Aug 27,	1999	Feb DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

>A>	AB	BAYSHORE PHARMS LLC	100MG	A091158	001	Jul 27, 2012	Aug CAHN
>D>	AB	INVAGEN PHARMS	100MG	A091158	001	Jul 27, 2012	Aug CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	ACCORD HLTHCARE	EQ 30MG BASE	A214726	001	Jul 25, 2022	Jul NEWA
AB		EQ 45MG BASE	A214726	002	Jul 25, 2022	Jul NEWA
AB		EQ 75MG BASE	A214726	003	Jul 25, 2022	Jul NEWA
	FOR SUSPENSION;ORAL					
	OSELTAMIVIR PHOSPHATE					
AB	ALVOGEN	EQ 6MG BASE/ML	A208823	001	Oct 31, 2017	May CAHN
	@ APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Mar DISC
AB	HETERO LABS LTD V	EQ 6MG BASE/ML	A209590	001	Mar 28, 2022	Mar NEWA
AB	LEADING	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Feb NEWA
AB	MSN	EQ 6MG BASE/ML	A215313	001	May 02, 2022	Apr NEWA
	@ STRIDES PHARMA	EQ 6MG BASE/ML	A211894	001	Jan 13, 2022	Jul DISC
AB		EQ 6MG BASE/ML	A211894	001	Jan 13, 2022	Jan NEWA

OTESECONAZOLE

CAPSULE;ORAL

VIVJOA

+!	MYCOVIA PHARMS	150MG	N215888	001	Apr 26, 2022	Apr NEWA
----	----------------	-------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>D>	AP	PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug DISC
>A>		@	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug DISC
>D>	AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug DISC
>A>		@	EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug DISC
		@ STERISCIENCE	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Feb CAHN
		@	EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Feb CAHN
AP	WYTELLS PHARMA		EQ 1GM BASE/VIAL	A201539	001	Jan 18, 2013	Jul CAHN
AP			EQ 2GM BASE/VIAL	A201539	002	Jan 18, 2013	Jul CAHN
AP			EQ 10GM BASE/VIAL	A201538	001	Jan 18, 2013	Jul CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

@	CHARTWELL MOLECULAR	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Mar CAHN
@		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Mar CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	UNITED RES LABS	10MG	A071026	002	Aug 10, 1987	Apr CAHN
AB		15MG	A071026	003	Aug 10, 1987	Apr CAHN
AB		30MG	A071026	001	Aug 10, 1987	Apr CAHN
	SERAX					
	+ @ ALPHARMA US PHARMS	10MG	N015539	002		Jan CRLD
	+ @	15MG	N015539	004		Jan CRLD
	+ @	30MG	N015539	006		Jan CRLD

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

>A>	AB	RUBICON	300MG/5ML	A215726	001	Aug 30, 2022	Aug NEWA
-----	----	---------	-----------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		@ CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar CAHN
AA	!	LANNETT CO INC	5MG/5ML	A074520	001	Mar 29, 1996	Mar CHRS
AA	@ WOCKHARDT BIO AG		5MG/5ML	A074868	001	Feb 12, 1997	Mar DISC
	TABLET;ORAL						
	OXYBUTYNIN CHLORIDE						
AB	BEXIMCO PHARMS USA	5MG		A213550	001	Jul 14, 2022	Jul NEWA

	TABLET;ORAL OXYBUTYNIN CHLORIDE					
AB	STRIDES PHARMA	5MG		A208165	001	Dec 17, 2020
	<u>OXYCODONE HYDROCHLORIDE</u>					
	SOLUTION;ORAL OXYCODONE HYDROCHLORIDE					
	@ NOVEL LABS INC	100MG/5ML		A204603	001	Apr 29, 2015
	@ WOCKHARDT BIO AG	5MG/5ML		A206456	001	Jun 16, 2015
	TABLET;ORAL ROXYBOND					
	PROTEGA PHARMS	5MG		N209777	001	Apr 20, 2017
	@	5MG		N209777	001	Apr 20, 2017
		15MG		N209777	002	Apr 20, 2017
	@	15MG		N209777	002	Apr 20, 2017
		30MG		N209777	003	Apr 20, 2017
	@	30MG		N209777	003	Apr 20, 2017
	<u>PACLITAXEL</u>					
	INJECTABLE;INJECTION PACLITAXEL					
AP	GLAND PHARMA LTD	6MG/ML		A207326	001	Aug 23, 2016
	POWDER;INTRAVENOUS PACLITAXEL					
	+! HBT LABS INC	100MG/VIAL		N211875	001	Jul 27, 2022
	<u>PACRITINIB CITRATE</u>					
	CAPSULE;ORAL VONJO					
	+! CTI BIOPHARMA CORP	EQ 100MG BASE		N208712	001	Feb 28, 2022
	<u>PALIPERIDONE</u>					
	TABLET, EXTENDED RELEASE;ORAL PALIPERIDONE					
AB	LUPIN LTD	1.5MG		A208643	001	Jun 29, 2022
AB		3MG		A208643	002	Jun 29, 2022
AB		6MG		A208643	003	Jun 29, 2022
AB		9MG		A208643	004	Jun 29, 2022
	<u>PALONOSETRON HYDROCHLORIDE</u>					
	INJECTABLE;INTRAVENOUS PALONOSETRON HYDROCHLORIDE					
	! EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)		A202951	001	Jun 29, 2021
	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)		A202951	001	Jun 29, 2021
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		A202951	002	Jun 29, 2021
	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		A202951	002	Jun 29, 2021
	<u>PANTOPRAZOLE SODIUM</u>					
	INJECTABLE;INTRAVENOUS PANTOPRAZOLE SODIUM					
AP	ASPIRO	EQ 40MG BASE/VIAL		A213778	001	May 18, 2022
AP	BE PHARMS	EQ 40MG BASE/VIAL		A216171	001	May 18, 2022
AP	GLAND PHARMA LTD	EQ 40MG BASE/VIAL		A204400	001	May 18, 2022
AP	KNACK	EQ 40MG BASE/VIAL		A214680	001	May 19, 2022
>A> AP	NANJING KING-FRIEND	EQ 40MG BASE/VIAL		A215860	001	Aug 29, 2022
	TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM					
AB	MANKIND PHARMA	EQ 40MG BASE		A215880	001	Jul 26, 2022
	<u>PARICALCITOL</u>					
	SOLUTION;INTRAVENOUS PARICALCITOL					
>D> AP	AKORN	0.005MG/ML (0.005MG/ML)		A207692	001	Oct 16, 2017
>A>	@	0.01MG/2ML (0.005MG/ML)		A207692	001	Oct 16, 2017
	@ RISING	0.002MG/ML (0.002MG/ML)		A203897	001	Nov 02, 2017

PAROXETINE HYDROCHLORIDE

	CAPSULE;ORAL						
	PAXIL						
	+ @ APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN	
	+ @	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN	
	+ @	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN	
	+ @	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN	
	SUSPENSION;ORAL						
	PAXIL						
AB	+! APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN	
	TABLET;ORAL						
	PAROXETINE HYDROCHLORIDE						
AB	CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar CAHN	
AB		EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar CAHN	
AB		EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar CAHN	
AB		EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar CAHN	
	PAXIL						
AB	+ APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN	
AB	+	EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN	
AB	+	EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN	
AB	+!	EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN	
	@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN	
	TABLET, EXTENDED RELEASE;ORAL						
	PAROXETINE HYDROCHLORIDE						
	@ SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC	
	@	EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC	
AB		EQ 37.5MG BASE	A213612	003	May 26, 2022	May NEWA	
	PAXIL CR						
AB	+ APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN	
AB	+	EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN	
AB	+!	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN	

PAROXETINE MESYLATE

	TABLET;ORAL						
	PEXEVA						
	+ @ SEBELA IRELAND LTD	EQ 40MG BASE	N021299	004	Jul 03, 2003	Jun DISC	

PEGAPANTIB SODIUM

	INJECTABLE;INTRAVITREAL						
	MACUGEN						
	+ @ BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Jun CAHN	

PEMETREXED

	SOLUTION;INTRAVENOUS						
	PEMETREXED						
	+! ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May CMFD	
	+!	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May CMFD	
	+!	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May CMFD	

PEMETREXED DISODIUM

	POWDER;INTRAVENOUS						
	ALIMTA						
AP	+! LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG	
AP	+!	EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG	
	PEMETREXED DISODIUM						
AP	ACCORD HLTHCARE	EQ 100MG BASE/VIAL	A203485	001	May 25, 2022	May NFTG	
AP		EQ 500MG BASE/VIAL	A203485	002	May 25, 2022	May NFTG	
AP		EQ 1GM BASE/VIAL	A203485	003	May 25, 2022	May NEWA	
AP	AMNEAL	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jul NEWA	
AP	APOTEX	EQ 100MG BASE/VIAL	A203774	001	May 25, 2022	May NFTG	
AP		EQ 500MG BASE/VIAL	A203774	002	May 25, 2022	May NFTG	
AP		EQ 750MG BASE/VIAL	A209851	001	May 25, 2022	May NEWA	
AP		EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	May NEWA	
>A> AP	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	Aug NEWA	
>A> AP		EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	Aug NEWA	
AP	BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	May NEWA	
AP	DR REDDYS	EQ 100MG BASE/VIAL	A202596	001	May 25, 2022	May NFTG	
AP		EQ 500MG BASE/VIAL	A202596	002	May 25, 2022	May NFTG	
AP		EQ 1GM BASE/VIAL	A202596	003	May 25, 2022	May NEWA	
AP	EUGIA PHARMA	EQ 100MG BASE/VIAL	A214632	001	May 25, 2022	May NFTG	
AP		EQ 500MG BASE/VIAL	A214632	002	May 25, 2022	May NFTG	

POWDER; INTRAVENOUS
PEMETREXED DISODIUM

AP	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A214632	003	May 25, 2022	May NEWA
AP		EQ 100MG BASE/VIAL	A090384	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A090384	002	May 25, 2022	May NFTG
AP	!	EQ 750MG BASE/VIAL	A090384	003	May 25, 2022	May NEWA
AP	!	EQ 1GM BASE/VIAL	A090384	004	May 25, 2022	May NEWA
>D>	HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	Aug CAHN
>A>		EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	Aug CAHN
AP		EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	May NFTG
>D>		EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	Aug CAHN
>A>		EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	Aug CAHN
AP		EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	May NFTG
>D>		EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	Aug CAHN
>A>		EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	Aug CAHN
AP		EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	May NEWA
AP	JIANGSU HANSOH PHARM	EQ 100MG BASE/VIAL	A208696	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A208696	002	May 25, 2022	May NFTG
AP	NANG KUANG PHARM CO	EQ 100MG BASE/VIAL	A207352	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A207352	002	May 25, 2022	May NFTG
AP	QILU PHARM HAINAN	EQ 100MG BASE/VIAL	A204890	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A204890	002	May 25, 2022	May NFTG
AP	WAVERLEY PHARMA INC	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	May NFTG
AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL	A214073	001	May 25, 2022	May NFTG
AP		EQ 500MG BASE/VIAL	A214073	002	May 25, 2022	May NFTG
AP		EQ 1GM BASE/VIAL	A214073	003	May 25, 2022	May NEWA
SOLUTION; INTRAVENOUS PEMETREXED						
>D>	+! HOSPIRA INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Aug CTNA
>D>	+!	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Jun NEWA
>D>	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Aug CTNA
	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Jun NEWA
>D>	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Aug CTNA
	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Jun NEWA
>D>	+! SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	Aug CTNA
	+!	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
>D>	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	Aug CTNA
	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
>D>	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	Aug CTNA
	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA
PEMETREXED DISODIUM						
	+! ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jul NEWA
	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jul NEWA
	+!	EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jul NEWA
	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jul NEWA
>A>	+! HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Aug CTNA
>A>	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Aug CTNA
>A>	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Aug CTNA
>A>	+! SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	Aug CTNA
>A>	+!	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	Aug CTNA
>A>	+!	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	Aug CTNA

PEMETREXED DITROMETHAMINE

POWDER; INTRAVENOUS PEMETREXED						
>D>	+! HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CAHN
	+!	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Jun NEWA
>D>	+!	EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CAHN
	+!	EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Jun NEWA
>D>	+!	EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CAHN

POWDER; INTRAVENOUS

PEMETREXED

+!		EQ 1GM BASE/VIAL	N 208746	003	Jun 10, 2022	Jun NEWA
	PEMETREXED DITROMETHAMINE					
>A>	+! HOSPIRA	EQ 100MG BASE/VIAL	N 208746	001	Jun 10, 2022	Aug CAHN
>A>	+!	EQ 500MG BASE/VIAL	N 208746	002	Jun 10, 2022	Aug CAHN
>A>	+!	EQ 1GM BASE/VIAL	N 208746	003	Jun 10, 2022	Aug CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP	XGEN PHARMS	300MG/VIAL	A 206982	001	Mar 17, 2022	Mar NEWA
----	-------------	------------	----------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

>D> AP	CUSTOPHARM INC	50MG/ML	A 203619	001	Nov 13, 2017	Aug CAHN
>A> AP	HIKMA	50MG/ML	A 203619	001	Nov 13, 2017	Aug CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	APPCO	2MG	A 210163	001	May 18, 2022	May NEWA
AB		4MG	A 210163	002	May 18, 2022	May NEWA
AB		8MG	A 210163	003	May 18, 2022	May NEWA
AB		16MG	A 210163	004	May 18, 2022	May NEWA
@	MYLAN	2MG	A 206691	001	Apr 14, 2017	Mar DISC
@		4MG	A 206691	002	Apr 14, 2017	Mar DISC
@		8MG	A 206691	003	Apr 14, 2017	Mar DISC
@		16MG	A 206691	004	Apr 14, 2017	Mar DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	CHARTWELL	35MG	A 089452	001	Oct 30, 1991	Apr CAHN
----	-----------	------	----------	-----	--------------	----------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	10MG	A 215042	001	Jul 19, 2022	Jul NEWA
----	-----------------	------	----------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	+! SANDOZ	30MG	A 087190	001		Feb CRLD
AA	TABLET; ORAL					
	PHENTERMINE HYDROCHLORIDE					
@	LANNETT	37.5MG	A 040555	001	Apr 15, 2005	Jul DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

BIORPHEN

+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N 212909	001	Oct 21, 2019	Jun CAHN
+ @		10MG/ML (10MG/ML)	N 212909	002	Mar 11, 2021	Jun CAHN

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A 213237	001	Jul 01, 2020	Feb CMFD
AP1		50MG/5ML (10MG/ML)	A 213237	002	Jul 01, 2020	Feb CMFD
AP1		100MG/10ML (10MG/ML)	A 213237	003	Jul 01, 2020	Feb CMFD
>A> AP1	MANKIND PHARMA	10MG/ML (10MG/ML)	A 217069	001	Aug 30, 2022	Aug NEWA
>A> AP1		50MG/5ML (10MG/ML)	A 217069	002	Aug 30, 2022	Aug NEWA
>A> AP1		100MG/10ML (10MG/ML)	A 217069	003	Aug 30, 2022	Aug NEWA
	@ PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A 210025	001	Dec 21, 2018	Jan DISC

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

AB	+! VIATRIS	125MG/5ML	N 008762	001		Feb CAHN
	DILANTIN-30					
@	VIATRIS	30MG/5ML	N 008762	002		Feb CAHN
	PHENYTOIN					
AB	PAJ HOLDINGS PHARM	125MG/5ML	A 040420	001	Apr 19, 2002	Apr CAHN
AB	VISTAPHARM	125MG/5ML	A 040342	002	Aug 18, 2005	May CMS1

PHENYTOIN SODIUM

CAPSULE;ORAL					
DILANTIN					
AB +! VIATRIS	30MG EXTENDED	A084349	001		Feb CAHN
AB +!	100MG EXTENDED	A084349	002		Feb CAHN

PHYTONADIONE

INJECTABLE;INJECTION					
PHYTONADIONE					
AB2 @ CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022	Jul DISC
AB2 !	1MG/0.5ML	A212424	001	Apr 22, 2022	Apr NFTG
AB2 !	1MG/0.5ML	A214596	001	Apr 22, 2022	Jul CTEC
AB2 !	1MG/0.5ML	A214596	001	Apr 22, 2022	Jul CHRS
AB2 @	10MG/ML	A214596	001	Apr 22, 2022	Apr NFTG
AB2 !	10MG/ML	A212424	002	Apr 22, 2022	Jul DISC
AB2 !	10MG/ML	A212424	002	Apr 22, 2022	Apr NFTG
AB2 !	10MG/ML	A214596	002	Apr 22, 2022	Jul CTEC
AB2 !	10MG/ML	A214596	002	Apr 22, 2022	Jul CHRS
AB2 DR REDDYS	10MG/ML	A214596	002	Apr 22, 2022	Apr NFTG
VITAMIN K1	10MG/ML	A207719	001	May 22, 2019	Apr CTEC
AB1 +! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Apr CTEC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC					
ISOPTO CARPINE					
AT +! NOVARTIS	1%	N200890	001	Jun 22, 2010	May CHRS
AT +!	2%	N200890	002	Jun 22, 2010	May CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION					
PIPERACILLIN AND TAZOBACTAM					
AP STERISCIENCE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May CMFD
AP @	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb CAHN
AP @	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May CMFD
AP @	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb CAHN
AP @	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May CMFD
AP @	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb CAHN
AP WYTELLS PHARMA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	Jul CAHN
AP @	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	Jul CAHN
AP @	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	Jul CAHN

PIRFENIDONE

CAPSULE;ORAL					
PIRFENIDONE					
AB ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan NEWA
AB AMNEAL	267MG	A212569	001	Jan 03, 2022	May CMFD
AB @	267MG	A212569	001	Jan 03, 2022	Jan DISC
AB LAURUS	267MG	A212724	001	Jul 19, 2022	Jul NEWA
AB SANDOZ INC	267MG	A212600	001	Jun 13, 2022	Jun NEWA
AB SCIEGEN PHARMS INC	267MG	A212077	001	Aug 01, 2022	Jul NEWA
TABLET;ORAL					
ESBRIET					
AB + GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan CFTG
AB +!	801MG	N208780	003	Jan 11, 2017	Jan CFTG
PIRFENIDONE					
AB ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan NFTG
AB @	801MG	A212730	002	Jan 25, 2022	Jan NFTG
AB AIZANT	267MG	A212747	001	Jul 21, 2022	Jul NEWA
AB @	534MG	A212747	002	Jul 21, 2022	Jul NEWA
AB @	801MG	A212747	003	Jul 21, 2022	Jul NEWA
AB ALEMBIC PHARMS LTD	267MG	A212708	001	May 20, 2022	May NEWA
AB @	801MG	A212708	002	May 20, 2022	May NEWA
AB AMNEAL	267MG	A212570	001	Mar 25, 2022	Mar NEWA

TABLET;ORAL
PIRFENIDONE

AB		801MG	A212570	002	Mar 25, 2022	Mar NEWA
AB	LAURUS	267MG	A212722	001	Jul 19, 2022	Jul NEWA
AB		534MG	A212722	002	Jul 19, 2022	Jul CTEC
AB		534MG	A212722	002	Jul 19, 2022	Jul NEWA
AB		801MG	A212722	003	Jul 19, 2022	Jul NEWA
AB	MICRO LABS	267MG	A212680	001	May 18, 2022	May NEWA
AB		801MG	A212680	002	May 18, 2022	May NEWA
AB	MSN	267MG	A212772	001	May 24, 2022	May NEWA
AB		801MG	A212772	002	May 24, 2022	May NEWA
AB	SANDOZ INC	267MG	A212560	001	Apr 28, 2022	Apr NEWA
AB		801MG	A212560	002	Apr 28, 2022	Apr NEWA
AB	SCIEGEN PHARMS INC	267MG	A212078	001	Aug 01, 2022	Jul NEWA
AB		801MG	A212078	002	Aug 01, 2022	Jul NEWA
AB	TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan NFTG
AB		801MG	A212759	002	Jan 25, 2022	Jan NFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE**FOR SOLUTION;ORAL**

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@ NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A090019	001	May 27, 2009	Feb DISC
------------------	---	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE;ORAL
POMALIDOMIDE

AB	@ MYLAN	1MG	A210275	001	Jan 26, 2022	Feb CAHN
	@	1MG	A210275	001	Jan 26, 2022	Feb DISC
AB	@	1MG	A210275	001	Jan 26, 2022	Jan NEWA
	@	2MG	A210275	002	Jan 26, 2022	Feb CAHN
AB	@	2MG	A210275	002	Jan 26, 2022	Feb DISC
	@	2MG	A210275	002	Jan 26, 2022	Jan NEWA
AB	@	3MG	A210275	003	Jan 26, 2022	Feb CAHN
	@	3MG	A210275	003	Jan 26, 2022	Feb DISC
AB	@	3MG	A210275	003	Jan 26, 2022	Jan NEWA
	@	4MG	A210275	004	Jan 26, 2022	Feb CAHN
AB	@	4MG	A210275	004	Jan 26, 2022	Feb DISC
AB		4MG	A210275	004	Jan 26, 2022	Jan NEWA
AB	TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Apr NEWA
AB		2MG	A209956	002	May 04, 2022	Apr NEWA
AB		3MG	A209956	003	May 04, 2022	Apr NEWA
AB		4MG	A209956	004	May 04, 2022	Apr NEWA
	POMALYST					
AB	+ CELGENE	1MG	N204026	001	Feb 08, 2013	Apr CTEC
	+	1MG	N204026	001	Feb 08, 2013	Feb CTEC
AB	+	1MG	N204026	001	Feb 08, 2013	Jan CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Apr CTEC
	+	2MG	N204026	002	Feb 08, 2013	Feb CTEC
AB	+	2MG	N204026	002	Feb 08, 2013	Jan CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Apr CTEC
	+	3MG	N204026	003	Feb 08, 2013	Feb CTEC
AB	+	3MG	N204026	003	Feb 08, 2013	Jan CTEC
AB	+!	4MG	N204026	004	Feb 08, 2013	Apr CTEC
	+!	4MG	N204026	004	Feb 08, 2013	Feb CTEC
AB	+!	4MG	N204026	004	Feb 08, 2013	Jan CTEC

PONESIMOD

TABLET;ORAL
PONVORY

>D>	+ JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Aug CHRS
>A>	+!	2MG	N213498	001	Mar 18, 2021	Aug CHRS
>D>	+!	20MG	N213498	010	Mar 18, 2021	Aug CHRS
>A>	+	20MG	N213498	010	Mar 18, 2021	Aug CHRS

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL
NOXAFIL POWDERMIX KIT

+ @ MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan DISC
SOLUTION;INTRAVENOUS					
NOXAFIL					
AP +! MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May CFTG

SOLUTION; INTRAVENOUS

POSACONAZOLE

AP	PAR STERILE PRODUCTS	300MG/16.7ML (18MG/ML)	A208768	001	May 25, 2022	May NFTG
	TABLET, DELAYED RELEASE; ORAL					
	POSACONAZOLE					
AB	BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan NEWA
AB	DR REDDYS	100MG	A212500	001	Apr 07, 2022	Apr NEWA
AB	SPECGX LLC	100MG	A212226	001	May 10, 2022	Apr NEWA

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

@ EXELA PHARMA 2MEQ/ML

A212692 001 Oct 20, 2021 Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@ LANNETT CO INC 8MEQ
@ 10MEQA204210 001 Mar 28, 2016 Mar DISC
A204210 002 Mar 28, 2016 Mar DISC

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

@ GRANULES 20MEQ
20MEQA213467 001 Jan 27, 2022 Jul DISC
A213467 001 Jan 27, 2022 Jan NEWA

AA RUBICON 20MEQ

A214108 001 Mar 24, 2022 Mar NEWA

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ

AP FRESENIUS KABI USA 14.9MG/ML
AP 746MG/100MLA211087 001 Sep 09, 2020 Mar CMFD
A211087 002 Sep 09, 2020 Mar CMFD

POTASSIUM CHLORIDE 20MEQ

AP FRESENIUS KABI USA 29.8MG/ML

A211087 003 Sep 09, 2020 Mar CMFD

AP 1.49GM/100ML

A211087 005 May 07, 2021 Mar CMFD

POTASSIUM CHLORIDE 40MEQ

AP FRESENIUS KABI USA 2.98GM/100ML

A211087 004 Sep 09, 2020 Mar CMFD

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA RUBICON 20MEQ/15ML

A214656 001 Jan 13, 2022 Jan NEWA

AA 40MEQ/15ML

A214656 002 Jan 13, 2022 Jan NEWA

@ TRIS PHARMA INC 20MEQ/15ML

A214076 001 Jan 26, 2022 Apr DISC

AA 20MEQ/15ML

A214076 001 Jan 26, 2022 Jan NEWA

@ 40MEQ/15ML

A214076 002 Jan 26, 2022 Apr DISC

AA 40MEQ/15ML

A214076 002 Jan 26, 2022 Jan NEWA

AA WES PHARMA INC 20MEQ/15ML

A213062 001 Jun 06, 2022 May NEWA

AA 40MEQ/15ML

A213062 002 Jun 06, 2022 May NEWA

TABLET, EXTENDED RELEASE; ORAL

K-TAB

+ @ ABBVIE 8MEQ

N018279 002 Aug 01, 1988 Mar DISC

POTASSIUM CHLORIDE

AB1 AMTA 10MEQ

A214395 001 Jan 28, 2021 Jul CMFD

AB1 20MEQ

A214395 002 Jan 28, 2021 Jul CMFD

AB3 RUBICON 10MEQ

A215725 001 Jul 25, 2022 Jul NEWA

AB3 20MEQ

A215725 002 Jul 25, 2022 Jul NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

>D> +! BAXTER HLTHCARE 150MG/100ML; 450MG/100ML

N017648 005 Nov 26, 2002 Aug CTEC

>A> AP +! 150MG/100ML; 450MG/100ML

N017648 005 Nov 26, 2002 Aug CTEC

>D> @ FRESENIUS KABI USA 150MG/100ML; 450MG/100ML

A212347 001 Sep 17, 2020 Aug CMFD

>A> AP 150MG/100ML; 450MG/100ML

A212347 001 Sep 17, 2020 Aug CMFD

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

>D> @ FRESENIUS KABI USA 150MG/100ML; 900MG/100ML

A212347 003 Jun 02, 2021 Aug CMFD

>A> AP 150MG/100ML; 900MG/100ML

A212347 003 Jun 02, 2021 Aug CMFD

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

>D> +! BAXTER HLTHCARE 300MG/100ML; 900MG/100ML

N017648 002 Aug CTEC

>A> AP +! 300MG/100ML; 900MG/100ML

N017648 002 Aug CTEC

>D> @ FRESENIUS KABI USA 300MG/100ML; 900MG/100ML

A212347 002 Sep 17, 2020 Aug CMFD

>A> AP 300MG/100ML; 900MG/100ML

A212347 002 Sep 17, 2020 Aug CMFD

PRAMIPEXOLE DIHYDROCHLORIDE

	TABLET;ORAL MIRAPEX						
+ @	BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997	Mar DISC	
+ @		0.25MG	N020667	002	Jul 01, 1997	Mar DISC	
+ @		0.5MG	N020667	006	Feb 12, 1998	Mar DISC	
+ @		0.75MG	N020667	007	Jul 30, 2007	Mar DISC	
+ @		1MG	N020667	003	Jul 01, 1997	Mar DISC	
+ @		1.5MG	N020667	005	Jul 01, 1997	Mar DISC	
	PRAMIPEXOLE DIHYDROCHLORIDE						
AB	! GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar CHRS	
	TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE						
AB	ALEMBIC PHARMS LTD	0.375MG	A204518	001	Jan 02, 2019	Apr CMFD	
AB		0.75MG	A204518	002	Jan 02, 2019	Apr CMFD	
AB		1.5MG	A204518	003	Jan 02, 2019	Apr CMFD	
AB		2.25MG	A204518	004	Jan 02, 2019	Apr CMFD	
AB		3MG	A204518	005	Jan 02, 2019	Apr CMFD	
AB		3.75MG	A204518	006	Jan 02, 2019	Apr CMFD	
AB		4.5MG	A204518	007	Jan 02, 2019	Apr CMFD	
AB	NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan NEWA	
AB		0.75MG	A213444	002	Feb 03, 2022	Jan NEWA	
AB		1.5MG	A213444	003	Feb 03, 2022	Jan NEWA	
AB		2.25MG	A213444	004	Feb 03, 2022	Jan NEWA	
AB		3MG	A213444	005	Feb 03, 2022	Jan NEWA	
AB		3.75MG	A213444	006	Feb 03, 2022	Jan NEWA	
AB		4.5MG	A213444	007	Feb 03, 2022	Jan NEWA	

PRASUGREL HYDROCHLORIDE

	TABLET;ORAL PRASUGREL						
>A>	@ CHARTWELL RX	EQ 5MG BASE	A205790	001	Oct 16, 2017	Aug CAHN	
>A>	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Aug CAHN	
>D>	@ USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Aug CAHN	
	@	EQ 5MG BASE	A205790	001	Oct 16, 2017	Apr DISC	
>D>	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Aug CAHN	
	@	EQ 10MG BASE	A205790	002	Oct 16, 2017	Apr DISC	

PRAZOSIN HYDROCHLORIDE

	CAPSULE;ORAL PRAZOSIN HYDROCHLORIDE						
>D> AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Aug DISC	
>A>	@	EQ 1MG BASE	A072577	002	May 16, 1989	Aug DISC	
>D> AB		EQ 2MG BASE	A072577	001	May 16, 1989	Aug DISC	
>A>	@	EQ 2MG BASE	A072577	001	May 16, 1989	Aug DISC	
	@	EQ 5MG BASE	A072577	003	May 16, 1989	Feb DISC	

PREDNISOLONE

	TABLET;ORAL PREDNISOLONE						
+ !	WATSON LABS	5MG	A080354	001		Mar CRLD	
>D>	PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM						
>D>	SUSPENSION;OPHTHALMIC						
>D>	BLEPHAMIDE						
>D>	+! ALLERGAN	0.2%;10%	N012813	002		Aug DISC	
>A>	+ @	0.2%;10%	N012813	002		Aug DISC	

PREDNISOLONE SODIUM PHOSPHATE

	TABLET, ORALLY DISINTEGRATING;ORAL PREDNISOLONE SODIUM PHOSPHATE						
@	RISING	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul CAHN	
@		EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul CAHN	
@		EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul CAHN	

PREDNISONE

	SOLUTION;ORAL PREDNISONE						
+ !	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984	May CRLD	

TABLET;ORAL

PREDNISONE

AB	AUROBINDO PHARMA LTD	2.5MG	A215672	001	Mar 28, 2022	Mar NEWA
AB		5MG	A215672	002	Mar 28, 2022	Mar NEWA
AB		10MG	A215672	003	Mar 28, 2022	Mar NEWA
AB		20MG	A215672	004	Mar 28, 2022	Mar NEWA
AB		50MG	A215672	005	Mar 28, 2022	Mar NEWA

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	ALLIED	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb CAHN
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb NEWA
AB		50MG	A212988	002	Mar 08, 2022	Feb NEWA
AB		75MG	A212988	003	Mar 08, 2022	Feb NEWA
AB		100MG	A212988	004	Mar 08, 2022	Feb NEWA
AB		150MG	A212988	005	Mar 08, 2022	Feb NEWA
AB		200MG	A212988	006	Mar 08, 2022	Feb NEWA
AB		225MG	A212988	007	Mar 08, 2022	Feb NEWA
AB		300MG	A212988	008	Mar 08, 2022	Feb NEWA
AB	@ LUPIN LTD	25MG	A091040	001	May 03, 2022	Jul DISC
AB		25MG	A091040	001	May 03, 2022	Apr NEWA
AB	@	50MG	A091040	002	May 03, 2022	Jul DISC
AB	@	50MG	A091040	002	May 03, 2022	Apr NEWA
AB	@	75MG	A091040	003	May 03, 2022	Jul DISC
AB	@	75MG	A091040	003	May 03, 2022	Apr NEWA
AB	@	100MG	A091040	004	May 03, 2022	Jul DISC
AB	@	100MG	A091040	004	May 03, 2022	Apr NEWA
AB	@	150MG	A091040	005	May 03, 2022	Jul DISC
AB	@	150MG	A091040	005	May 03, 2022	Apr NEWA
AB	@	200MG	A091040	006	May 03, 2022	Jul DISC
AB	@	200MG	A091040	006	May 03, 2022	Apr NEWA
AB	@	225MG	A091040	007	May 03, 2022	Jul DISC
AB	@	225MG	A091040	007	May 03, 2022	Apr NEWA
AB	@	300MG	A091040	008	May 03, 2022	Jul DISC
AB	@	300MG	A091040	008	May 03, 2022	Apr NEWA
AB	MARKSANS PHARMA	25MG	A216197	001	Jul 18, 2022	Jul NEWA
AB		50MG	A216197	002	Jul 18, 2022	Jul NEWA
AB		75MG	A216197	003	Jul 18, 2022	Jul NEWA
AB		100MG	A216197	004	Jul 18, 2022	Jul NEWA
AB		150MG	A216197	005	Jul 18, 2022	Jul NEWA
AB		200MG	A216197	006	Jul 18, 2022	Jul NEWA
AB		225MG	A216197	007	Jul 18, 2022	Jul NEWA
AB		300MG	A216197	008	Jul 18, 2022	Jul NEWA
>A> AB	PRINSTON INC	25MG	A207883	001	Sep 01, 2022	Aug NEWA
>A> AB		50MG	A207883	002	Sep 01, 2022	Aug NEWA
>A> AB		75MG	A207883	003	Sep 01, 2022	Aug NEWA
>A> AB		100MG	A207883	004	Sep 01, 2022	Aug NEWA
>A> AB		150MG	A207883	005	Sep 01, 2022	Aug NEWA
>A> AB		200MG	A207883	006	Sep 01, 2022	Aug NEWA
>A> AB		225MG	A207883	007	Sep 01, 2022	Aug NEWA
>A> AB		300MG	A207883	008	Sep 01, 2022	Aug NEWA
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Jul CAHN
AB		75MG	A210585	002	Dec 26, 2019	Jul CAHN
AB		100MG	A210585	003	Dec 26, 2019	Jul CAHN
AB		150MG	A210585	004	Dec 26, 2019	Jul CAHN
AB		200MG	A210585	005	Dec 26, 2019	Jul CAHN
AB		300MG	A210585	006	Dec 26, 2019	Jul CAHN

SOLUTION;ORAL

PREGABALIN

AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb NEWA
TABLET, EXTENDED RELEASE;ORAL						
	PREGABALIN					
AB	@ MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar DISC
AB	@	82.5MG	A211948	001	Apr 13, 2021	Mar CAHN
AB	@	165MG	A211967	001	Nov 04, 2021	Mar DISC
AB	RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar NEWA
AB		165MG	A215249	002	Mar 22, 2022	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB		330MG	A215249	003	Mar 22, 2022	Mar NEWA
>A> AB	ZYDUS PHARMS	82.5MG	A215577	001	Aug 26, 2022	Aug NEWA
>A> AB		165MG	A215577	002	Aug 26, 2022	Aug NEWA
>A> AB		330MG	A215577	003	Aug 26, 2022	Aug NEWA

PRIMIDONE

TABLET;ORAL
PRIMIDONE

AB	RUBICON	50MG	A214896	001	Jun 28, 2022	Jun NEWA
AB		250MG	A214896	002	Jun 28, 2022	Jun NEWA

PROBENECID

TABLET;ORAL
PROBENECID
@ AUROBINDO PHARMA USA 500MG

A084211 002 Jul CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	EUGIA PHARMA	EQ 5MG BASE/ML	A213873	001	Jul 14, 2022	Jul NEWA
----	--------------	----------------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATE

TABLET;ORAL
PROCHLORPERAZINE MALEATE

AB	NOVITIUM PHARMA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jul CAHN
AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jul CAHN
AB	ZENARA	EQ 5MG BASE	A216202	001	Jun 13, 2022	Jun NEWA
AB		EQ 10MG BASE	A216202	002	Jun 13, 2022	Jun NEWA
AB	ZYDUS	EQ 5MG BASE	A216495	001	Aug 08, 2022	Jul NEWA
AB		EQ 10MG BASE	A216495	002	Aug 08, 2022	Jul NEWA

PROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
SPARINE
@ HIKMA 25MG/ML
@ 50MG/ML

N010349 008 Jul CAHN
N010349 006 Jul CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE
@ ATLANTIDE 25MG/ML
@ 50MG/ML
AP +! WEST-WARD PHARMS INT 25MG/ML
AP +! 50MG/ML

A040785 001 Sep 26, 2008 Mar CAHN
A040785 002 Sep 26, 2008 Mar CAHN
A083312 001 Apr CRLD
A083312 002 Apr CRLD

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
LARGON
@ HIKMA 20MG/ML

N012382 002 Jul CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
PROPRANOLOL HYDROCHLORIDE
@ ATHENEX INC 1MG/ML
@ CHARTWELL INJECTABLE 1MG/ML
AP ! HIKMA FARMACEUTICA 1MG/ML

A075792 001 Aug 29, 2000 Feb DISC
A075792 001 Aug 29, 2000 Mar CAHN
A077760 001 Jan 31, 2008 Feb CTEC

SOLUTION;ORAL

PROPRANOLOL HYDROCHLORIDE
@ PAI HOLDINGS PHARM 20MG/5ML
@ 40MG/5ML

A071984 001 Mar 03, 1989 Apr CAHN
A071985 001 Mar 03, 1989 Apr CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE
@ CHARTWELL RX 10MG
@ 20MG
@ 40MG
@ 60MG
@ 80MG

A070663 001 Jun 13, 1986 Mar CAHN
A070664 001 Jun 13, 1986 Mar CAHN
A070665 001 Jun 13, 1986 Mar CAHN
A070666 001 Oct 10, 1986 Mar CAHN
A070667 001 Jun 13, 1986 Mar CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>A>	@ CHARTWELL MOLECULAR	50MG	A080016	001	Aug CAHN
>D>	@ LANNETT	50MG	A080016	001	Aug CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA	MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022	Apr NEWA
AB	IMPAX LABS	30MG	A211181	002	May 14, 2019	Jun CTEC
AB	EYWA	30MG	A040502	002	Jun 28, 2022	Jun NEWA

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	HETERO LABS LTD V	EQ 25MG BASE	A204316	001	Jun 16, 2022	Jun NEWA
AB		EQ 50MG BASE	A204316	002	Jun 16, 2022	Jun NEWA
AB		EQ 100MG BASE	A204316	003	Jun 16, 2022	Jun NEWA
AB		EQ 200MG BASE	A204316	004	Jun 16, 2022	Jun NEWA
AB		EQ 300MG BASE	A204316	005	Jun 16, 2022	Jun NEWA
AB		EQ 400MG BASE	A204316	006	Jun 16, 2022	Jun NEWA
>A> AB	PRINSTON INC	EQ 25MG BASE	A206954	001	Aug 24, 2022	Aug NEWA
>A> AB		EQ 50MG BASE	A206954	002	Aug 24, 2022	Aug NEWA
>A> AB		EQ 100MG BASE	A206954	003	Aug 24, 2022	Aug NEWA
>A> AB		EQ 200MG BASE	A206954	004	Aug 24, 2022	Aug NEWA
>A> AB		EQ 300MG BASE	A206954	005	Aug 24, 2022	Aug NEWA
>A> AB		EQ 400MG BASE	A206954	006	Aug 24, 2022	Aug NEWA
TABLET, EXTENDED RELEASE;ORAL						
QUETIAPINE FUMARATE						
AB	PRINSTON INC	EQ 50MG BASE	A208781	001	Apr 26, 2022	Apr NEWA
AB		EQ 150MG BASE	A208781	002	Apr 26, 2022	Apr NEWA
AB		EQ 200MG BASE	A208781	003	Apr 26, 2022	Apr NEWA
AB		EQ 300MG BASE	A208781	004	Apr 26, 2022	Apr NEWA
>A> AB	UNICHEM	EQ 50MG BASE	A215478	001	Aug 15, 2022	Aug NEWA
>A> AB		EQ 150MG BASE	A215478	002	Aug 15, 2022	Aug NEWA
>A> AB		EQ 200MG BASE	A215478	003	Aug 15, 2022	Aug NEWA
>A> AB		EQ 300MG BASE	A215478	004	Aug 15, 2022	Aug NEWA
>A> AB		EQ 400MG BASE	A215478	005	Aug 15, 2022	Aug NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB	@ CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
AB	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
AB	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
AB	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

>D>	@ EYWA	324MG	A212589	001	Sep 17, 2021	Aug CMFD
>A> AB		324MG	A212589	001	Sep 17, 2021	Aug CMFD
	@	324MG	A212589	001	Sep 17, 2021	Mar DISC
>D>	! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Aug CTEC
>A> AB	!	324MG	A089338	001	Feb 11, 1987	Aug CTEC
	!	324MG	A089338	001	Feb 11, 1987	Mar CTEC

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

+! MSD SUB MERCK

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013 Jun CAHN

TABLET;ORAL

ISENTRESS

+! MSD SUB MERCK

EQ 400MG BASE

N022145 001 Oct 12, 2007 Jun CAHN

ISENTRESS HD

EQ 600MG BASE

N022145 002 May 26, 2017 Jun CAHN

+! MSD SUB MERCK

TABLET, CHEWABLE;ORAL

ISENTRESS

+ MSD SUB MERCK

EQ 25MG BASE

N203045 001 Dec 21, 2011 Jun CAHN

+!

EQ 100MG BASE

N203045 002 Dec 21, 2011 Jun CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

>A> AB ENALTEC 8MG A215435 001 Aug 24, 2022 Aug NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ CHARTWELL RX

1.25MG

A077514 001 Jun 18, 2008 Mar CAHN

@

2.5MG

A077514 002 Jun 18, 2008 Mar CAHN

@

5MG

A077514 003 Jun 18, 2008 Mar CAHN

@

10MG

A077514 004 Jun 18, 2008 Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

@ MYLAN LABS LTD

EQ 25MG BASE/ML

A079076 001 Jun 09, 2016 Jul DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC

EQ 15MG BASE/ML

A078890 001 Jul 01, 2010 Jul DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZY SPRINKLE

+ SPIL

500MG

N216018 001 Feb 28, 2022 Mar CAHN

+!

1GM

N216018 002 Feb 28, 2022 Mar CAHN

+ SUN PHARMA GLOBAL

500MG

N216018 001 Feb 28, 2022 Feb NEWA

+!

1GM

N216018 002 Feb 28, 2022 Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB HETERO LABS LTD III 500MG A212788 001 May 05, 2022 Apr NEWA
AB 1GM A212788 002 May 05, 2022 Apr NEWA
AB I3 PHARMS 500MG A213517 001 Apr 27, 2022 Apr NEWA
AB 1GM A213517 002 Apr 27, 2022 Apr NEWA
AB VKT PHARMA 500MG A214035 001 Jan 19, 2022 Jan NEWA
AB 1GM A214035 002 Jan 19, 2022 Jan NEWARASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@ DR REDDYS

EQ 0.5MG BASE

A201942 001 Nov 18, 2021 Jan DISC

@

EQ 1MG BASE

A201942 002 Nov 18, 2021 Jan DISC

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP +! ASTELLAS RAGADENOSON 0.4MG/5ML (0.08MG/ML) N022161 001 Apr 10, 2008 Apr CFTG
AP IMS LTD REGADENOSON 0.4MG/5ML (0.08MG/ML) A214252 001 May 23, 2022 May NEWA
AP ACCORD HLTHCARE 0.4MG/5ML (0.08MG/ML) A213236 001 Apr 11, 2022 Apr NFTG
AP APOTEX 0.4MG/5ML (0.08MG/ML) A207604 001 Apr 11, 2022 Apr NFTG
AP DR REDDYS 0.4MG/5ML (0.08MG/ML) A213210 001 Apr 11, 2022 Apr NFTG
AP GLAND PHARMA LTD 0.4MG/5ML (0.08MG/ML) A207320 001 Jul 12, 2022 Jul NEWA
AP HONG KONG 0.4MG/5ML (0.08MG/ML) A212806 001 Apr 11, 2022 Apr NFTG
>A> AP HOSPIRA 0.4MG/5ML (0.08MG/ML) A214349 001 Aug 31, 2022 Aug NEWA
AP IMS LTD 0.4MG/5ML (0.08MG/ML) A214252 001 May 23, 2022 May CMS1REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP HIKMA EQ 1MG BASE/VIAL A210594 001 Oct 13, 2020 Jul CAHN
AP EQ 2MG BASE/VIAL A210594 002 Oct 13, 2020 Jul CAHN
AP EQ 5MG BASE/VIAL A210594 003 Oct 13, 2020 Jul CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

>D>	AB	BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Aug DISC
>A>	@		0.5MG	A091517	001	Apr 24, 2015	Aug DISC
>D>	AB		1MG	A091517	002	Apr 24, 2015	Aug DISC
>A>	@		1MG	A091517	002	Apr 24, 2015	Aug DISC
>D>	AB		2MG	A091517	003	Apr 24, 2015	Aug DISC
>A>	@		2MG	A091517	003	Apr 24, 2015	Aug DISC

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

AB	CHARTWELL MOLECULAR	150MG	A065390	001	Mar 28, 2008	Jun CAHN
AB		300MG	A065390	002	Mar 28, 2008	Jun CAHN

RILUZOLE

FILM;ORAL

EXSERVAN

>A>	AB	+! AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Aug CAHN
>D>		+! MITSUBISHI HOLDINGS	50MG	N212640	001	Nov 22, 2019	Aug CAHN
		SUSPENSION;ORAL					
		TIGLUTIK KIT					
		+! ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Jun CAHN

RIOCIGUAT

TABLET;ORAL

ADEMPAS

>D>	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Aug CFTG
>A>	AB	+	0.5MG	N204819	001	Oct 08, 2013	Aug CFTG
>D>	+		1MG	N204819	002	Oct 08, 2013	Aug CFTG
>A>	AB	+	1MG	N204819	002	Oct 08, 2013	Aug CFTG
>D>	+		1.5MG	N204819	003	Oct 08, 2013	Aug CFTG
>A>	AB	+	1.5MG	N204819	003	Oct 08, 2013	Aug CFTG
>D>	+		2MG	N204819	004	Oct 08, 2013	Aug CFTG
>A>	AB	+	2MG	N204819	004	Oct 08, 2013	Aug CFTG
>D>	+		2.5MG	N204819	005	Oct 08, 2013	Aug CFTG
>A>	AB	+	2.5MG	N204819	005	Oct 08, 2013	Aug CFTG
>A>		RIOCGUAT					
>A>	AB	MSN	0.5MG	A211135	001	Sep 01, 2022	Aug NFTG
>A>	AB		1MG	A211135	002	Sep 01, 2022	Aug NFTG
>A>	AB		1.5MG	A211135	003	Sep 01, 2022	Aug NFTG
>A>	AB		2MG	A211135	004	Sep 01, 2022	Aug NFTG
>A>	AB		2.5MG	A211135	005	Sep 01, 2022	Aug NFTG

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

>D>	AB	+	APIL	5MG	N020835	002	Apr 14, 2000	Aug DISC
>A>		+	@	5MG	N020835	002	Apr 14, 2000	Aug DISC
>D>	AB	+		30MG	N020835	001	Mar 27, 1998	Aug DISC
>A>		+	@	30MG	N020835	001	Mar 27, 1998	Aug DISC

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

>D>		@ ATLANTIDE	1MG/ML	A078744	001	Oct 08, 2009	Apr CAHN
>A>	AA	@ CHARTWELL MOLECULAR	1MG/ML	A202386	001	Jan 12, 2015	Aug CMFD
			1MG/ML	A202386	001	Jan 12, 2015	Aug CMFD
		@	1MG/ML	A202386	001	Jan 12, 2015	May CAHN
AA		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May CAHN

RITONAVIR

TABLET;ORAL

RITONAVIR

AB	CIPLA	100MG	A202573	001	Jan 15, 2015	Mar CAHN
AB		100MG	A203759	001	May 10, 2022	Apr NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

>D>	AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Aug CAHN
>D>	AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Aug CAHN
>D>	AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Aug CAHN
>A>	AB	ZYDUS PHARMS	4.6MG/24HR	A206318	001	Mar 04, 2019	Aug CAHN
>A>	AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Aug CAHN
>A>	AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Aug CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL
MAXALT

	+ @ ORGANON LLC	EQ 5MG BASE	N020864	001	Jun 29, 1998	Jul CAHN
AB	+!	EQ 10MG BASE	N020864	002	Jun 29, 1998	Jul CAHN
	RIZATRIPTAN BENZOATE					
AB	CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	May CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	May CAHN
	@ JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	May DISC
	@	EQ 10MG BASE	A203252	002	Dec 31, 2014	May DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	PRINSTON INC	50MG/5ML (10MG/ML)	A212668	001	May 26, 2022	May NEWA
AP		100MG/10ML (10MG/ML)	A212668	002	May 26, 2022	May NEWA

ROFLUMILAST

CREAM;TOPICAL
ZORYVE

+! ARCUTIS 0.3%

TABLET;ORAL
DALIRESP

>D>	+	ASTRAZENECA	250MCG	N022522	002	Jan 23, 2018	Aug CFTG
>A>	AB	+	250MCG	N022522	002	Jan 23, 2018	Aug CFTG
		ROFLUMILAST					
>D>		@ MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Aug CMFD
>A>	AB		500MCG	A208180	001	Mar 22, 2019	Aug CMFD
>A>	AB	MSN	250MCG	A208256	001	Sep 07, 2022	Aug NFTG
>A>	AB		500MCG	A208256	002	Sep 07, 2022	Aug NEWA
>D>		@ MYLAN	500MCG	A208257	001	Jul 13, 2018	Aug CMFD
>A>	AB		500MCG	A208257	001	Jul 13, 2018	Aug CMFD
AB	PRINSTON INC	500MCG	A208299	001	May 10, 2022	Apr NEWA	
	@ ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Jul DISC	
AB		500MCG	A208303	001	Feb 10, 2022	Feb NEWA	

ROMIDEPSIN

SOLUTION;INTRAVENOUS
ROMIDEPSIN

+ @ TEVA PHARMS USA INC 27.5MG/5.5ML (5MG/ML)

N208574 002 Mar 13, 2020 Jul DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

AB	PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr NEWA
AB		EQ 4MG BASE	A204413	002	May 11, 2022	Apr NEWA
AB		EQ 6MG BASE	A204413	003	May 11, 2022	Apr NEWA
AB		EQ 8MG BASE	A204413	004	May 11, 2022	Apr NEWA
AB		EQ 12MG BASE	A204413	005	May 11, 2022	Apr NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

>A>	AP	GLAND PHARMA LTD	200MG/100ML (2MG/ML)	A210102	001	Aug 18, 2022	Aug NEWA
			400MG/200ML (2MG/ML)	A210102	002	Aug 18, 2022	Aug NEWA

ROSVUSTATIN CALCIUM

TABLET;ORAL

ROSVUSTATIN CALCIUM

@ STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan CAHN
@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan CAHN
@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan CAHN
@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan CAHN
@ ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar CAHN
@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar CAHN
@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Mar CAHN
@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Mar CAHN

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

@ LUPIN LTD	40MG/ML	A213457	001	Dec 18, 2020	Apr DISC
TABLET;ORAL					
>A> RUFINAMIDE					
>A> LUPIN LTD	100MG	A204964	001	Aug 17, 2022	Aug NFTG

>A> AB
>A> AB
>A> AB

200MG
400MG

A204964 002 Aug 17, 2022 Aug NEWA
A204964 003 Aug 17, 2022 Aug NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE;INJECTION

QUADRAMET

+ @ LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997	Jan DISC
----------------------	----------	---------	-----	--------------	----------

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

>A> AB ANNORA PHARMA	100MG/PACKET	A215420	001	Aug 18, 2022	Aug NEWA
>A> AB	500MG/PACKET	A215420	002	Aug 18, 2022	Aug NEWA
AB DR REDDYS	500MG/PACKET	A215798	001	May 13, 2022	May NEWA
TABLET;ORAL					
SAPROPTERIN DIHYDROCHLORIDE					
>A> AB ANNORA PHARMA	100MG	A215534	001	Aug 23, 2022	Aug NEWA

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Apr DISC
------------	-----	---------	-----	--------------	----------

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

! PADAGIS US	2.5%	A089996	001	Jan 10, 1991	Jun CTEC
@ WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983	Jun DISC

SELINEXOR

TABLET;ORAL

XPOVIO

+ KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Mar CHRS
+!	60MG	N212306	004	Apr 15, 2021	Mar CHRS

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

+! NOVO	8MG/3ML (2.68MG/ML)	N209637	003	Mar 28, 2022	Apr NEWA
---------	---------------------	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL

ZOLOFT

AA +! VIATRIS	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jan CAHN
TABLET;ORAL					
ZOLOFT					
AB + VIATRIS	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jan CAHN
AB +	EQ 50MG BASE	N019839	001	Dec 30, 1991	Jan CAHN
AB +!	EQ 100MG BASE	N019839	002	Dec 30, 1991	Jan CAHN
+ @	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jan CAHN
+ @	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jan CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

@ LUPIN LTD	800MG/PACKET	A201513	001	Dec 23, 2021	Jul DISC
@	2.4GM/PACKET	A201513	002	Dec 23, 2021	Jul DISC

TABLET;ORAL

SEVELAMER CARBONATE

@ LUPIN LTD	800MG	A204600	001	Jan 14, 2021	May DISC
MICRO LABS	800MG	A215537	001	Feb 07, 2022	Jan NEWA
@ STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020	Jan CAHN

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIO

AB +! VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb CAHN
AB LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022	Mar NEWA

AB MSN	EQ 10MG BASE/ML	A214641	001	Feb 08, 2022	Jan NEWA
AB @ TRIS PHARMA INC	EQ 10MG BASE/ML	A212312	001	Nov 17, 2021	Apr DISC

SOLUTION;INTRAVENOUS
REVATIO

AP +! VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb CAHN
---------------	---	---------	-----	--------------	----------

TABLET;ORAL
REVATIO

AB +! VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb CAHN
AB VIAGRA					

AB + VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb CAHN
AB +	EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb CAHN

AB +!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb CAHN
-------	---------------	---------	-----	--------------	----------

SILODOSIN

CAPSULE;ORAL

SILODOSIN

@ UPSHER SMITH LABS	4MG	A213230	001	Jan 03, 2022	Feb DISC
@	8MG	A213230	002	Jan 03, 2022	Feb DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

@ CHARTWELL RX	5MG	A077766	001	Dec 20, 2006	Mar CAHN
@	10MG	A077766	002	Dec 20, 2006	Mar CAHN
@	20MG	A077766	003	Dec 20, 2006	Mar CAHN
@	40MG	A077766	004	Dec 20, 2006	Mar CAHN
@	80MG	A077766	005	Dec 20, 2006	Mar CAHN

SIROLIMUS

GEL;TOPICAL

HYFTOR

+! NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022	Mar NEWA
----------------	------	---------	-----	--------------	----------

SOLUTION;ORAL

SIROLIMUS

@ TORRENT	1MG/ML	A215016	001	Dec 27, 2021	Jun DISC
-----------	--------	---------	-----	--------------	----------

SODIUM BICARBONATEINJECTABLE;INJECTION
SODIUM BICARBONATE

AP ! HOSPIRA	0.5MEQ/ML	A202981	001	Mar 04, 2016	Apr CHRS
--------------	-----------	---------	-----	--------------	----------

SODIUM CHLORIDESOLUTION;INTRAVENOUS
SODIUM CHLORIDE 23.4%

AP FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
AP +! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
 SODIUM FLUORIDE F 18
 + @ NIH NCI DCTD 10-200mCi/ML N022494 001 Jan 26, 2011 Mar CRLD

SODIUM IODIDE I-123

CAPSULE; ORAL
 SODIUM IODIDE I 123
 >A> @ GE HEALTHCARE 200uCi N017630 003 Jan 08, 1993 Aug NEWA

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
 SODIUM NITROPRUSSIDE
 @ AKORN 25MG/ML A208635 001 May 04, 2017 Jun DISC
 AP BE PHARMS 25MG/ML A214971 001 Jul 12, 2021 Apr CMFD
 @ 25MG/ML A214971 001 Jul 12, 2021 Jan DISC
 AP CAPLIN 25MG/ML A211016 001 Nov 29, 2019 Mar CAHN
 SOLUTION; INTRAVENOUS
 NIPRIDE RTU IN SODIUM CHLORIDE 0.9%
 >D> +! EXELA PHARMA 20MG/100ML (0.2MG/ML) N209387 003 Jul 13, 2018 Aug CFTG
 >A> AP +! 20MG/100ML (0.2MG/ML) N209387 003 Jul 13, 2018 Aug CFTG
 >D> +! 50MG/100ML (0.5MG/ML) N209387 001 Mar 08, 2017 Aug CFTG
 >A> AP +! 50MG/100ML (0.5MG/ML) N209387 001 Mar 08, 2017 Aug CFTG
 >A> SODIUM NITROPRUSSIDE
 >A> HAINAN POLY 10MG/50ML (0.2MG/ML) A215846 001 Aug 26, 2022 Aug NFTG
 >A> AP 20MG/100ML (0.2MG/ML) A215846 002 Aug 26, 2022 Aug NFTG
 >A> AP 50MG/100ML (0.5MG/ML) A215846 003 Aug 26, 2022 Aug NFTG

SODIUM PHENYLBUTYRATE

PELLETS; ORAL
 PHEBURANE
 +! MEDUNIK 84GM/BOT N216513 001 Jun 17, 2022 Jun NEWA

>D> SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

>D> TABLET; ORAL
 >D> VISICOL
 >D> @ SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000 Aug CAIN

>A> SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

>A> TABLET; ORAL
 >A> VISICOL
 >A> @ SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000 Aug CAIN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
 SODIUM PHOSPHATES
 AP FRESENIUS KABI USA 142MG/ML,276MG/ML A209997 001 Mar 30, 2022 Mar NFTG
 SODIUM PHOSPHATES IN PLASTIC CONTAINER
 AP +! HOSPIRA 142MG/ML;276MG/ML N018892 001 May 10, 1983 Mar CFTG

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
 SODIUM POLYSTYRENE SULFONATE
 + @ PAI HOLDINGS PHARM 453.6GM/BOT A088786 001 Sep 11, 1984 Apr CAHN
 SUSPENSION; ORAL, RECTAL
 KIONEX
 AA ANI PHARMS 15GM/60ML A040028 001 Sep 17, 2007 Mar CMFD
 SPS
 AA +! CMP PHARMA INC 15GM/60ML A087859 001 Dec 08, 1982 Mar CTEC

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION
 SODIUM TETRADECYL SULFATE
 >D> AP CUSTOPHARM INC 60MG/2ML (30MG/ML) A209937 001 Dec 09, 2019 Aug CAHN
 >A> AP HIKMA 60MG/2ML (30MG/ML) A209937 001 Dec 09, 2019 Aug CAHN

SOFOSBUVIR

	TABLET;ORAL SOFOSBUVIR						
AB	@ TEVA PHARMS USA INC	400MG 400MG		A211353	001	Jan 27, 2022	Jul DISC
	SOVALDI			A211353	001	Jan 27, 2022	Jan NFTG
AB	+! GILEAD SCIENCES INC	400MG 400MG		N204671	001	Dec 06, 2013	Jul CTEC
	+!			N204671	001	Dec 06, 2013	Jan CFTG

SOLIFENACIN SUCCINATE

	TABLET;ORAL SOLIFENACIN SUCCINATE						
AB	@ ACCORD HLTHCARE	5MG		A207477	001	Jan 04, 2022	Jul DISC
	@	10MG		A207477	002	Jan 04, 2022	Jul DISC
AB	@ AMNEAL PHARMS CO	5MG		A209719	001	May 20, 2019	Jan DISC
	@	10MG		A209719	002	May 20, 2019	Jan DISC
AB	ANNORA PHARMA	5MG		A215761	001	Jun 15, 2022	Jun NEWA
AB		10MG		A215761	002	Jun 15, 2022	Jun NEWA

SOLRIAMFETOL HYDROCHLORIDE

	TABLET;ORAL SUNOSI						
AB	+ AXSOME MALTA	EQ 75MG BASE		N211230	001	Jun 17, 2019	May CAHN
	+!	EQ 150MG BASE		N211230	002	Jun 17, 2019	May CAHN

SONIDEGRIB PHOSPHATE

	CAPSULE;ORAL ODOMZO						
AB	+! SUN PHARM	EQ 200MG BASE		N205266	001	Jul 24, 2015	Feb CAHN

SORAFENIB TOSYLATE

	TABLET;ORAL NEXAVAR						
AB	+! BAYER HLTHCARE	EQ 200MG BASE		N021923	001	Dec 20, 2005	Apr CTEC
	SORAFENIB TOSYLATE						
AB	DR REDDYS	EQ 200MG BASE		A216073	001	Jun 07, 2022	May NEWA
AB	MYLAN	EQ 200MG BASE		A207012	001	Sep 10, 2020	Apr CMFD

SOTALOL HYDROCHLORIDE

	SOLUTION;ORAL SOTYLINE						
AB	+! AZURITY	5MG/ML (5MG/ML)		N205108	001	Oct 22, 2014	Mar CAHN

STERILE WATER FOR INJECTION

	LIQUID;N/A STERILE WATER FOR INJECTION						
AP	! MEDEFIL INC	100% (5ML)		A211188	004	Dec 02, 2019	Feb CTEC
AP	NEPHRON	100% (5ML)		A211222	001	Feb 10, 2021	Feb CMFD

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE;INJECTION SUCCINYLCHOLINE CHLORIDE						
>D> AP	BE PHARMS	20MG/ML		A216003	001	Feb 07, 2022	Aug DISC
>A>	@	20MG/ML		A216003	001	Feb 07, 2022	Aug DISC
AP		20MG/ML		A216003	001	Feb 07, 2022	Jan NEWA
AP	MEITHEAL	20MG/ML		A214514	001	Oct 19, 2021	Mar CAHN

SUCRALFATE

	SUSPENSION;ORAL SUCRALFATE						
AB	VISTAPHARM	1GM/10ML		A211884	001	Mar 15, 2022	Mar NEWA
	TABLET;ORAL SUCRALFATE						
AB	AMNEAL PHARMS	1GM		A215576	001	Apr 15, 2022	Apr NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	@ LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
	NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA

SULINDAC

TABLET;ORAL

SULINDAC

@ RISING	150MG	A073039	002	Jun 22, 1993	Jul CAHN
@	200MG	A073039	001	Jun 22, 1993	Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

@ STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr NEWA
AB		EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr NEWA
AB		EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr NEWA
AB		EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr NEWA

TADALAFIL

SUSPENSION;ORAL

TADLIQ

+! CMP DEV LLC	20MG/5ML
----------------	----------

N214522 001 Jun 17, 2022 Jun NEWA

TABLET;ORAL

TADALAFIL

AB1	AUSTARPHARMA	2.5MG	A208824	001	Oct 27, 2020	Mar CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar CAHN
	@ CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020	May CAHN
	@	5MG	A210716	002	Dec 29, 2020	May CAHN
	@	10MG	A210716	003	Dec 29, 2020	May CAHN
	@	20MG	A210716	004	Dec 29, 2020	May CAHN
>A> AB1	PRINSTON INC	2.5MG	A210609	001	Aug 11, 2022	Aug NEWA
>A> AB1		5MG	A210609	002	Aug 11, 2022	Aug NEWA
>A> AB1		10MG	A210609	003	Aug 11, 2022	Aug NEWA
>A> AB2		20MG	A210608	001	Aug 11, 2022	Aug NEWA
>A> AB1		20MG	A210609	004	Aug 11, 2022	Aug NEWA

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018	Jul CAHN
----	-------------------	---------------	---------	-----	--------------	----------

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT	SANDOZ INC	0.0015%	A209040	001	Jan 28, 2022	Jan NEWA
AT	+! THEA PHARMA	0.0015%	N202514	001	Feb 10, 2012	Apr CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB	ACME LABS	0.4MG	A214730	001	May 04, 2022	Apr NEWA
----	-----------	-------	---------	-----	--------------	----------

TAPINAROF

CREAM;TOPICAL

VTAMA

+!	DERMAVANT SCI	1%	N215272	001	May 23, 2022	May NEWA
----	---------------	----	---------	-----	--------------	----------

<u>TAVABOROLE</u>					
SOLUTION;TOPICAL					
TAVABOROLE					
AB	CHARTWELL RX	5%	A211963	001	Feb 03, 2021
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021
<u>TAZAROTENE</u>					
LOTION;TOPICAL					
ARAZLO					
+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019
<u>TECHNETIUM TC-99M SUCCIMER</u>					
POWDER; INTRAVENOUS					
NEPHROSCAN					
+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022
<u>TECHNETIUM TC-99M SUCCIMER KIT</u>					
POWDER; INTRAVENOUS					
NEPHROSCAN					
+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022
<u>TECHNETIUM TC-99M TETROFOSMIN KIT</u>					
INJECTABLE; INJECTION					
MYOVIEW					
+!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996
<u>TECOVIRIMAT</u>					
SOLUTION; INTRAVENOUS					
TPOXX					
+!	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)	N214518	001	May 18, 2022
<u>TEDUGLUTIDE RECOMBINANT</u>					
POWDER; SUBCUTANEOUS					
GATTEX KIT					
+!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012
<u>TEGASEROD MALEATE</u>					
TABLET; ORAL					
ZELNORM					
+ @	ALFASIGMA	EQ 6MG BASE	N021200	002	Jul 24, 2002
<u>TEMOZOLOMIDE</u>					
CAPSULE; ORAL					
TEMOZOLOMIDE					
@	ANI PHARMS	5MG	A203490	001	Jul 13, 2016
@		20MG	A203490	002	Jul 13, 2016
@		100MG	A203490	003	Jul 13, 2016
@		140MG	A203490	004	Jul 13, 2016
@		180MG	A203490	005	Jul 13, 2016
@		250MG	A203490	006	Jul 13, 2016
AB	HERITAGE	5MG	A078879	001	Mar 01, 2010
AB		20MG	A078879	002	Mar 01, 2010
AB		100MG	A078879	003	Mar 01, 2010
AB		140MG	A078879	005	Mar 01, 2010
AB		180MG	A078879	006	Mar 01, 2010
AB		250MG	A078879	004	Mar 01, 2010
<u>TENAPANOR HYDROCHLORIDE</u>					
TABLET; ORAL					
IBSRELA					
+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019
<u>TENOFOVIR DISOPROXIL FUMARATE</u>					
TABLET; ORAL					
TENOFOVIR DISOPROXIL FUMARATE					
AB	CHARTWELL	300MG	A206481	001	Jul 26, 2018
					Jul CMFD

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Mar CMFD
	@ HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007	Jul DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

>D> AP	AKORN	1MG/ML	A078151	001	Jan 07, 2008	Aug DISC
>A>	@	1MG/ML	A078151	001	Jan 07, 2008	Aug DISC
AP	! CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004	Mar CAHN

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

+ @ ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan DISC
+ @	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan DISC
+ @	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan DISC
+ @	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan DISC

TESTOSTERONE

AB1	! ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan CHRS
AB2	! PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan CHRS

TESTOSTERONE CYPIONATE

SOLUTION;INTRAMUSCULAR

TESTOSTERONE CYPIONATE

+! SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jun NEWA
------------------------	---------------------	---------	-----	--------------	----------

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

KYZATREX

+ MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022	Jul NEWA
+	150MG	N213953	002	Jul 27, 2022	Jul NEWA
+!	200MG	N213953	003	Jul 27, 2022	Jul NEWA
TLANDO					
+! ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022	Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

@ HIKMA	12.5MG	A209739	001	Apr 08, 2019	Feb DISC
@	25MG	A209739	002	Apr 08, 2019	Feb DISC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP	EUGIA PHARMA	100MG/ML	A208703	001	Apr 20, 2022	Apr NEWA
----	--------------	----------	---------	-----	--------------	----------

THIOGUANINE

TABLET;ORAL

THIOGUANINE

+! WOODWARD SPECL	40MG	N012429	001		Apr CAHN
-------------------	------	---------	-----	--	----------

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB	AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb NEWA
AB		2MG	A215456	002	Feb 28, 2022	Feb NEWA
AB		5MG	A215456	003	Feb 28, 2022	Feb NEWA
AB		10MG	A215456	004	Feb 28, 2022	Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

@ AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Jul DISC
@	4MG	A208181	002	Dec 08, 2017	Jul DISC
@	12MG	A208181	003	Dec 08, 2017	Jul DISC
@	16MG	A208181	004	Dec 08, 2017	Jul DISC

TICAGRELOR

TABLET; ORAL						
BRILINTA						
+ ASTRAZENECA	60MG		N022433	002	Sep 03, 2015	Feb CTEC
TICAGRELOR						
@ MYLAN	60MG		A208597	001	Jul 09, 2021	Feb DISC
@	90MG		A208597	002	Jul 09, 2021	Feb DISC

TIGECYCLINE

POWDER; INTRAVENOUS						
TIGECYCLINE						
@ XELLIA PHARMS APS	50MG/VIAL		A205722	001	Oct 18, 2019	Jun DISC

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC						
BETIMOL						
AT +! THEA PHARMA	EQ 0.25% BASE		N020439	001	Mar 31, 1995	Apr CAHN
AT +!	EQ 0.5% BASE		N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC						
TIMOLOL MALEATE						
AB GLAND PHARMA LTD	EQ 0.25% BASE		A214645	001	Jun 24, 2022	Jun NEWA
TIMOPTIC-XE						
AB + BAUSCH	EQ 0.25% BASE		N020330	001	Nov 04, 1993	Apr CAHN
AB +	EQ 0.5% BASE		N020330	002	Nov 04, 1993	Apr CAHN
AB + BAUSCH AND LOMB INC	EQ 0.25% BASE		N020330	001	Nov 04, 1993	Jul CAHN
AB +	EQ 0.5% BASE		N020330	002	Nov 04, 1993	Jul CAHN
SOLUTION/DROPS; OPHTHALMIC						
TIMOLOL MALEATE						
@ AKORN	EQ 0.5% BASE		A074516	001	Mar 25, 1997	Jul DISC
MICRO LABS	EQ 0.5% BASE		A216596	001	Sep 07, 2022	Aug NEWA
TIMOPTIC						
AT1 + BAUSCH	EQ 0.25% BASE		N018086	001		Apr CAHN
AT1 +	EQ 0.5% BASE		N018086	002		Apr CAHN
AT1 + BAUSCH AND LOMB INC	EQ 0.25% BASE		N018086	001		Jul CAHN
AT1 +	EQ 0.5% BASE		N018086	002		Jul CAHN
TIMOPTIC IN OCUDOSE						
AT3 +! BAUSCH AND LOMB INC	EQ 0.25% BASE		N019463	001	Nov 05, 1986	Feb CAHN
AT3 +!	EQ 0.5% BASE		N019463	002	Nov 05, 1986	Feb CAHN

TIOPRONIN

TABLET; ORAL						
TIOPRONIN						
AB PAR PHARM INC	100MG		A216198	001	Jun 02, 2022	May NEWA

TIRZEPATIDE

SOLUTION; SUBCUTANEOUS						
MOUNJARO						
+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N215866	001	May 13, 2022	May NEWA
+!	5MG/0.5ML (5MG/0.5ML)		N215866	002	May 13, 2022	May NEWA
+!	7.5MG/0.5ML (7.5MG/0.5ML)		N215866	003	May 13, 2022	May NEWA
+!	10MG/0.5ML (10MG/0.5ML)		N215866	004	May 13, 2022	May NEWA
+!	12.5MG/0.5ML (12.5MG/0.5ML)		N215866	005	May 13, 2022	May NEWA
+!	15MG/0.5ML (15MG/0.5ML)		N215866	006	May 13, 2022	May NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION						
TOBRAMYCIN SULFATE						
>D> AP AKORN	EQ 40MG BASE/ML		A205179	001	Sep 16, 2014	Aug DISC
>A> @	EQ 40MG BASE/ML		A205179	001	Sep 16, 2014	Aug DISC

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE; ORAL						
TOFACITINIB						
@ ZYDUS PHARMS	EQ 11MG BASE		A214264	001	Aug 19, 2021	Jan DISC
@	EQ 22MG BASE		A214264	002	Aug 19, 2021	Jan DISC
XELJANZ XR						
+ PFIZER	EQ 11MG BASE		N208246	001	Feb 23, 2016	Jan CTEC
+!	EQ 22MG BASE		N208246	002	Dec 12, 2019	Jan CTEC

TOLVAPTAN

	TABLET;ORAL SAMSCA						
AB	+ OTSUKA TOLVAPTAN	15MG		N 022275	001	May 19, 2009	Feb CFTG
>A>	AB ALKEM LABS LTD	15MG		A 211891	003	Sep 06, 2022	Aug NEWA
>A>	AB APOTEX	15MG		A 207605	002	Sep 06, 2022	Aug NEWA
>A>	AB HETERO LABS LTD V	15MG		A 205646	002	Sep 06, 2022	Aug NEWA
AB	PAR PHARM INC	15MG		A 206119	001	Feb 15, 2022	Feb NFTG
AB		30MG		A 206119	002	Feb 15, 2022	Feb NEWA

TOPIRAMATE

	TABLET;ORAL TOPIRAMATE						
@	ATLANTIDE	25MG		A 090353	001	Sep 01, 2010	Apr CAHN
@		50MG		A 090353	002	Sep 01, 2010	Apr CAHN
@		100MG		A 090353	003	Sep 01, 2010	Apr CAHN
@		200MG		A 090353	004	Sep 01, 2010	Apr CAHN
@	UPSHER SMITH LABS	25MG		A 078499	001	Jan 07, 2010	Mar DISC
@		50MG		A 078499	002	Jan 07, 2010	Mar DISC
@		100MG		A 078499	003	Jan 07, 2010	Mar DISC
@		200MG		A 078499	004	Jan 07, 2010	Mar DISC

TOPOTECAN HYDROCHLORIDE

	INJECTABLE; INJECTION TOPOTECAN HYDROCHLORIDE						
AP	TEYRO LABS	EQ 4MG BASE/VIAL		A 091199	001	Dec 01, 2010	Apr CAHN
	SOLUTION; INTRAVENOUS TOPOTECAN HYDROCHLORIDE						
	@ MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A 206074	001	Nov 24, 2017	Mar DISC

TRAMADOL HYDROCHLORIDE

	TABLET;ORAL ULTRAM						
>D>	@ JANSSEN PHARMS	100MG		N 020281	001	Mar 03, 1995	Aug CRLD
>A>	+ @	100MG		N 020281	001	Mar 03, 1995	Aug CRLD
	TABLET, EXTENDED RELEASE; ORAL TRAMADOL HYDROCHLORIDE						
	@ MYLAN	200MG		A 205257	002	Dec 22, 2015	Jun DISC
	@	300MG		A 205257	003	Dec 22, 2015	Jun DISC

TRANEXAMIC ACID

	INJECTABLE; INJECTION TRANEXAMIC ACID						
@	AKORN	100MG/ML		A 206594	001	Sep 28, 2017	Jun DISC
@		100MG/ML		A 206634	001	Jun 09, 2016	Jun DISC

TRANYLCYPROMINE SULFATE

	TABLET;ORAL TRANYLCYPROMINE SULFATE						
AB	CROSSMEDIKA SA	EQ 10MG BASE		A 213503	001	Jun 27, 2022	Jun NEWA

TREPROSTINIL

	POWDER; INHALATION TYVASO DPI						
+	UNITED THERAP	0.016MG/INH		N 214324	001	May 23, 2022	May NEWA
+		0.032MG/INH		N 214324	002	May 23, 2022	May NEWA
+		0.048MG/INH		N 214324	003	May 23, 2022	May NEWA
+	!	0.064MG/INH		N 214324	004	May 23, 2022	May NEWA

TRIAMCINOLONE ACETONIDE

	AEROSOL, METERED; NASAL NASACORT						
@	CHATTEM SANOFI	0.055MG/INH		N 019798	001	Jul 11, 1991	Jan CAHN
@		0.055MG/INH		N 019798	001	Jul 11, 1991	Jan CAHN

CREAM; TOPICAL

	TRIAMCINOLONE ACETONIDE						
AT	ENCUBE	0.1%		A 208848	001	Sep 18, 2017	Jul CAHN

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+! PACIRA PHARMS INC 32MG/VIAL

N208845 001 Oct 06, 2017 Feb CAHN

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

AB CUSTOPHARM INC 40MG/ML
AB EUGIA PHARMA 40MG/ML
AB LONG GROVE PHARMS 40MG/MLA213543 001 Jan 19, 2022 Jan NEWA
A212400 001 Jul 05, 2022 Jun NEWA
A213543 001 Jan 19, 2022 Jan CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT ENCUBE 0.1%
SPRAY, METERED; NASAL
TRIAMCINOLONE ACETONIDE
@ PERRIGO PHARMA INTL 0.055MG/SPRAYA205373 001 May 13, 2016 Jul CAHN
A078104 001 Jul 30, 2009 Jan CAHNTRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+ @ SANDOZ INC 5MG/ML
+ @ 20MG/MLN016466 001 Jul DISC
N016466 002 Jul DISCTRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE

AB EYWA 50MG
AB 100MGA214768 001 Jul 06, 2022 Jun NEWA
A214768 002 Jul 06, 2022 Jun NEWATRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB HETERO LABS LTD III 250MG
@ LUPIN LTD 250MGA216356 001 Jun 23, 2022 Jun NEWA
A211637 001 May 21, 2020 Apr DISCTRIENTINE TETRAHYDROCHLORIDE

TABLET; ORAL

CUVRIOR

+! ORPHALAN 300MG

N215760 001 Apr 28, 2022 Apr NEWA

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

>D> AT AKORN 1%
>A> @ 1%A205438 001 Jul 28, 2017 Aug DISC
A205438 001 Jul 28, 2017 Aug DISCTRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

TRIPTODUR KIT

+! AZURITY EQ 22.5MG BASE/VIAL

N208956 001 Jun 29, 2017 Jun CAHN

TROSPiUM CHLORIDE

TABLET; ORAL

TROSPiUM CHLORIDE

AB AMICI 20MG
AB ENALTEC 20MG
AB ZAMEER PHARMS 20MGA215781 001 Feb 16, 2022 Feb NEWA
A215781 001 Feb 16, 2022 May CAHN
A215781 001 Feb 16, 2022 Jul CAHNTRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANEBLUE

+ @ DORC 0.15%

N022278 001 Feb 20, 2009 Jul DISC

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL

RINVOQ

+ ABBVIE INC 15MG
+ 30MG
+! 30MG
+! 45MGN211675 001 Aug 16, 2019 Jan CHRS
N211675 002 Jan 14, 2022 Apr CHRS
N211675 002 Jan 14, 2022 Jan NEWA
N211675 003 Mar 16, 2022 Mar NEWA

URSODIOL

CAPSULE;ORAL						
ACTIGALL						
AB	@ TEVA BRANDED PHARM	150MG	N 019594	001	Dec 31, 1987	Apr CAHN
+!		300MG	N 019594	002	Dec 31, 1987	Apr CAHN
	URSODIOL					
	@ VGYAAN	300MG	A 214329	001	Jul 28, 2021	Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL						
VALGANCICLOVIR HYDROCHLORIDE						
>D> AB	AIRIS PHARMA PVT LTD	50MG/ML	A 210169	001	Feb 17, 2022	Aug CAHN
AB		50MG/ML	A 210169	001	Feb 17, 2022	Feb NEWA
>A> AB	MSN	50MG/ML	A 210169	001	Feb 17, 2022	Aug CAHN
TABLET;ORAL						
VALGANCICLOVIR HYDROCHLORIDE						
AB	@ MYLAN	EQ 450MG BASE	A 205151	001	Mar 03, 2021	Mar DISC
		EQ 450MG BASE	A 205151	001	Mar 03, 2021	Mar CAHN

VALPROATE SODIUM

INJECTABLE;INJECTION						
VALPROATE SODIUM						
AB	@ MYLAN	EQ 100MG BASE/ML	A 208120	001	Dec 22, 2021	May DISC

VALPROIC ACID

SYRUP;ORAL						
VALPROIC ACID						
AB	@ WOCKHARDT BIO AG	250MG/5ML	A 070868	001	Jul 01, 1986	Mar DISC

VALRUBICIN

SOLUTION;INTRAVESICAL						
VALRUBICIN						
>D> AO	CUSTOPHARM INC	40MG/ML	A 206430	001	Apr 19, 2019	Aug CAHN
>A> AO	HIKMA	40MG/ML	A 206430	001	Apr 19, 2019	Aug CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION						
VANCOCIN HYDROCHLORIDE						
AP	@ STERISCIENCE	EQ 500MG BASE/VIAL	A 060180	001		Jan CAHN
AP	@	EQ 500MG BASE/VIAL	A 062476	001	Mar 15, 1984	Jan CAHN
AP	@	EQ 500MG BASE/VIAL	A 062716	001	Mar 13, 1987	Jan CAHN
AP	@	EQ 500MG BASE/VIAL	A 062812	001	Nov 17, 1987	Jan CAHN
AP	@	EQ 1GM BASE/VIAL	A 060180	002	Mar 21, 1986	Jan CAHN
AP	@	EQ 1GM BASE/VIAL	A 062476	002	Mar 21, 1986	Jan CAHN
AP	@	EQ 1GM BASE/VIAL	A 062716	002	Mar 13, 1987	Jan CAHN
AP	@	EQ 1GM BASE/VIAL	A 062812	002	Nov 17, 1987	Jan CAHN
AP	@	EQ 10GM BASE/VIAL	A 062812	003	Nov 17, 1987	Jan CAHN
AP	ASPIRO	EQ 500MG BASE/VIAL	A 216591	001	Jul 06, 2022	Jun NEWA
AP		EQ 1GM BASE/VIAL	A 216591	002	Jul 06, 2022	Jun NEWA
>D> AP	KNACK	EQ 500MG BASE/VIAL	A 213059	001	Feb 15, 2022	Aug DISC
>A>	@	EQ 500MG BASE/VIAL	A 213059	001	Feb 15, 2022	Aug DISC
AP		EQ 500MG BASE/VIAL	A 213059	001	Feb 15, 2022	Feb NEWA
>D> AP		EQ 750MG BASE/VIAL	A 213059	002	Feb 15, 2022	Aug DISC
>A>	@	EQ 750MG BASE/VIAL	A 213059	002	Feb 15, 2022	Aug DISC
AP		EQ 750MG BASE/VIAL	A 213059	002	Feb 15, 2022	Feb NEWA
>D> AP		EQ 1GM BASE/VIAL	A 213059	003	Feb 15, 2022	Aug DISC
>A>	@	EQ 1GM BASE/VIAL	A 213059	003	Feb 15, 2022	Aug DISC
AP		EQ 1GM BASE/VIAL	A 213059	003	Feb 15, 2022	Feb NEWA
AP	NANJING KING-FRIEND	EQ 500MG BASE/VIAL	A 215197	001	Jul 28, 2022	Jul NEWA
AP		EQ 1GM BASE/VIAL	A 215197	002	Jul 28, 2022	Jul NEWA
AP		EQ 5GM BASE/VIAL	A 215196	001	Jul 27, 2022	Jul NEWA
AP		EQ 10GM BASE/VIAL	A 215196	002	Jul 27, 2022	Jul NEWA

POWDER;INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

+ @ MYLAN LABS LTD	EQ 250MG BASE/VIAL	N 209481	001	Jul 10, 2018	Feb DISC
--------------------	--------------------	----------	-----	--------------	----------

VARDENAFIL HYDROCHLORIDE

	TABLET;ORAL LEVITRA					
	+ @ BAYER HLTHCARE	EQ 20MG BASE		N021400	004	Aug 19, 2003 Feb DISC
	VARDENAFIL HYDROCHLORIDE					
AB	! ZYDUS PHARMS	EQ 20MG BASE		A208960	004	Oct 31, 2018 Feb CHRS
	TABLET, ORALLY DISINTEGRATING;ORAL STAXYN					
	+ @ BAYER HLTHCARE	10MG		N200179	001	Jun 17, 2010 May DISC
	VARDENAFIL HYDROCHLORIDE					
AB	! ALEMBIC PHARMS LTD	10MG		A208324	001	Nov 16, 2018 May CHRS

VARENICLINE TARTRATE

>D>	SOLUTION;NASAL					
>D>	TYRVAYA					
>D>	+! OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY		N213978	001	Oct 15, 2021 Aug CDFR
>A>	SPRAY;NASAL					
>A>	TYRVAYA					
>A>	+! OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY		N213978	001	Oct 15, 2021 Aug CDFR
	TABLET;ORAL CHANTIX					
	+ @ PF PRISM CV	EQ 0.5MG BASE		N021928	001	May 10, 2006 Apr DISC
	+ @	EQ 1MG BASE		N021928	002	May 10, 2006 Apr DISC
AB	+	EQ 1MG BASE		N021928	002	May 10, 2006 Feb CHRS
	VARENICLINE TARTRATE					
	PAR PHARM INC	EQ 0.5MG BASE		A201785	001	Aug 11, 2021 Apr CTEC
	!	EQ 1MG BASE		A201785	002	Aug 11, 2021 Apr CTEC
AB	!	EQ 1MG BASE		A201785	002	Aug 11, 2021 Feb CHRS

VASOPRESSIN

	SOLUTION;INTRAVENOUS					
	VASOPRESSIN					
AP	AMNEAL	20UNITS/ML (20UNITS/ML)		A212944	001	Aug 05, 2022 Jul NEWA
AP	AMPHASTAR PHARMS INC	20UNITS/ML (20UNITS/ML)		A211857	001	Jul 18, 2022 Jul NEWA
>A> AP	EUGIA PHARMA	20UNITS/ML (20UNITS/ML)		A214314	001	Aug 15, 2022 Aug NEWA

VENLAFAXINE BESYLATE

	TABLET, EXTENDED RELEASE;ORAL					
	VENLAFAXINE BESYLATE					
	+! ALMATICA	EQ 112.5MG BASE		N215429	001	Jun 29, 2022 Jun NEWA

VENLAFAXINE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	VENLAFAXINE HYDROCHLORIDE					
>D>	@ YICHANG HUMANWELL	EQ 37.5MG BASE		A214654	001	Aug 06, 2021 Aug CMFD
>A> AB		EQ 37.5MG BASE		A214654	001	Aug 06, 2021 Aug CMFD
	@	EQ 37.5MG BASE		A214654	001	Aug 06, 2021 Jan DISC
>D>	@	EQ 75MG BASE		A214654	002	Aug 06, 2021 Aug CMFD
>A> AB		EQ 75MG BASE		A214654	002	Aug 06, 2021 Aug CMFD
	@	EQ 75MG BASE		A214654	002	Aug 06, 2021 Jan DISC
>D>	@	EQ 150MG BASE		A214654	003	Aug 06, 2021 Aug CMFD
>A> AB		EQ 150MG BASE		A214654	003	Aug 06, 2021 Aug CMFD
	@	EQ 150MG BASE		A214654	003	Aug 06, 2021 Jan DISC
	TABLET, EXTENDED RELEASE;ORAL					
	VENLAFAXINE HYDROCHLORIDE					
>A> AB	ZYDUS PHARMS	EQ 37.5MG BASE		A215622	001	Aug 30, 2022 Aug NEWA
>A> AB		EQ 75MG BASE		A215622	002	Aug 30, 2022 Aug NEWA
>A> AB		EQ 150MG BASE		A215622	003	Aug 30, 2022 Aug NEWA
>A> AB		EQ 225MG BASE		A215622	004	Aug 30, 2022 Aug NEWA

VERAPAMIL HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	VERELEN					
AB	+ SOCIETAL CDMO	120MG		N019614	001	May 29, 1990 Jun CAHN
AB	+	180MG		N019614	003	Jan 09, 1992 Jun CAHN
AB	+	240MG		N019614	002	May 29, 1990 Jun CAHN
	+!	360MG		N019614	004	May 10, 1996 Jun CAHN
	VERELEN PM					
	+ SOCIETAL CDMO	100MG		N020943	001	Nov 25, 1998 Jun CAHN
	+	200MG		N020943	002	Nov 25, 1998 Jun CAHN
	+!	300MG		N020943	003	Nov 25, 1998 Jun CAHN

INJECTABLE; INJECTION
VERAPAMIL HYDROCHLORIDE

AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar NEWA
AP	MANKIND PHARMA	2.5MG/ML	A214653	001	Jun 15, 2022	Jun NEWA
<u>TABLET; ORAL</u>						
	VERAPAMIL HYDROCHLORIDE					
@	CHARTWELL RX	40MG	A073168	001	Jul 31, 1992	Mar CAHN
@		80MG	A071423	001	May 24, 1988	Mar CAHN
@		120MG	A071424	001	May 25, 1988	Mar CAHN

VIGABATRIN

FOR SOLUTION; ORAL
VIGABATRIN

AA	ELITE LABS INC	500MG/PACKET	A214961	001	Jun 24, 2022	Jun NEWA
@	LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Jul DISC
AA		500MG/PACKET	A211790	001	Mar 10, 2022	Mar NEWA
>A> AA	MSN	500MG/PACKET	A215363	001	Sep 07, 2022	Aug NEWA
<u>TABLET; ORAL</u>						
	VIGABATRIN					
AB	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Jun NEWA
AB	AUROBINDO PHARMA LTD	500MG	A215601	001	May 10, 2022	Apr NEWA
>A> AB	HIKMA	500MG	A213104	001	Aug 29, 2022	Aug NEWA
AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VILAZODONE HYDROCHLORIDE

AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	May CMFD
AB		20MG	A208212	002	Sep 30, 2019	May CMFD
AB		40MG	A208212	003	Sep 30, 2019	May CMFD

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE

AP	! JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Apr CHRS
----	------------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

FOR SUSPENSION; ORAL
VORICONAZOLE

>D>	@ MYLAN PHARMS INC	200MG/5ML	A202361	001	May 28, 2013	Aug CAHN
>A>	@ RISING	200MG/5ML	A202361	001	May 28, 2013	Aug CAHN
<u>INJECTABLE; INTRAVENOUS</u>						
	VORICONAZOLE					
AP	HONG KONG	200MG/VIAL	A214516	001	May 09, 2022	Apr NEWA
AP	MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Jun CAHN

VORINOSTAT

CAPSULE; ORAL
ZOLINZA

+! MSD SUB MERCK 100MG

N021991 001 Oct 06, 2006 Jun CAHN

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL
TRINTELLIX

+ TAKEDA PHARMS USA EQ 5MG BASE
+ EQ 10MG BASE
+! EQ 20MG BASE

N204447 001 Sep 30, 2013 Mar CTEC
N204447 002 Sep 30, 2013 Mar CTEC
N204447 004 Sep 30, 2013 Mar CTEC

VORTIOXETINE HYDROBROMIDE

@ ZYDUS PHARMS EQ 5MG BASE
@ EQ 10MG BASE
@ EQ 20MG BASE

A211146 001 Sep 17, 2021 Mar DISC
A211146 002 Sep 17, 2021 Mar DISC
A211146 003 Sep 17, 2021 Mar DISC

VUTRISIRAN

SOLUTION; SUBCUTANEOUS
AMVUTTRA

+! ALNYLAM PHARMS INC 25MG/0.5ML (25MG/0.5ML)

N215515 001 Jun 13, 2022 Jun NEWA

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

>A>	AB	RISING PHARMS	10MG	A204928	001	Aug 25, 2022	Aug NEWA
>A>	AB		20MG	A204928	002	Aug 25, 2022	Aug NEWA

ZALEPLON

CAPSULE;ORAL

ZALEPLON

AB	CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar CAHN
AB		10MG	A077505	002	Jun 20, 2008	Mar CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

@ EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC
ZINC CHLORIDE IN PLASTIC CONTAINER		N018959	001	Jun 26, 1986	Feb CTEC

+! HOSPIRA

EQ 1MG ZINC/ML

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP	+! AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Apr CFTG
AP	+!	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Apr CFTG
AP	GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022	Apr NFTG
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022	Apr NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	+! VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan CAHN
AB	+	EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan CAHN
AB	+	EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan CAHN
AB	+	EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan CAHN

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR
GEODON

AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+!	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN
AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT
	POWDER; INTRAMUSCULAR GEODON					
AP	+! VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR
AP	ZIPRASIDONE MESYLATE					
AP	GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP	AMNEAL	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
	@ EUGIA PHARMA	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Jul DISC
	@	EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Jul DISC

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB	CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar CAHN
AB		10MG	A077388	002	Jul 30, 2012	Mar CAHN

ZONISAMIDE

SUSPENSION;ORAL

ZONISADE

+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022	Jul NEWA
----	---------	-----------	---------	-----	--------------	----------

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
ACETAMINOPHEN, ASPIRIN AND CAFFEINE
AUROBINDO PHARMA LTD 250MG;250MG;65MG A211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL;TOPICAL
ADAPALENE
TARO PHARMS 0.1% A215940 001 Jan 14, 2022 Jan NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL
GAVISCON
+ @ CHATTEM SANOFI 80MG;20MG N018685 001 Dec 09, 1983 May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
BAJAJ 5MG/5ML A091327 001 Oct 17, 2011 Jun CAHN
@ CHARTWELL RX 5MG/5ML A090378 002 May 09, 2008 Mar CAHN
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
BAJAJ 5MG/5ML A091327 002 Oct 17, 2011 Jun CAHN
@ CHARTWELL RX 5MG/5ML A090378 001 May 09, 2008 Mar CAHN
TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY
GLENMARK PHARMS INC 5MG A078427 003 Dec 28, 2007 May CAHN
10MG A078427 004 Dec 28, 2007 May CAHN
TABLET, CHEWABLE;ORAL
CHILDREN'S ZYRTEC ALLERGY
+ J AND J CONSUMER INC 2.5MG N021621 007 Nov 30, 2020 Jun CMFD
+ 10MG N021621 004 Nov 16, 2007 Jun CMFD

CLEMASTINE FUMARATE

TABLET;ORAL
CLEMASTINE FUMARATE
@ L PERRIGO CO 1.34MG A074512 001 Nov 22, 1995 Jul DISC

DICLOFENAC SODIUM

GEL;TOPICAL
DICLOFENAC SODIUM
AKORN 1% A209484 001 Nov 21, 2018 Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL
IBUPROFEN AND DIPHENHYDRAMINE CITRATE
AUROBINDO PHARMA LTD 38MG;200MG A216204 001 May 31, 2022 May NEWA

DOCOSANOL

CREAM;TOPICAL
DOCOSANOL
ALEOR DERMACEUTICALS 10% A215839 001 May 03, 2022 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM
GRAVITI PHARMS EQ 20MG BASE A216349 001 Jun 24, 2022 Jun NEWA
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM
+ @ DEXCEL PHARMA EQ 20MG BASE N214278 001 Oct 20, 2020 Jan DISC

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE
GLENMARK PHARMS INC 10MG A077146 001 Mar 07, 2005 Jun CAHN
20MG A090837 001 Aug 04, 2010 May CAHN
VKT PHARMA 10MG A215822 001 Jan 28, 2022 Jan NEWA
20MG A215822 002 Jan 28, 2022 Jan NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ATLANTIDE	30MG	A079112	002	Feb 08, 2012	Apr CAHN
@ SUN PHARM INDNS	30MG	A091567	002	Feb 06, 2012	Jun DISC
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES					
ATLANTIDE	30MG	A079112	001	Feb 08, 2012	Apr CAHN
@ SUN PHARM INDNS	30MG	A091567	001	Feb 06, 2012	Jun DISC
FEXOFENADINE HYDROCHLORIDE ALLERGY					
ATLANTIDE	60MG	A079112	004	Feb 08, 2012	Apr CAHN
	180MG	A079112	006	Feb 08, 2012	Apr CAHN
@ SUN PHARM INDNS	60MG	A091567	004	Feb 06, 2012	Jun DISC
FEXOFENADINE HYDROCHLORIDE HIVES					
ATLANTIDE	60MG	A079112	003	Feb 08, 2012	Apr CAHN
	180MG	A079112	005	Feb 08, 2012	Apr CAHN
@ SUN PHARM INDNS	60MG	A091567	003	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN
+!	60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION					
+! CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN
+!	180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
DR REDDYS	60MG;120MG	A215434	001	May 31, 2022	May NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

DR REDDYS	600MG	A215932	001	Mar 15, 2022	Mar NEWA
	1.2GM	A215932	002	Mar 15, 2022	Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	GRANULES	600MG;60MG	A216082	001	Aug 22, 2022	Aug NEWA
		1.2GM;120MG	A216082	002	Aug 22, 2022	Aug NEWA
>A>	L PERRIGO CO	600MG;60MG	A214407	001	Feb 01, 2022	Jan NEWA
		1.2GM;120MG	A214407	002	Feb 01, 2022	Jan NEWA

IBUPROFEN

SUSPENSION/DROPS;ORAL

IBUPROFEN

STRIDES PHARMA	50MG/1.25ML	A214071	001	Jun 09, 2022	Jun NEWA
----------------	-------------	---------	-----	--------------	----------

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+! ZUREX PHARMA	70%	N210872	001	Apr 26, 2019	Jul CMFD
-----------------	-----	---------	-----	--------------	----------

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

TEVA PHARMS USA	0.5%	A212485	001	Mar 21, 2022	Mar NEWA
-----------------	------	---------	-----	--------------	----------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CPOT
BAUSCH AND LOMB INC	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CAHN
CHILDREN'S ALAWAY					
+ BAUSCH AND LOMB	EQ 0.025% BASE	N021996	002	Feb 11, 2015	Mar CPOT
+	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Mar CTNA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
 LANSOPRAZOLE
 GLENMARK PHARMS INC 15MG A202727 001 May 18, 2012 May CAHN

LEVOSETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
 XYZAL ALLERGY 24HR
 +! CHATTEM SANOFI 2.5MG/5ML N209090 001 Jan 31, 2017 Jan CAHN
 TABLET;ORAL
 XYZAL ALLERGY 24HR
 +! CHATTEM SANOFI 5MG N209089 001 Jan 31, 2017 Jan CAHN

LEVONORGESTREL

TABLET;ORAL
 LEVONORGESTREL
 @ L PERRIGO CO 0.75MG A090740 001 Dec 30, 2010 May DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL
 LOPERAMIDE HYDROCHLORIDE
 @ AKORN 1MG/5ML A074352 001 Nov 17, 1995 Jun DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
 >A> GRANULES 2MG;125MG A215981 001 Aug 29, 2022 Aug NEWA

LORATADINE

TABLET, CHEWABLE;ORAL
 CHILDREN'S CLARITIN
 + BAYER HEALTHCARE LLC 5MG N021891 001 Aug 23, 2006 Apr CHRS
 CLARITIN
 +! BAYER HEALTHCARE LLC 10MG N021891 002 Nov 21, 2018 Apr CHRS

MINOXIDIL

AEROSOL, FOAM;TOPICAL
 MINOXIDIL
 PERRIGO PHARMA INTL 5% A091344 001 Apr 28, 2011 Jan CAHN
 SOLUTION;TOPICAL
 MINOXIDIL (FOR MEN)
 >D> AKORN 2% A074731 001 Dec 24, 1996 Aug DISC
 >A> @ 2% A074731 001 Dec 24, 1996 Aug DISC
 MINOXIDIL (FOR WOMEN)
 >D> AKORN 2% A074731 002 May 11, 2005 Aug DISC
 >A> @ 2% A074731 002 May 11, 2005 Aug DISC
 THEROXIDIL
 PURE SOURCE 2% A078176 001 Nov 09, 2007 Jun CAHN
 5% A076239 001 Aug 24, 2004 Jun CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL
 NASONEX 24HR ALLERGY
 +! PERRIGO PHARMA INTL 0.05MG/SPRAY N215712 001 Mar 17, 2022 Mar NEWA

NAPROXEN SODIUM

CAPSULE;ORAL
 NAPROXEN SODIUM
 >A> STRIDES PHARMA EQ 200MG BASE A215472 001 Aug 17, 2022 Aug NEWA
 TABLET;ORAL
 NAPROXEN SODIUM
 YICHANG HUMANWELL 220MG A212033 001 Aug 30, 2019 Jul CMFD

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
 ALEVE-D SINUS & COLD
 + @ BAYER 220MG;120MG N021076 001 Nov 29, 1999 Jan DISC
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
 AUROBINDO PHARMA LTD 220MG;120MG A211360 001 Jun 01, 2022 May NEWA
 ! PERRIGO 220MG;120MG A076518 001 Mar 17, 2004 Jan CHRS

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE
EQ 4MG BASEA215357 001 May 13, 2022 May NEWA
A215357 002 May 13, 2022 May NEWAOLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@ BAUSCH AND LOMB INC EQ 0.1% BASE
@ GLENMARK PHARMS INC EQ 0.1% BASE
@ MYLAN EQ 0.2% BASE
@ RISING EQ 0.1% BASE
@ EQ 0.2% BASEA206046 001 Jul 26, 2017 Jun CAHN
A200810 001 Jun 28, 2017 May CAHN
A204620 001 Jun 16, 2020 May DISC
A204392 001 Mar 21, 2018 Jul CAHN
A204620 001 Jun 16, 2020 Jul CAHNOMEPRAZOLETABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
OMEPRAZOLE

+! DEXCEL PHARMA 20MG

N209400 001 Jul 05, 2017 Feb CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

L PERRIGO CO EQ 20MG BASE

A216096 001 May 24, 2022 May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@ CHARTWELL RX 20MG;1.1GM
ZEGERID OTC+! RILEY CONSUMER 20MG;1.1GM
FOR SUSPENSION;ORAL
ZEGERID OTC

+! RILEY CONSUMER 20MG/PACKET;1.68GM/PACKET

A204137 001 Jul 15, 2016 Jul CAHN

N022281 001 Dec 01, 2009 Mar CAHN

N022283 001 Jun 17, 2013 Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

+ @ ROXANE 1GM/ML

N018551 001 Feb 19, 1982 Jan CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

! L PERRIGO CO 120MG
SUDAFED 12 HOUR
@ MCNEIL CONS 120MG

A075153 001 Feb 26, 1999 Jun CHRS

A073585 001 Oct 31, 1991 Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

THINQ PHARM-CRO PVT EQ 75MG BASE
EQ 150MG BASEA210250 001 Aug 30, 2019 Jul CAHN
A210228 001 Aug 30, 2019 Jul CAHN

ZANTAC 150

+ @ CHATTEM SANOFI EQ 150MG BASE

N021698 001 Aug 31, 2004 Jan CAHN

+ @ EQ 150MG BASE

N021698 002 Mar 13, 2007 Jan CAHN

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE

N020520 001 Dec 19, 1995 Jan CAHN

TABLET, EFFERVESCENT;ORAL

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE

N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY
+! 0.055MG/SPRAYN020468 002 Oct 11, 2013 Jan CAHN
N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2022

NO AUGUST 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2022 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11255842	Jan 10, 2040		U-3322		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034		U-3195		
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	>A> 10239883	Jul 11, 2032		U-2666		
	>A> 10239883	Jul 11, 2032		U-2668		
	>A> 10272083	Jan 21, 2035		U-2519		
	>A> 10272083	Jan 21, 2035		U-2682		
	>A> 10272083	Jan 21, 2035		U-2683		
	>A> 10272083	Jan 21, 2035		U-2684		
	>A> 10272083	Jan 21, 2035		U-2685		
	>A> 10272083	Jan 21, 2035		U-2686		
	>A> 10272083	Jan 21, 2035		U-2687		
	>A> 11059829	Jul 01, 2036	DS DP	U-2145		
	>A> 11059829	Jul 01, 2036	DS DP	U-2666		
	>A> 11059829	Jul 01, 2036	DS DP	U-2667		
	>A> 11059829	Jul 01, 2036	DS DP	U-2668		
	>A> 11059829	Jul 01, 2036	DS DP	U-2669		
	>A> 11059829	Jul 01, 2036	DS DP	U-2670		
	>A> 11059829	Jul 01, 2036	DS DP	U-2671		
	>A> 7459554	Nov 24, 2026	DS			
	>A> 9290504	Jul 11, 2032	DS DP			
	>A> 9758524	Jul 11, 2032		U-2145		
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 002	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIE</u>						
N 201292 003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026		U-1950		
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001 >A>	11395889	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			
	11357935	Sep 24, 2038	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	8357713	Dec 22, 2029	DP	U-2104		
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	8357713	Dec 22, 2029	DP	U-2104		
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Sep 28, 2030	DS	DP	NCE	May 24, 2024
	8476268	Sep 10, 2029	DS	DP		
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Sep 28, 2030	DS	DP	NCE	May 24, 2024
	8476268	Sep 10, 2029	DS	DP		
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Sep 28, 2030	DS	DP	NCE	May 24, 2024
	8476268	Sep 10, 2029	DS	DP		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11197835	Dec 02, 2030		U-2106		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11197835	Dec 02, 2030		U-2106		
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPE</u>						
N 208078 001 >A>	10626088	Feb 25, 2037	DP			
	11268128	Jun 29, 2032		U-2956		
	11274331	Jun 29, 2032		U-2956		
	11274332	Jun 29, 2032		U-2956		
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11235169	Oct 15, 2040		U-3303		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	11357753	Feb 09, 2038		U-2754		
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038		U-2754		
	9084765	Mar 10, 2031		U-1744		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11364230	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
<u>AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK</u>						
N 215153 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
<u>AMPHOTERICIN B - AMPHOTERICIN B</u>						
A 212514 001					CGT	Aug 14, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</u>						
A 212025 001					CGT	Aug 24, 2022
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001 >A> 11419769		Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002 >A> 11419769		Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003 >A> 11419769		Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004 >A> 11419769		Dec 16, 2031	DP U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005 >A> 11419769		Dec 16, 2031	DP U-2825			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6962940	Mar 19, 2023	U-1504	I-884	Dec 20, 2024	
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-1504	I-884	Dec 20, 2024	
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	>A> 11344547	Sep 24, 2033	U-1632			
	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
	>A> 11400087	Sep 24, 2033	U-1632			
	>A> 11400087	Sep 24, 2033	U-3245			
	>A> 11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	>A> 11344547	Sep 24, 2033	U-1632			
	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
	>A> 11400087	Sep 24, 2033	U-1632			
	>A> 11400087	Sep 24, 2033	U-3245			
	>A> 11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	>A> 11344547	Sep 24, 2033	U-1632			
	>A> 11344547	Sep 24, 2033	U-3245			
	>A> 11344547	Sep 24, 2033	U-814			
	>A> 11400087	Sep 24, 2033	U-1632			
	>A> 11400087	Sep 24, 2033	U-3245			
	>A> 11400087	Sep 24, 2033	U-814			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	11229378	Jul 11, 2031	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11273158	Apr 06, 2039	U-543			
	>A> 11406632	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11273158	Apr 06, 2039	U-543			
	>A> 11406632	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11273158	Apr 06, 2039	U-543			
	>A> 11406632	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11273158 >A> 11406632	Apr 06, 2039 Mar 19, 2035		U-543 U-2402		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	11273158	Apr 06, 2039		U-543		
<u>ASCIMINIB HYDROCHLORIDE - SCENBLIX</u>						
N 215358 001	>A> 11407735 8829195	May 14, 2040 May 13, 2033	DS DS	U-1374	ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCENBLIX</u>						
N 215358 002	>A> 11407735 8829195	May 14, 2040 May 13, 2033	DS DS	U-1374	ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 001					CGT	Jan 29, 2023
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 002					CGT	Jan 29, 2023
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001					ODE-377	Oct 07, 2028
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Jan 12, 2037		U-3044		
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Jan 12, 2037		U-3044		
<u>AZACITIDINE - VIDAZA</u>						
N 050794 001					I-889	May 20, 2025
<u>BACLOFEN - FLEQSUUVY</u>						
N 215602 001	11324696	Sep 29, 2037	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	11261198 11306106 11306106	Sep 25, 2038 Aug 09, 2037 Aug 09, 2037	DP U-2816 U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	11261198 11306106 11306106	Sep 25, 2038 Aug 09, 2037 Aug 09, 2037	DP U-2816 U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	11261198 11306106 11306106	Sep 25, 2038 Aug 09, 2037 Aug 09, 2037	DP U-2816 U-3000			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11261198 11306106 11306106	Sep 25, 2038 Aug 09, 2037 Aug 09, 2037	DP U-2816 U-3000			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	11045474 9089574	Nov 30, 2032 Nov 30, 2032	U-3372 U-3372		I-890 I-891	Jun 13, 2025 May 10, 2025
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	11045474 9089574	Nov 30, 2032 Nov 30, 2032	U-3372 U-3372		I-890 I-891	Jun 13, 2025 May 10, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	>A> 11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	>A> 11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	>A> 11395888	Jan 26, 2038	DP			
	>A> 11395889	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	>A> 11395888	Jan 26, 2038	DP			
	>A> 11395889	May 18, 2031	DP			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	11311541	Apr 09, 2035	U-3369			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001				>A> ODE*		Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002				>A> ODE*		Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003				>A> ODE*		Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004				>A> ODE*		Dec 07, 2022
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001				>A> ODE*		Dec 07, 2022
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	11230530	Mar 09, 2035	U-3300			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	11230530	Mar 09, 2035	U-3300			
<u>BETAINE - BETAINE</u>						
A 214864 001					CGT	Aug 02, 2022
<u>BEXAROTENE - BEXAROTENE</u>						
A 215398 001					CGT	Nov 13, 2022
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002					NCE	Feb 07, 2023
					ODE-378	Oct 07, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002					NCE ODE-378	Feb 07, 2023 Oct 07, 2028
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001					NPP	Jun 16, 2025
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BREXPIPRAZOLE - REXULTI</u>						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	9012462	Apr 28, 2031	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	9012462	Apr 28, 2031	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	9012462	Apr 28, 2031	DS			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001					NP	Dec 15, 2024
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	11311558	Jan 29, 2023		DP		
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	11311558	Jan 29, 2023		DP		
	11311558*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122 001	11331442	May 10, 2038		DP		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
>A>	11426348	Jan 22, 2041	DP U-3380			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
>A>	11426348	Jan 22, 2041	DP U-3380			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	>A> 11400019	Jan 12, 2041		DP		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	11253504	Mar 13, 2034		U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	11253504	Mar 13, 2034		U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	11253504	Mar 13, 2034		U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	11253504	Mar 13, 2034		U-3118		
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11278544	Apr 21, 2024	U-1583			
	11324741	May 29, 2029	U-1583			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
>A>	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
>A>	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
>A>	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11298349	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11298349	Feb 10, 2032	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11253528	Mar 14, 2034	DP			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
>A>	11400055	Oct 13, 2035	U-3071			
>A>	11406623	Mar 01, 2041	U-3233			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 001					NPP	Nov 23, 2023
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 002					NPP	Nov 23, 2023
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 003					NPP	Nov 23, 2023
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10420841	Mar 14, 2034	U-1672		NPP	Apr 21, 2025
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11246863	Nov 27, 2038	DP			
	11369566	Apr 21, 2029	DP			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001 >A>	11337989	Mar 15, 2033	U-1			
	6706276	Mar 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
	8865690	Jul 24, 2023	U-2942			
	9211295	Jul 24, 2023	DP			
	9433628	Feb 28, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A 214668 001					>A> CGT	Feb 01, 2023
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP GAIN	Dec 07, 2024 Dec 07, 2029
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN</u>						
A 212845 001					CGT	Oct 09, 2022
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776			
	10478400*PED	Dec 29, 2036				
	10590102	Jun 30, 2036	DS DP U-1776			
	10590102*PED	Dec 30, 2036				
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				
	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	>A> 7825137	May 12, 2027	U-3057		>A> I-897	Jul 14, 2025
	>A> 7825137	May 12, 2027	U-3058			
	>A> 7825137	May 12, 2027	U-3403			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	>A> 7825137	May 12, 2027	U-3057		>A> I-897	Jul 14, 2025
	>A> 7825137	May 12, 2027	U-3058			
	>A> 7825137	May 12, 2027	U-3403			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	10993952	Feb 15, 2036	DP			
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROSYSBI</u>						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					>A> I-894	Jun 22, 2025
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					>A> I-894	Jun 22, 2025
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	>A> 7758890	Jun 30, 2025	DP			
	>A> 8604072	Jul 20, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005					M-238	Feb 22, 2022
<u>DAPSONE - ACZONE</u>						
N 207154 001	11273132	Nov 18, 2033	DP			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP			
<u>DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8501238	Dec 19, 2028	DS DP U-1636			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	11357731	Oct 25, 2038	U-3083			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11236328	Jun 22, 2032	U-3301			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Jun 19, 2031	DS			
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7728143	Jun 19, 2031	DS			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11357772*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP	U-1995		
	11179386	Mar 15, 2038	DP	U-3055		
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036		U-1995		
	11357772	Mar 07, 2036		U-3055		
	11357772*PED	Sep 07, 2036				
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	11304961	Dec 18, 2037	DP	U-3344		
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	10792246	Jun 26, 2039	DP	U-3350	NP	Apr 05, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	10792246	Jun 26, 2039	DP	U-3350	NP	Apr 05, 2025
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP	U-3340		
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP	U-3340		
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP	U-3340		
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP	U-3340		
	9474722	Oct 24, 2033	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	11241414	Mar 27, 2029	DP			
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976 001	11344520	Feb 20, 2035	U-3393			
	11351133	Feb 20, 2035	U-3393			
<u>DIGOXIN - DIGOXIN</u>						
A 214982 001					CGT	Aug 16, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESMA</u>						
N 213436 001	11266799	Nov 05, 2036	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	11246850	Nov 16, 2035	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	11246850	Nov 16, 2035	U-1384			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
<u>DONEPEZIL HYDROCHLORIDE - ADALERT</u>						
N 212304 001	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADALERT</u>						
N 212304 002	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPAZ HYDROCHLORIDE - DOXEPAZ HYDROCHLORIDE</u>						
A 213796 001					CGT	Oct 29, 2022
<u>DOXEPAZ HYDROCHLORIDE - SILENOR</u>						
N 022036 001	11234954	Jan 18, 2028	U-620			
<u>DOXEPAZ HYDROCHLORIDE - SILENOR</u>						
N 022036 002	11234954	Jan 18, 2028	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	11253472	Aug 06, 2028	DS DP			
<u>DROSPIRENONONE - SLYND</u>						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
>A>	11413249	Jun 28, 2031	U-2553			
<u>DROSPIRENONONE - DROSPIRENONONE</u>						
N 216285 001	10179140	Jun 28, 2031	U-2553			
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
>A>	11413249	Jun 28, 2031	U-2553			
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	11312718	Jan 10, 2032	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	11312718	Jan 10, 2032	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	10987341	Nov 01, 2039	DP		NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	11344551	Mar 14, 2034	U-3388			
	11344551	Mar 14, 2034	U-3389			
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261 001					NPP	Dec 09, 2024
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCovy</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	11253515	Jul 18, 2038	DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	11253515	Jul 18, 2038	DP			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11241400	May 16, 2040	U-3183			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	10869845	Jan 22, 2040	DP			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 001	11141540	Oct 20, 2036	DP U-3379			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 002	11141540	Oct 20, 2036	DP U-3379			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	>A> 6214865	Jul 20, 2023	DS			
	>A> 6214865*PED	Jan 20, 2024				
	>A> RE46965	Jan 08, 2027	DP			
	>A> RE46965*PED	Jul 08, 2027				
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001				M-275	Sep 17, 2024	
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002				M-275	Sep 17, 2024	
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001				M-275	Sep 17, 2024	
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002				M-275	Sep 17, 2024	
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003				M-275	Sep 17, 2024	
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004				M-275	Sep 17, 2024	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001					M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002					M-275	Sep 17, 2024
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	8785500	Mar 05, 2033	U-2502			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001 >A> 8058280		Jan 28, 2024	DS			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001 >A>	11400092	Sep 24, 2039	U-3409			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Jun 29, 2038	U-2859		I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	10950331	Sep 28, 2035	U-3098			
	10950331*PED	Mar 28, 2036				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
>A>	11406606	Aug 02, 2037	U-3406			
>A>	11406606	Aug 02, 2037	U-3407			
>A>	11406606*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				
<u>FENOPROFEN CALCIUM - FENOPROFEN CALCIUM</u>						
A 214475 001					>A> CGT	Feb 11, 2023
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	11234938	Nov 26, 2034	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	9993483	Jul 02, 2030	DP			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 001				NPP		Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 002				NPP		Mar 22, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 003					NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648 004					NPP	Mar 22, 2025
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u>						
N 208798 008	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030		DP		
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032		DP		
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031		DP		
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025		DP		
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024		DP		
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031		DP		
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035		DP		
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035		DP		
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALER</u>						
N 208799 004	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039		DP		
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038		DP		
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038		DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALER</u>						
N 208799 005	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039		DP		
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038		DP		
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038		DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALER</u>						
N 208799 006	11173259	Jul 06, 2040		DP		
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041		DP		
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039		DP		
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038		DP		
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038		DP		
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001					D-186	May 02, 2025
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-186	May 02, 2025
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	11312698	May 23, 2032	DS DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	11312698	May 23, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	RE48898	Jan 19, 2026	DP			
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001				ODE-383 W		Aug 21, 2026 Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	11027031	Jul 28, 2035	U-3317			
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	11369590	Aug 15, 2028	DS DP U-3400		NP	Mar 23, 2025
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	10603308 7858609 8022054 8318714 8367651 8618087 9029355 9056116	Aug 10, 2037 Nov 28, 2026 Nov 28, 2026 Nov 28, 2026 Nov 28, 2026 Nov 28, 2026 Nov 28, 2026 Nov 28, 2026	U-3374 DP DP DP DP U-3374 DP U-3374		NCE	Jun 01, 2027
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	11028392	Oct 03, 2034	DS DP U-2672			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	11246866 11246866*PED RE48923 RE48923*PED	Jun 24, 2036 Dec 24, 2036 May 08, 2035 Nov 08, 2035	DP DS			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	RE48923 RE48923*PED	May 08, 2035 Nov 08, 2035	DS			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	11278683	Aug 16, 2026	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NPP	Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	11235168 11311620	Jan 04, 2038 Dec 19, 2036	U-2250 U-2250			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE</u>						
A 215586 001					CGT	Oct 09, 2022
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	11304908 11304909	Aug 24, 2027 Aug 24, 2027	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	11304908 11304909	Aug 24, 2027 Aug 24, 2027	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	11304908 11304909	Aug 24, 2027 Aug 24, 2027	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027		U-1556		
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	11304962	May 02, 2036	U-2236			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				
	>A> 10016435	Jun 03, 2031	U-1650			
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10294231	Jun 03, 2033	DP			
	>A> 10294231*PED	Dec 03, 2033				
	>A> 10294232	Jun 03, 2033	DP			
	>A> 10294232*PED	Dec 03, 2033				
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10752634	Jun 03, 2033	DP			
	>A> 10752634*PED	Dec 03, 2033				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2219			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026		U-1491		
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031		U-1456		
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8999999	Jun 03, 2031		U-1683		
	>A> 8999999	Jun 03, 2031		U-1684		
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031		U-1745		
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS DP			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS DP			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9540382	Aug 18, 2033	U-1456			
	>A> 9540382	Aug 18, 2033	U-1650			
	>A> 9540382	Aug 18, 2033	U-1684			
	>A> 9540382	Aug 18, 2033	U-1946			
	>A> 9540382	Aug 18, 2033	U-1947			
	>A> 9540382*PED	Feb 18, 2034				
	>A> 9713617	Jun 03, 2033	DP			
	>A> 9713617*PED	Dec 03, 2033				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2150			
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031		U-2159		
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031		U-1947		
	>A> 9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	>A> 10016435	Jun 03, 2031		U-1650		
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10294231	Jun 03, 2033	DP			
	>A> 10294231*PED	Dec 03, 2033				
	>A> 10294232	Jun 03, 2033	DP			
	>A> 10294232*PED	Dec 03, 2033				
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2219			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8957079	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	>A> 8957079*PED	Jun 28, 2027				
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2228			
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9540382	Aug 18, 2033	U-1456			
	>A> 9540382	Aug 18, 2033	U-1491			
	>A> 9540382	Aug 18, 2033	U-1650			
	>A> 9540382	Aug 18, 2033	U-1946			
	>A> 9540382	Aug 18, 2033	U-1947			
	>A> 9540382*PED	Feb 18, 2034				
	>A> 9713617	Jun 03, 2033	DP			
	>A> 9713617*PED	Dec 03, 2033				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031	U-1947			
	>A> 9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10010507*PED	Sep 03, 2036				
	>A> 10016435	Jun 03, 2031	U-1650			
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10213386	Mar 03, 2036	DP			
	>A> 10213386*PED	Sep 03, 2036				
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10752634	Jun 03, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	>A> 10752634*PED	Dec 03, 2033				
	>A> 10828259	Mar 03, 2036	DP			
	>A> 10828259*PED	Sep 03, 2036				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8957079*PED	Jun 28, 2027				
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9655857*PED	Sep 03, 2036				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031	U-1947			
	>A> 9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10010507*PED	Sep 03, 2036				
	>A> 10016435	Jun 03, 2031	U-1650			
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10213386	Mar 03, 2036	DP			
	>A> 10213386*PED	Sep 03, 2036				
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10828259	Mar 03, 2036	DP			
	>A> 10828259*PED	Sep 03, 2036				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8957079*PED	Jun 28, 2027				
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9655857*PED	Sep 03, 2036				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031	U-1947			
	>A> 9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10010507*PED	Sep 03, 2036				
	>A> 10016435	Jun 03, 2031	U-1650			
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10213386	Mar 03, 2036	DP			
	>A> 10213386*PED	Sep 03, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10828259	Mar 03, 2036	DP			
	>A> 10828259*PED	Sep 03, 2036				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8957079*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9655857*PED	Sep 03, 2036				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031	U-1947			
	>A> 9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 004	>A> 10004746	Jun 03, 2031	U-1684			
	>A> 10004746	Jun 03, 2031	U-1946			
	>A> 10004746	Jun 03, 2031	U-2241			
	>A> 10004746	Jun 03, 2031	U-2242			
	>A> 10004746*PED	Dec 03, 2031				
	>A> 10010507	Mar 03, 2036	DP			
	>A> 10010507*PED	Sep 03, 2036				
	>A> 10016435	Jun 03, 2031	U-1650			
	>A> 10016435*PED	Dec 03, 2031				
	>A> 10106548	Jun 03, 2033	DS DP			
	>A> 10106548*PED	Dec 03, 2033				
	>A> 10125140	Jun 03, 2033	DS DP			
	>A> 10125140*PED	Dec 03, 2033				
	>A> 10213386	Mar 03, 2036	DP			
	>A> 10213386*PED	Sep 03, 2036				
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439*PED	Dec 03, 2031				
	>A> 10653696	Jun 03, 2031	U-1456			
	>A> 10653696*PED	Dec 03, 2031				
	>A> 10695350	Oct 24, 2034	U-2846			
	>A> 10695350*PED	Apr 24, 2035				
	>A> 10751342	Jun 03, 2031	U-1491			
	>A> 10751342	Jun 03, 2031	U-1946			
	>A> 10751342	Jun 03, 2031	U-2943			
	>A> 10751342	Jun 03, 2031	U-2944			
	>A> 10751342*PED	Dec 03, 2031				
	>A> 10828259	Mar 03, 2036	DP			
	>A> 10828259*PED	Sep 03, 2036				
	>A> 10961251	Jun 03, 2033	DP			
	>A> 10961251*PED	Dec 03, 2033				
	>A> 7514444	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	>A> 7514444*PED	Jun 28, 2027				
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8008309*PED	May 13, 2028				
	>A> 8476284	Dec 28, 2026	U-1456			
	>A> 8476284	Dec 28, 2026	U-1650			
	>A> 8476284	Dec 28, 2026	U-1946			
	>A> 8476284	Dec 28, 2026	U-1947			
	>A> 8476284	Dec 28, 2026	U-2241			
	>A> 8476284*PED	Jun 28, 2027				
	>A> 8497277	Dec 28, 2026	U-1456			
	>A> 8497277	Dec 28, 2026	U-1491			
	>A> 8497277	Dec 28, 2026	U-1650			
	>A> 8497277	Dec 28, 2026	U-1946			
	>A> 8497277	Dec 28, 2026	U-1947			
	>A> 8497277	Dec 28, 2026	U-2241			
	>A> 8497277	Dec 28, 2026	U-2242			
	>A> 8497277*PED	Jun 28, 2027				
	>A> 8563563	Apr 26, 2027	U-1491			
	>A> 8563563	Apr 26, 2027	U-1650			
	>A> 8563563	Apr 26, 2027	U-1946			
	>A> 8563563	Apr 26, 2027	U-2241			
	>A> 8563563	Apr 26, 2027	U-2242			
	>A> 8563563*PED	Oct 26, 2027				
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8697711*PED	Jun 28, 2027				
	>A> 8703780	Dec 28, 2026	U-1491			
	>A> 8703780	Dec 28, 2026	U-2242			
	>A> 8703780*PED	Jun 28, 2027				
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8735403*PED	Jun 28, 2027				
	>A> 8754090	Jun 03, 2031	U-1456			
	>A> 8754090*PED	Dec 03, 2031				
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8754091*PED	Jun 28, 2027				
	>A> 8952015	Dec 28, 2026	U-1456			
	>A> 8952015	Dec 28, 2026	U-1491			
	>A> 8952015	Dec 28, 2026	U-1650			
	>A> 8952015	Dec 28, 2026	U-1946			
	>A> 8952015	Dec 28, 2026	U-1947			
	>A> 8952015	Dec 28, 2026	U-2241			
	>A> 8952015	Dec 28, 2026	U-2242			
	>A> 8952015*PED	Jun 28, 2027				
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 8957079*PED	Jun 28, 2027				
	>A> 8999999	Jun 03, 2031	U-1491			
	>A> 8999999	Jun 03, 2031	U-1946			
	>A> 8999999	Jun 03, 2031	U-2241			
	>A> 8999999	Jun 03, 2031	U-2242			
	>A> 8999999*PED	Dec 03, 2031				
	>A> 9125889	Jun 03, 2031	U-1650			
	>A> 9125889*PED	Dec 03, 2031				
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9181257*PED	Jun 28, 2027				
	>A> 9296753	Oct 30, 2033	DS			
	>A> 9296753*PED	Apr 30, 2034				
	>A> 9655857	Mar 03, 2036	DP			
	>A> 9655857*PED	Sep 03, 2036				
	>A> 9725455	Jun 03, 2033	DS			
	>A> 9725455*PED	Dec 03, 2033				
	>A> 9795604	Oct 24, 2034	U-2969			
	>A> 9795604	Oct 24, 2034	U-2970			
	>A> 9795604*PED	Apr 24, 2035				
	>A> 9801881	Jun 03, 2031	U-1491			
	>A> 9801881	Jun 03, 2031	U-2242			
	>A> 9801881*PED	Dec 03, 2031				
	>A> 9801883	Jun 03, 2031	U-2159			
	>A> 9801883	Jun 03, 2031	U-2243			
	>A> 9801883*PED	Dec 03, 2031				
	>A> 9814721	Jun 03, 2031	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004 >A>	9814721*PED	Dec 03, 2031				
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	11318130	Dec 11, 2029	U-68			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>INDIGOTINDISULFONATE SODIUM - BLUDIGO</u>						
N 216264 001	10927258	Dec 23, 2037	DS		>A> NCE	Jul 08, 2027
<u>IODIXANOL - IODIXANOL</u>						
A 214271 001					CGT	Jan 09, 2023
<u>IODIXANOL - IODIXANOL</u>						
A 214271 002					CGT	Jan 09, 2023
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11369597	Jun 12, 2033	U-1848			
<u>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</u>						
A 211290 001					CGT	Jun 20, 2022
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	11147770	Feb 27, 2033	DP U-3339			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	11147770	Feb 27, 2033	DP U-3339			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	11147770	Feb 27, 2033	DP	U-3339		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	8846718	Jul 02, 2029	U-1908			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	8846718	Jul 02, 2029	U-2375			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	8846718	Jul 02, 2029	U-2375			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785			
	10610125	Jun 21, 2030	U-3385			
	10653710	Oct 18, 2036	U-3387			
	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					NPP	Oct 14, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u> N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 001					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 002					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 003					PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u> A 201452 004					PC	Aug 30, 2022
<u>LENVATINIB MESYLATE - LENVIMA</u> N 206947 001					M-272	Dec 19, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u> N 206947 002					M-272	Dec 19, 2024
<u>LESINURAD - ZURAMPIC</u> N 207988 001 8357713		Dec 22, 2029		DP U-1801		
	8357713	Dec 22, 2029		DP U-1802		
	8357713	Dec 22, 2029		DP U-1803		
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u> N 209935 001 8415355		Mar 13, 2031	DS DP		NPP	Dec 10, 2024
<u>LEVOKETOCONAZOLE - RECORLEV</u> N 214133 001 10098877		Jan 10, 2026		U-3283		
	10517868	Jan 10, 2026		U-3283		
	10835530	Jan 10, 2026		U-3283		
	11020393	Mar 02, 2040		U-3282		
	11278547	Mar 02, 2040		U-3282		
	9918984	Jan 10, 2026		U-3283		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 013 10537538		Feb 28, 2037		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 014 10537538		Feb 28, 2037		DP		
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u> N 206977 015 10537538		Feb 28, 2037		DP		
<u>LEVOTHYROXINE SODIUM - ERMEZA</u> N 215809 001 9345772		Feb 27, 2035		DP		
<u>LIDOCAINE - ZTLIDO</u> N 207962 001 11278623		May 10, 2031		DP		
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u> N 206321 001 11311679		Jan 20, 2026		DP		
<u>LORAZEPAM - LOREEV XR</u> N 214826 004 8999393		Jan 08, 2034		DP U-3210		
<u>LORLATINIB - LORBRENA</u> N 210868 001 11299500		Oct 04, 2038	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
LORLATINIB - LORBRENA						
N 210868 002	11299500	Oct 04, 2038	DS			
LOTEPREDNOL ETABONATE - INVELTYS						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	11219596	May 03, 2033	U-2985			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB						
N 213135 001	11382864	Aug 04, 2037	U-3164			
MARALIXIBAT CHLORIDE - LIVMARLI						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	11260053	May 26, 2031	U-3290			
	11376251	Oct 26, 2032	U-3290			
MARAVIROC - MARAVIROC						
A 203347 001					PC	Aug 06, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARAVIROC - MARAVIROC</u>						
A 203347 002					PC	Aug 06, 2022
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	9181200 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373		NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	9181200 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373		NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	9181200 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373		NCE	Apr 28, 2027
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	9181200 9585883	Jun 19, 2034 Jun 19, 2034	DS DP U-3373		NCE	Apr 28, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	11253478	May 26, 2030	DP U-3318			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	11344622 6992207	Apr 25, 2032 Jun 25, 2023	U-3093 DS DP U-3093			
<u>MESALAMINE - MESALAMINE</u>						
A 214585 001					CGT	Nov 14, 2022
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11241391 11241392	Mar 23, 2032 Mar 23, 2032	U-2357 DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001					NP	Jun 19, 2023
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997 001	7973031	Oct 09, 2028	U-2007			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2028	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
>A>	11426396	May 30, 2038	DS			
>A>	8592362	Feb 12, 2029	U-2371		Y	
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
>A>	11400101	Sep 04, 2034	U-3297			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	9937189	Sep 04, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	11135155	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11027072	May 24, 2039	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
<u>NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE</u>						
A 216291 001				CGT		Jan 21, 2023
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001				ODE-380		Sep 23, 2028
				PED		Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002				ODE-380		Sep 23, 2028
				PED		Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003				ODE-380		Sep 23, 2028
				PED		Mar 23, 2029
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
	>A> 11413277	Apr 16, 2038	DP U-2804			
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	11291793	Aug 18, 2025	DP			
	>A> 11383059	Aug 18, 2025	U-3037			
<u>OBETICOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Feb 21, 2027	DS DP			
<u>OBETICOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Feb 21, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11338011	Feb 03, 2036		U-2857		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3187		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3187		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3187		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3187		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11241425	Aug 23, 2031		U-3137		
	11351166	Aug 23, 2031		U-3140		
	11351166	Aug 23, 2031		U-3141		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11241425	Aug 23, 2031		U-3137		
	11351166	Aug 23, 2031		U-3140		
	11351166	Aug 23, 2031		U-3141		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11241425	Aug 23, 2031		U-3137		
	11351166	Aug 23, 2031		U-3140		
	11351166	Aug 23, 2031		U-3141		
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11241425	Aug 23, 2031		U-3137		
	11351166	Aug 23, 2031		U-3140		
	11351166	Aug 23, 2031		U-3141		
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027		U-2101	I-885	Mar 11, 2025
	8071579	Aug 12, 2027		U-2103		
	8071579	Aug 12, 2027		U-2480		
	8071579	Aug 12, 2027		U-2481		
	8071579	Aug 12, 2027		U-2482		
	8071579	Aug 12, 2027		U-2483		
	8071579	Aug 12, 2027		U-2716		
	8071579	Aug 12, 2027		U-2819		
	8071579	Aug 12, 2027		U-2820		
	8071579	Aug 12, 2027		U-2821		
	8071579	Aug 12, 2027		U-2822		
	8071579	Aug 12, 2027		U-2823		
	8071579	Aug 12, 2027		U-2824		
	8071579	Aug 12, 2027		U-2832		
	8071579	Aug 12, 2027		U-2833		
	8071579	Aug 12, 2027		U-3333		
	8143241	Aug 12, 2027		U-2101		
	8143241	Aug 12, 2027		U-2103		
	8143241	Aug 12, 2027		U-2480		
	8143241	Aug 12, 2027		U-2481		
	8143241	Aug 12, 2027		U-2482		
	8143241	Aug 12, 2027		U-2483		
	8143241	Aug 12, 2027		U-2716		
	8143241	Aug 12, 2027		U-2819		
	8143241	Aug 12, 2027		U-2820		
	8143241	Aug 12, 2027		U-2821		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101	I-885	Mar 11, 2025	
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
<u>OTESECONAZOLE - VIVJOA</u>						
N 215888 001	10414751	Mar 17, 2036	DS DP			
	11247981	May 09, 2033	U-3366			
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039		U-2849		
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	8153632	Jan 17, 2029	DS DP	U-3331		
	8153632	Jan 17, 2029	DS DP	U-3332		
	8980873	Mar 25, 2030	DS DP	U-3331		
	8980873	Mar 25, 2030	DS DP	U-3332		
	9573964	May 05, 2028		U-3331		
	9573964	May 05, 2028		U-3332		
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP	U-3291		
	9061057	Aug 26, 2033	DS DP	U-3291		
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP	U-3291		
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP	U-3291		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11304951	May 07, 2041		U-3349		
	11324751	May 07, 2041		U-3359		
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11304951	May 07, 2041		U-3349		
	11324751	May 07, 2041		U-3359		
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11292815	Nov 15, 2033	DS DP	U-3124		
	11292815	Nov 15, 2033	DS DP	U-3354		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2023	DS DP	U-106		
	6949571	Jun 08, 2023	DS DP	U-2088		
	6949571	Jun 08, 2023	DS DP	U-2089		
	6949571	Jun 08, 2023	DS DP	U-2428		
	6949571	Jun 08, 2023	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2023	DS DP	U-106		
	6949571	Jun 08, 2023	DS DP	U-2088		
	6949571	Jun 08, 2023	DS DP	U-2089		
	6949571	Jun 08, 2023	DS DP	U-2428		
	6949571	Jun 08, 2023	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2023	DS DP	U-106		
	6949571	Jun 08, 2023	DS DP	U-2088		
	6949571	Jun 08, 2023	DS DP	U-2089		
	6949571	Jun 08, 2023	DS DP	U-2428		
	6949571	Jun 08, 2023	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2023	DS DP	U-106		
	6949571	Jun 08, 2023	DS DP	U-2088		
	6949571	Jun 08, 2023	DS DP	U-2089		
	6949571	Jun 08, 2023	DS DP	U-2428		
	6949571	Jun 08, 2023	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2023	DS DP	U-106		
	6949571	Jun 08, 2023	DS DP	U-2088		
	6949571	Jun 08, 2023	DS DP	U-2089		
	6949571	Jun 08, 2023	DS DP	U-2428		
	6949571	Jun 08, 2023	DS DP	U-2429		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11266750	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11266750	Mar 16, 2037		U-665		
>A>	11395856	Dec 28, 2035	DS DP	U-665		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	8580299	Jun 14, 2029		U-3399		
	8895057	Jun 09, 2028		U-3398		
	9011906	Jun 09, 2028		U-3398		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	8580299	Jun 14, 2029		U-3399		
	8895057	Jun 09, 2028		U-3398		
	9011906	Jun 09, 2028		U-3398		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	8580299	Jun 14, 2029		U-3399		
	8895057	Jun 09, 2028		U-3398		
	9011906	Jun 09, 2028		U-3398		
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	8580299	Jun 14, 2029		U-3399		
	8895057	Jun 09, 2028		U-3398		
	9011906	Jun 09, 2028		U-3398		
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 001					CGT	Oct 30, 2022
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214596 002					CGT	Oct 30, 2022
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	11285134	Apr 24, 2039		U-3252		
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	May 10, 2028		DP U-2361		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8383150	May 10, 2028		DP U-2361		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8383150	May 10, 2028	DP	U-2361		
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8383150	May 10, 2028	DP	U-2361		
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001 >A>	8207197	Mar 07, 2030	DS	DP		
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002 >A>	8207197	Mar 07, 2030	DS	DP		
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	11319346	Mar 01, 2032	DP			
<u>PONATINIB HYDROCHLORIDE - ICLOSIG</u>						
N 203469 001	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
>A>	11384086	Dec 12, 2033	DS	DP U-1700		
>A>	11384086	Dec 12, 2033	DS	DP U-1701		
>A>	11384086	Dec 12, 2033	DS	DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLOSIG</u>						
N 203469 002	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
>A>	11384086	Dec 12, 2033	DS	DP U-1700		
>A>	11384086	Dec 12, 2033	DS	DP U-1701		
>A>	11384086	Dec 12, 2033	DS	DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLOSIG</u>						
N 203469 003	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
>A>	11384086	Dec 12, 2033	DS	DP U-1700		
>A>	11384086	Dec 12, 2033	DS	DP U-1701		
>A>	11384086	Dec 12, 2033	DS	DP U-1948		
<u>PONATINIB HYDROCHLORIDE - ICLOSIG</u>						
N 203469 004	11192897	Dec 12, 2033	DS	U-1700		
	11192897	Dec 12, 2033	DS	U-1701		
	11192897	Dec 12, 2033	DS	U-1948		
>A>	11384086	Dec 12, 2033	DS	DP U-1700		
>A>	11384086	Dec 12, 2033	DS	DP U-1701		
>A>	11384086	Dec 12, 2033	DS	DP U-1948		
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001					I-881	Jun 17, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11273160	Apr 03, 2039	U-2952			
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8957054	Jan 08, 2030	U-1922			
<u>RANOLAZINE - ASPIRUZYO SPRINKLE</u>						
N 216018 002	10898444	Jan 24, 2038	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	10961250	Jul 10, 2027	DP	U-2968		
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11247969	Mar 10, 2025	DP			
<u>RIBOCICLIB SUCCINATE - KISOQALI</u>						
N 209092 001	8415355	Mar 13, 2031	DS	DP	NPP	Dec 10, 2024
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS	DP	U-1153	
	7125879	Apr 21, 2025	DS	DP	U-1307	
	7125879	Apr 21, 2025	DS	DP	U-1740	
	7125879	Apr 21, 2025	DS	DP	U-3353	
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	11203593	Feb 18, 2034	DS	DP	U-2834	
	11203593	Feb 18, 2034	DS	DP	U-2835	
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	11203593	Feb 18, 2034	DS	DP	U-2834	
	11203593	Feb 18, 2034	DS	DP	U-2835	
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	11203593	Feb 18, 2034	DS	DP	U-2834	
	11203593	Feb 18, 2034	DS	DP	U-2835	
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	11203593	Feb 18, 2034	DS	DP	U-2834	
	11203593	Feb 18, 2034	DS	DP	U-2835	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIPRETTINIB - QINLOCK</u>						
N 213973 001	11266635	Aug 12, 2040		U-3330		
	11344536	Aug 12, 2040		U-3381		
>A>	11395818	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					NPP	May 27, 2025
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	>A> 10940142	Jun 07, 2037	DP		>A> NP	Jul 29, 2025
	>A> 11129818	Aug 25, 2037	DP U-3408			
	>A> 9884050	Jun 07, 2037	DP			
	>A> 9907788	Jun 07, 2037	DP U-3408			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 10610530	Jun 12, 2028	U-3229		>A> I-896	Jul 18, 2025
	>A> 10610530	Jun 12, 2028	U-3404			
	>A> 10869870	May 20, 2031	U-3229			
	>A> 10869870	May 20, 2031	U-3404			
	11219624	May 20, 2031	DP U-3229			
	>A> 8822481	Jun 12, 2028	U-3229			
	>A> 8822481	Jun 12, 2028	U-3404			
	>A> 9079912	Dec 12, 2026	U-3229			
	>A> 9079912	Dec 12, 2026	U-3404			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 9974790	Dec 12, 2026	U-3229			
	>A> 9974790	Dec 12, 2026	U-3404			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	11311679	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	11311679	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	11382957	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	11382957	Dec 16, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	11382957	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	11318191	Feb 17, 2041	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	11318191	Feb 17, 2041	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001				I-892		Jun 16, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	Aug 27, 2028	DS DP	M-274		Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	Aug 27, 2028	DS DP	M-274		Mar 01, 2025
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	7939519	Aug 27, 2028	DS DP	M-274		Mar 01, 2025
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001				NP		Mar 22, 2025
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	9687506	Dec 24, 2031	DS DP U-3394			
	9687506	Dec 24, 2031	DS DP U-3395			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	10479686	Mar 29, 2031	DS DP U-3390			
	9687506	Dec 24, 2031	DS DP U-3394			
	9687506	Dec 24, 2031	DS DP U-3395			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-1532			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	10479686	Mar 29, 2031	DS DP U-3390			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKEELMA</u>						
N 207078 001	>A> 11406662	Feb 10, 2032	DS			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKEELMA</u>						
N 207078 002	>A> 11406662	Feb 10, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u> N 212480 001					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOFOSBUVIR - SOVALDI</u> N 212480 002					ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u> N 208341 001				>A> M-277		Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u> N 208341 002				>A> M-277		Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u> N 214187 001				>A> M-277		Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u> N 214187 002				>A> M-277		Apr 27, 2025
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u> N 209195 001	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
<u>SONIDEGIB PHOSPHATE - ODOMZO</u> N 205266 001	10266523	Mar 30, 2036	DS DP			
<u>SOTORASIB - LUMAKRAS</u> N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
<u>SPINOSAD - NATROBA</u> N 022408 001	9895388	Nov 25, 2033	U-3365			
<u>SPIRONOLACTONE - CAROSPIR</u> N 209478 001	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
<u>SUCRALFATE - SUCRALFATE</u> A 211884 001					CGT	Sep 11, 2022
<u>SUMATRIPTAN - TOSYMRA</u> N 210884 001	11337962	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u> N 208223 001	11364224	Jan 29, 2036	U-72			
<u>TACROLIMUS - ENVARSUS XR</u> N 206406 001	11077096	Aug 30, 2024	DP			
	>A> 11419823	May 30, 2028	DP			
<u>TACROLIMUS - ENVARSUS XR</u> N 206406 002	11077096	Aug 30, 2024	DP			
	>A> 11419823	May 30, 2028	DP			
<u>TACROLIMUS - ENVARSUS XR</u> N 206406 003	11077096	Aug 30, 2024	DP			
	>A> 11419823	May 30, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>Tadalafil - Tadliq</u>						
N 214522 001	11382917	Dec 24, 2038	DP	U-3397		
<u>Tapentadol Hydrochloride - Nucynta ER</u>						
N 200533 001	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
<u>Tapentadol Hydrochloride - Nucynta ER</u>						
N 200533 002	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
<u>Tapentadol Hydrochloride - Nucynta ER</u>						
N 200533 003	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
<u>Tapentadol Hydrochloride - Nucynta ER</u>						
N 200533 004	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
<u>Tapentadol Hydrochloride - Nucynta ER</u>						
N 200533 005	11344512	Apr 21, 2028		U-3391		
	11344512	Apr 21, 2028		U-3392		
<u>Tapinarof - VTAMA</u>						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036		U-2625		
	10647649	Nov 13, 2038	DS			
<u>Tasimelteon - Hetlioz</u>						
N 205677 001	11266622	Aug 29, 2035		U-3003		
	11285129	Jan 25, 2033		U-3342		
	11285129	Jan 25, 2033		U-3343		
<u>Tasimelteon - Hetlioz LQ</u>						
N 214517 001	11266622	Aug 29, 2035		U-3003		
	11285129	Jan 25, 2033		U-3342		
<u>Tazarotene - Arazlo</u>						
N 211882 001	11311482	May 11, 2038		U-2368		
<u>Technetium TC-99m Tilmanocept - Lymphoseek Kit</u>						
N 202207 001	9439985	Jan 30, 2029	DP			
<u>Tecovirimat - Tpoxx</u>						
N 208627 001	>A> 7737168	Sep 04, 2031		U-2346		
<u>Tecovirimat - Tpoxx</u>						
N 214518 001	10576165	Aug 02, 2031	DP		NCE	Jul 13, 2023
	>A> 7737168	Sep 04, 2031		U-3377		
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS	DP		
	8530509	Jun 18, 2024		DP		
	8802714	Jun 18, 2024		U-3377		
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031		U-3377		
<u>Teduglutide Recombinant - Gattex Kit</u>						
N 203441 001	7847061	Nov 01, 2025	DP	U-1320	Y	
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	DP	U-1320	Y	
	9060992*PED	May 01, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794 001	7709493	Feb 28, 2031	DS	U-1979		
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318 001	11311554	Mar 25, 2039	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	11331325	Jan 06, 2027	U-2506			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	>A> 10576089	Dec 31, 2030	DP U-2506		>A> NP	Jul 27, 2025
	>A> 10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	>A> 10576089	Dec 31, 2030	DP U-2506		>A> NP	Jul 27, 2025
	>A> 10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	>A> 10576089	Dec 31, 2030	DP U-2506		>A> NP	Jul 27, 2025
	>A> 10576090	Dec 31, 2030	DP			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
TICAGRELOR - BRILINTA						
N 022433 002	RE46276*PED	Apr 30, 2025				
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 001					CGT	Aug 25, 2022
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 002					CGT	Aug 25, 2022
TIRZEPATIDE - MOUNJARO						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	6821987	Apr 26, 2023	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	6821987	Apr 26, 2023	DS DP U-3100			
TOFACITINIB CITRATE - XELJANZ						
N 203214 001					I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ						
N 203214 002					I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 206119 001				PC	Sep 06, 2022	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001				>A> I-895	Jun 22, 2025	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002				>A> I-895	Jun 22, 2025	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003				>A> I-895	Jun 22, 2025	
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	11324710	Aug 22, 2038	U-2368			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001				M-271		Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10995095	Oct 17, 2036	U-3298	I-880	Dec 14, 2024	
	11365198	Oct 17, 2036	U-3275	I-883	Jan 14, 2025	
	8962629	Jan 15, 2031	DS	U-3255	I-886	Mar 16, 2025
	8962629	Jan 15, 2031	DS	U-3275	I-888	Apr 29, 2025
	8962629	Jan 15, 2031	DS	U-3341		
	8962629	Jan 15, 2031	DS	U-3371		
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	10344036	Oct 17, 2036	DP	I-883	Jan 14, 2025	
	10550126	Oct 17, 2036	U-3298	I-886	Mar 16, 2025	
	10730883	Oct 17, 2036	DP	NCE	Aug 16, 2024	
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	10202393	Oct 17, 2036	DP	I-886	Mar 16, 2025	
	10981923	Oct 17, 2036	DS	NCE	Aug 16, 2024	
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS	U-3341		
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11224598	Oct 19, 2035	U-1900			
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538 001				PC	Jul 17, 2022	
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	11369599	May 23, 2032	DP			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	11369599	May 23, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	11369599	May 23, 2032	DP			
<u>VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE</u>						
N 215429 001	6717015	Mar 27, 2023	DS DP U-451			
	7776358	May 16, 2028	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2023	DS DP U-3056			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
<u>VUTRISIRAN - AMVUTTRA</u>						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396			
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
>A>	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 001					CGT	Dec 24, 2022
<u>ZINC SULFATE - ZINC SULFATE</u>						
A 216249 002					CGT	Dec 24, 2022
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	-------------------------	-----------------------------------

ZIPRASIDONE HYDROCHLORIDE - GEODON

N 020825 004

M-232

Jan 28, 2025

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm